[go: up one dir, main page]

US20050065099A1 - Treatment of mitochondrial diseases - Google Patents

Treatment of mitochondrial diseases Download PDF

Info

Publication number
US20050065099A1
US20050065099A1 US10/941,126 US94112604A US2005065099A1 US 20050065099 A1 US20050065099 A1 US 20050065099A1 US 94112604 A US94112604 A US 94112604A US 2005065099 A1 US2005065099 A1 US 2005065099A1
Authority
US
United States
Prior art keywords
chroman
hydroxy
tetramethyl
trimethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/941,126
Inventor
Gail Walkinshaw
Sekhar Bodupalli
Bing Wang
Guy Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Edison Phamaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/941,126 priority Critical patent/US20050065099A1/en
Assigned to GALILEO PHARMACEUTICALS, INC. reassignment GALILEO PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BODDUPALLI, SEKHAR, MILLER, GUY, WALKINSHAW, GAIL, WANG, BING
Publication of US20050065099A1 publication Critical patent/US20050065099A1/en
Assigned to ALLOY VENTURES, INC. reassignment ALLOY VENTURES, INC. SECURITY AGREEMENT Assignors: GALILEO PHARMACEUTICALS, INC.
Assigned to GALILEO PHARMACEUTICALS, INC. reassignment GALILEO PHARMACEUTICALS, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: ALLOY VENTURES, INC. AS SECURED PARTY AND AS COLLATERAL AGENT FOR ADDITIONAL SECURED PARTIES UNDER THE SECURED NOTE PURCHASE AGREEMENT DATED AS OF DECEMBER 22, 2005
Assigned to EDISON PHARMACEUTICALS INC reassignment EDISON PHARMACEUTICALS INC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GALILEO PHARMACEUTICALS, INC.
Assigned to AMPERE LIFE SCIENCES, INC. reassignment AMPERE LIFE SCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EDISON PHARMACEUTICALS, INC.
Priority to US13/869,872 priority patent/US20130267538A1/en
Assigned to EDISON PHARMACEUTICALS, INC. reassignment EDISON PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AMPERE LIFE SCIENCES, INC.
Priority to US15/189,948 priority patent/US20160324823A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to a method of treatment, amelioration, or prevention of mitochondrial diseases with certain pharmaceutical formulations containing chroman derivatives.
  • Mitochondrial dysfunction leads to impaired calcium buffering, generation of free radicals that may participate in intracellular and extracellular processes, changes in mitochondrial permeability and oxidative damage which is observed in several neurodegenerative diseases.
  • Some disorders involved in mitochondrial dysfunction affecting cellular processes include but are not limited to as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia and other ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS) and other motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy.
  • FRDA Friedreich's ataxia
  • Ataxia results from the degeneration of nerve tissue in the spinal cord and of nerves that control muscle movement in the arms and legs. Symptoms usually begin between the ages of 5 and 15 but can appear as early as 18 months or as late as 30 years of age. The first symptom is usually difficulty in walking. The ataxia gradually worsens and slowly spreads to the arms and then the trunk. Foot deformities such as clubfoot, flexion (involuntary bending) of the toes, hammer toes, or foot inversion (turning in) may be early signs.
  • MELAS Mitochondrial myopathy, encephalopathy, lactacidosis, stroke
  • MELAS mitochondrial encephalomyopathy
  • lactic acidosis lactic acidosis
  • stroke like episodes Other features, such as diabetes mellitus and hearing loss, clearly are part of the disorder.
  • MELAS is characterized by stroke-like episodes and a mitochondrial myopathy.
  • AD Alzheimer's disease
  • a progressive disease of the human central nervous system It is manifested by dementia in the elderly, by disorientation, loss of memory, difficulty with language, calculation, or visual-spatial skills, and by psychiatric manifestations. It is associated with degenerating neurons in several regions of the brain.
  • Alzheimer's disease is reviewed by Price, D. L. et al. ( Clin. Neuropharm. 14:S9-S14 (1991)); Pollwein, P. et al. ( Nucl. Acids Res. 20:63-68 (1992)); Regland, B. et al. ( Med. Hypoth. 38:11-19 (1992)) and Johnson, S. A. (In: Review of Biological Research in Aging , Vol. 4., Rothstein, M. (Ed.), Wiley-Liss, NY, 163-170 (1990)).
  • Parkinson's disease is a neurodegenerative disease especially affecting the dopaminergic neurons of the substantia nigra—pars compacta—and its nigrostriatal projections in nearly one million Americans.
  • the symptomatic manifestations are motor disorders such as tremor, muscular rigidity, bradykinesia, poor balance, and walking problems. Secondary symptoms include depression, sleep disturbances, dizziness, stooped posture, constipation, dementia, and problems with speech, breathing, swallowing, and sexual function symptoms.
  • ALS Amyotrophic lateral sclerosis
  • Lou Gehrig's disease or Charcot syndrome is a progressive motor neuron disease characterized by both upper and lower motor neuron damage.
  • the disease is characterized by degeneration of motor neurons in the cortex, brainstem and spinal cord (Principles of Internal Medicine, 1991 McGraw-Hill, Inc., New York; Tandan et al. Ann. Neurol., 18:271-280, 419-431, 1985).
  • the onset is between the third and sixth decade, typically in the sixth decade.
  • Symptoms may include tripping, stumbling and falling, loss of muscle control and strength in hands and arms, difficulty speaking, swallowing and/or breathing, chronic fatigue, and muscle twitching and/or cramping.
  • Symptoms of upper motor neuron damage include stiffness (spasticity), muscle twitching (fasciculations), and muscle shaking (clonus).
  • Symptoms of lower motor neuron damage include muscle weakness and muscle shrinking (atrophy).
  • Triphenyl phosphonium tocopherol analogs having cardioprotective or mitochondrially targeted antioxidant properties have been described by Gisar, J M in EP 545,283 and by Murphy, M. in Annals of the New York Academy of Sciences (2002), 959, 263-274 and in U.S. Pat. No. 6,331,532, US 2202/00523242 and US 2003/0069208.
  • antioxidants targeted to mitochondria shown to be effective at slowing disease progression has been reported by Jauslin, M L in FASEB Journal , express article 10.1096/fj.03-0240fje.
  • Therapeutic benefit of administering ⁇ -tocopherol derivatives and metabolites as antioxidants and nitrogen oxide scavengers which treat high blood pressure, thromboembolic diseases, cardiovascular disease, cancer, natriuretic disease, formation of neuropathological lesion and reduced immune system response are disclosed in U.S. Pat. Nos. 6,555,575; 6,242,479; 6,150,402; and 6,410,589.
  • the use of certain chroman derivatives in cosmetic and dermatological preparations is disclosed in US 2002/0127252. Beneficial effects of Vitamin E in the progression of a number of major degenerative diseases of the nervous system is examined in Fryer, Nutritional Neuroscience , (1998) Vol.1, 327-351.
  • the present invention addresses the desire to provide new therapies for conditions characterized by mitochondrial dysfunction.
  • the present invention particularly addresses the method of treating or ameliorating the symptoms of Friedreich's ataxia, a condition affecting young children, for which there is no effective cure or treatment. Most children afflicted by this debilitating condition, Friedreich's ataxia, die in or before early adulthood.
  • the present invention relates to the method of treating or ameliorating a subject suffering from a mitochondrial disorder comprising administering to said subject a therapeutically effective amount of a compound of Formula I or Formula II: wherein:
  • the method of treating or ameliorating a subject suffering from a mitochondrial disorder comprises administering to said subject a therapeutically effective amount of a compound of Formula I; in another preferred embodiment the method comprises administering a compound of Formula I wherein R 3 is hydrogen, C 1-6 alkyl, or C 2-20 alkenyl and in another embodiment the method comprises administering a compound of Formula I wherein R 5 and R 6 are C 1-4 alkyl or halogen, preferably wherein R 5 and R 6 are C 1-4 alkyl or halogen and R 1 is C 1-6 alkyl and R 2 is C 1-20 alkyl.
  • the method comprises administering a compound of Formula I wherein R 1 is C 1-6 alkyl and R 2 is C 16 alkyl or C 16 alkenyl
  • the method comprises administering a compound of Formula I wherein R 5 and R 6 taken together with the carbon to which they are attached form a 5-6 membered carbocyclic ring, which may be optionally substituted with C 1-6 alkyl, C 1-6 alkoxy, hydroxy, carboxy, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, or hydroxyalkyl.
  • the method of treating or ameliorating a subject suffering from a mitochondrial disorder comprises administering to said subject a therapeutically effective amount of a compound of Formula II; and in another preferred embodiment the method comprises administering a compound of Formula II wherein R 12 is —COOH or —COOR 13 and R 13 is C 1-6 alkyl.
  • the invention relates to a method of treating or ameliorating a subject suffering from disorders including but not limited to a disease involving mitochondrial disorders selected from Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy by administering to said subject a therapeutically effective amount of a compound of Formula I or Formula II or a pharmaceutically acceptable salt thereof.
  • the invention relates to a method of treating or ameliorating a subject suffering from Friedreich's ataxia, MELAS, or MERFF by administering to said subject a therapeutically effective amount of a compound of Formula I or Formula II.
  • the treatment comprises protecting or ameliorating a subject in need of protection of Friedreich's ataxia comprising administering a therapeutically effective amount of a tocopherol selected from beta-tocopherol, delta-tocopherol, gamma-tocopherol, alpha-tocotrienol, beta-tocotrienol, delta-tocotrienol, or gamma-tocotrienol.
  • a tocopherol selected from beta-tocopherol, delta-tocopherol, gamma-tocopherol, alpha-tocotrienol, beta-tocotrienol, delta-tocotrienol, or gamma-tocotrienol.
  • optionally substituted alkyl means either “alkyl” or “substituted alkyl,” as defined below.
  • acyl refers to the groups —C(O)—H, —C(O)-(optionally substituted alkyl), —C(O)-(optionally substituted cycloalkyl), —C(O)-(optionally substituted alkenyl), —C(O)-(optionally substituted cycloalkenyl), —C(O)-(optionally substituted aryl), and —C(O)-(optionally substituted heterocyclyl).
  • alkenyl refers to a monoradical branched or unbranched, unsaturated or polyunsaturated hydrocarbon chain, having from about 2 to 20 carbon atoms, more preferably about 2 to 10 carbon atoms. This term is exemplified by groups such as ethenyl, but-2-enyl, 3-methyl-but-2-enyl (also referred to as “prenyl”, octa-2,6-dienyl, 3,7-dimethyl-octa-2,6-dienyl (also referred to as “geranyl”), and the like.
  • alkoxy refers to the groups —O-alkyl, —O-alkenyl, —O-cycloalkyl, —O-cycloalkenyl, and —O-alkynyl.
  • Preferred alkoxy groups are —O-alkyl and include, by way of example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like.
  • alkyl refers to a monoradical branched or unbranched saturated hydrocarbon chain preferably having from about 1 to 20 carbon atoms, more preferably about 1 to 10 carbon atoms, and even more preferably about 1 to 6 carbon atoms.
  • alkyl also means a combination of linear or branched and cyclic saturated hydrocarbon radical consisting solely of carbon and hydrogen atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, n-hexyl, n-decyl, tetradecyl, and the like.
  • lower alkyl refers to a monoradical branched or unbranched saturated hydrocarbon chain of 1 to 6 atoms.
  • substituted alkyl refers to an alkyl group in which 1 or more (up to about 5, preferably up to about 3) hydrogen atoms is replaced by a substituent independently selected from the group: ⁇ O, ⁇ S, acyl, acyloxy, optionally substituted alkoxy, optionally substituted amino (wherein the amino group may be a cyclic amine), azido, carboxyl, (optionally substituted alkoxy)carbonyl, (optionally substituted amino)carbonyl, cyano, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, halogen, hydroxyl, nitro, sulfamoyl, sulfanyl, sulfinyl, sulfonyl, and sulfonic acid.
  • hydroxyalkyl groups such as 2-hydroxyethyl, 3-hydroxypropyl, 3-hydroxybutyl, 4-hydroxybutyl, and the like
  • dihydroxyalkyl groups such as 2,3-dihydroxypropyl, 3,4-dihydroxybutyl, 2,4-dihydroxybutyl, and the like
  • aminoalkyl groups such as dimethyl aminoalkyl, piperidinylalkyl, morpholinylalkyl, and those compounds known as polyethylene glycols, polypropylene glycols and polybutylene glycols, and the like.
  • Another preferred optional substituent for alkyl is sulfanyl exemplified by allylsulfanyl, carboxypropylsulfanyl, 2-methyl-propionyl-pyrrolidine-2-carboxylic acid, 5-methyl-1-H-benzimidazol-2-yl-sulfanyl, sulfoxyethylsulfanyl, 4,6-dimethyl-pyrimidin-2-ylsulfanyl, 4 carboxy-benzyl-sulfanyl, isobutylsulfanyl, and the like.
  • Other preferred optional substituents for alkyl are —N-hydroxyureidyl, —N-hydroxythioureidyl or —N-hydroxyacetamide.
  • amino refers to the group —NH 2 as well as to the groups —NHR or —NRR where each R is independently selected from the group: optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted cycloalkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, acyl, optionally substituted alkoxy, carboxy and alkoxycarbonyl, and where —NRR may be a cyclic amine.
  • amino acid or “natural amino acid” refers to any of the twenty (20) common amino acids as generally accepted in the peptide art.
  • aralkyl refers to the moiety “-alkylene-aryl” each having the meaning as defined herein.
  • aryl refers to an aromatic cyclic hydrocarbon group of from 6 to 20 carbon atoms having a single ring (e.g., phenyl) or multiple condensed (fused) rings (e.g., naphthyl or anthryl). Preferred aryls include phenyl, naphthyl and the like.
  • substituted aryl refers to an aryl group as defined above, which unless otherwise constrained by the definition for the aryl substituent, is substituted with from 1 to 5 substituents, and preferably 1 to 3 substituents, independently selected from the group consisting of: hydroxy, thiol, acyl, acyloxy, optionally substituted alkenyl, optionally substituted alkoxy, optionally substituted alkyl (such as tri-halomethyl), optionally substituted alkynyl, optionally substituted amino, optionally substituted aryl, optionally substituted aryloxy, azido, carboxyl, (optionally substituted alkoxy)carbonyl, (optionally substituted amino)carbonyl, cyano, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, halogen, optionally substituted heterocyclyl, optionally substituted heterocyclooxy, hydroxyl, nitro, sulfanyl, sulfin
  • Preferred aryl substituents include alkyl, alkenyl, alkoxy, halo, cyano, nitro, trihalomethyl, carboxy, amino, amido, sulfonamido, and sulfinyl.
  • carbonyl refers to the di-radical “—C( ⁇ O)—”, which is also illustrated as “—C(O)—”.
  • (optionally substituted amino)carbonyl refers to the group —C(O)-(optionally substituted amino). This moiety is also referred to as a primary, secondary or tertiary carboxamide.
  • cycloalkyl refers to non-aromatic cyclic hydrocarbon groups of having about 3 to 40 (preferably about 4 to 15) carbon atoms having a single ring or multiple condensed or bridged rings.
  • Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like, or multiple ring structures such as adamantanyl, and the like.
  • cycloalkyl additionally encompasses spiro systems wherein the cycloalkyl ring has a carbon ring atom in common with another ring.
  • halo or “halogen” refers to fluoro, chloro, bromo and iodo.
  • heterocycle refers to a monovalent, saturated, partially unsaturated or unsaturated (aromatic), carbocyclic radical having one or more rings incorporating one, two, three or four heteroatoms within the ring (chosen from nitrogen, oxygen, and/or sulfur).
  • Preferred heterocycles include morpholine, piperidine, piperazine, thiazole, thiazolidine, isothiazole, oxazole, isoxazole, pyrazole, pyrazolidine, pyrazoline, imidazole, imidazolidine, benzothiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrrole, pyrrolidine, quinoline, quinazoline, purine, carbazole, benzimidazole, pyrimidine, thiophene, benzothiophene, pyran, tetrahydropyran, benzopyran, furan, tetrahydrofuran, indole, indoline, indazole, xanthene, thioxanthene, acridine, quinuclidine, and the like.
  • substituted heterocycle refers to a heterocycle group as defined above, which unless otherwise constrained by the definition for the heterocycle, is substituted with from 1 to 5 substituents, and preferably 1 to 3 substituents, independently selected from the group consisting of: hydroxy, thiol, acyl, acyloxy, optionally substituted alkenyl, optionally substituted alkoxy, optionally substituted alkyl (such as tri-halomethyl), optionally substituted alkynyl, optionally substituted amino, optionally substituted aryl, optionally substituted aryloxy, azido, carboxyl, (optionally substituted alkoxy)carbonyl, (optionally substituted amino)carbonyl, cyano, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, halogen, optionally substituted heterocyclyl, optional
  • heterocycloalkyl refers to the moiety “-alkylene-heterocycle” each having the meaning as defined herein.
  • substituted heterocycloalkyl refers to the moiety” -(optionally substituted alkylene)-(optionally substituted heterocycle)”, each having the meaning as defined herein.
  • mitochondrial diseases or disorders can cause a complex variety of symptoms. These include muscle weakness, muscle cramps, seizures, food reflux, learning disabilities, deafness, short stature, paralysis of eye muscles, diabetes, cardiac problems and stroke—like episodes, to name a few.
  • the symptoms can range in severity from life-threatening to almost unnoticeable, sometimes taking both extremes in members of the same family.
  • Kearns-Sayre syndrome (KSS), Leigh's syndrome, maternally inherited Leigh's syndrome (MILS), Myogastrointestinal encephalomyopathy (MNGIE), Neuropathy, ataxia and retinitis pigmentosa (NARP), Friedreich's ataxia (FRDA), amyotrophic lateral sclerosis (ALS) and other motor neuron diseases, Huntington's disease, macular degeneration, epilepsy, Alzheimer's, Leber's hereditary optic neuropathy (LHON), Progressive external ophthalmoplegia (PEO), and Pearson syndrome.
  • KSS Kearns-Sayre syndrome
  • MILS maternally inherited Leigh's syndrome
  • MNGIE Myogastrointestinal encephalomyopathy
  • NARP ataxia and retinitis pigmentosa
  • FRDA Friedreich's ataxia
  • ALS amyotrophic lateral sclerosis
  • Huntington's disease macular degeneration
  • epilepsy Alzheimer's
  • Neurodegenerative disorders refers to disorders characterized by a loss of neurons and may or may not include an inflammatory process.
  • Neurodegenerative disorders include stroke, head trauma, cerebral hypoxia, spinal cord injury, senile dementia, Alzheimer's disease, amyotrophic lateral sclerosis (ALS) and other motor neuron diseases, cerebral amyloid angiopathy, HIV-related dementia, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, Down's syndrome, Creutzfeldt-Jakob disease, Friedreich's ataxia (FRDA), Fergusson and Critchley's ataxia and other ataxias, Leber's hereditary optic neuropathy diabetic neuropathy (LHON), neuropathic pain, encephalitis, meningitis, and Duchenne's muscular dystrophy.
  • ALS amyotrophic lateral sclerosis
  • FRDA Friedreich's ataxia
  • pharmaceutically acceptable carrier or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • pharmaceutically acceptable salt refers to salts which retain the biological effectiveness and properties of the compounds of this invention and which are not biologically or otherwise undesirable.
  • the compounds of this invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases, include by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, cycloalkyl amines, di(cycloalkyl) amines, tri(cycloalkyl) amines, substituted cycloalkyl amines, disubstituted cycloalkyl amine, trisubstituted cycloalkyl amines, cycloalkenyl amines, di(cycloalkeny
  • Suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.
  • Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.
  • seizure is used herein as meaning the physical affliction characterized by transient clouding of consciousness, generally associated with a disturbance in the electrical activity of the cortex of the brain. Illustrative of such seizures are those associated with petit mal epilepsy.
  • therapeutically effective amount refers to that amount of a compound of this invention that is sufficient to effect treatment, as defined below, when administered to a mammal in need of such treatment.
  • the therapeutically effective amount will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the particular compound chosen, the dosing regimen to be followed, timing of administration, the manner of administration and the like, all of which can readily be determined by one of ordinary skill in the art.
  • tocopherol means any of a family of molecules (including both tocopherols and tocotrienols and derivatives therof) which are characterized by a chroman-6-ol ring structure and a side chain at the 2-position. Tocopherols possess a 4′,8′,12′-trimethyltridecyl phytyl side chain and the trocotrienols differ by the presence of double bonds at 3′,7′,11′′ positions of the side chain.
  • the chemical names for the tocopherols are:
  • treatment means any treatment of a disease or disorder in a mammal, including:
  • solvent inert organic solvent
  • solvents employed in synthesis of the compounds of the invention include, for example, methanol (“MeOH”), acetone, water, acetonitrile, 1,4-dioxane, dimethylformamide (“DMF”), benzene, toluene, tetrahydrofuran (“THF”), chloroform, methylene chloride (also named dichloromethane( (“DCM”), diethyl ether, ethyl acetate (“EtOAc”), pyridine and the like, as well as mixtures thereof.
  • the solvents used in the reactions of the present invention are inert organic solvents.
  • q.s. means adding a quantity sufficient to achieve a stated function, e.g., to bring a solution to the desired volume (i.e., 100%).
  • the reactions described herein take place at atmospheric pressure within a temperature range from 0° C. to 110° C. (preferably from 0° C. to 25° C.; most preferably at “room” or “ambient” temperature (“RT”), e.g., 20° C.).
  • RT room or “ambient” temperature
  • the reaction times and conditions are intended to be approximate, e.g., taking place at about atmospheric pressure within a temperature range of about 0° C. to about 110° C. (preferably from about 0° C. to about 25° C.; most preferably at about “room” or “ambient” temperature, e.g., approximately 20° C.) over a period of about 1 to about 10 hours (preferably about 5 hours).
  • Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, or a combination of these procedures.
  • suitable separation and isolation procedures can be had by reference to the examples herein below. However, other equivalent separation or isolation procedures can also be used.
  • the compounds of Formula I or Formula II encompass the chroman derivatives of the invention as disclosed, and/or the pharmaceutically acceptable salts of such compounds.
  • the compounds of this invention include the individual stereochemical isomers and mixtures thereof, arising from the selection of substituent groups. It will be understood by those skilled in the art with respect to any group containing one or more substituents that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical and/or synthetically non-feasible.
  • Preferred for the compounds, pharmaceutical formulations, methods of manufacture and use of the present invention are the following combinations and permutations of substituent groups of Formula I and Formula II.
  • Compound, compositions, formulations, and methods of the present invention are useful for the treatment of disorders characterized by defective mitochondrial activity.
  • compounds of the present invention can be used in the treatment of diseases such as degenerative diseases of the brain ((Wernicke-Korsakoff disease, Kreuzfeldt-Jakob disease (KJD), Hallervorden-Spatz disease, Schilder's disease, Alzheimer's disease, senile dementia, Down's syndrome in middle age, Abercrombie's disease, Prion diseases, Zellweger syndrome, Alper's Syndrome), spinocerebellar degenerations (spinal ataxia, cerebellar cortical degenerations, Friedreich's ataxia (FRDA) and other ataxias), multiple system degenerations (Menzel, Dejerine-Thomas, Shy-Drager, and Machado Joseph), systemic disorders (Refsum disease, ataxia telangiectasia), epilepsy, mitochondrial disorders (MELAS, MERFF, KSS,
  • Certain compounds of the present invention are also useful in treating conditions falling with the group of dermatologic conditions, in particular prevention and protecting skin tissue against age-related damage or damage resulting from insults such as harmful ultraviolet (UV) radiation, stress and fatigue, and in the treatment of contact dermatitis, skin irritation, skin pigmentation, psoriasis, or acne.
  • insults such as harmful ultraviolet (UV) radiation, stress and fatigue
  • UV radiation harmful ultraviolet
  • contact dermatitis skin irritation, skin pigmentation, psoriasis, or acne.
  • compositions incorporating compositions of the present invention are selected, using in vitro and/or in vivo animal models, for example, and used as therapeutic interventions in the exemplary indications, i.e., stroke, epilepsy, Parkinson's disease, Friedreich's ataxia, MELAS, macular degeneration, ALS, and Alzheimer's disease.
  • exemplary indications i.e., stroke, epilepsy, Parkinson's disease, Friedreich's ataxia, MELAS, macular degeneration, ALS, and Alzheimer's disease.
  • MPTP/MPP + -induced neurodegeneration of dopaminergic neurons is a well characterized model which is therefore widely used to understand the pathogenesis of Parkinson's disease.
  • the compounds were tested on MPTP/MPP + induced neuronal death in vitro and in vivo as shown in the following examples.
  • MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • MPTP is metabolized by astrocytes into 1-methyl-4-phenylpyridinium (MPP + ), a substrate for the dopamine transporter which then selectively inhibits complex 1 of the mitochondrial electron transport chain. This results in depletion of ATP, the production of reactive oxygen species and, consequently cell death.
  • MPTP produces an irreversible and severe parkinsonian syndrome which includes virtually all the clinical features of the disease.
  • the striking pathologic and clinical similarities between idiopathic Parkinson's disease and MPTP-induced Parkinsonism suggest that the two disorders share common pathogenic mechanism.
  • a cellular assay using FRDA-patient derived fibroblasts (as described by Jauslin, M L et al, Human Molecular Genetics 11; 3055-3063 (2002)); is used to determine the cell protecting effect of the test compounds by analyzing survival of dermal fibroblasts taken from FRDA patients and unaffected normal donors under conditions of partial GSH depletion.
  • Exposure of FRDA fibroblasts to BSO (L-buthionine (S,R)-sulfoximine) under conditions of restricted selenium causes depletion of cellular glutathione (GSH) and severe plasma membrane damage leading to cell death.
  • Preincubation with the test compounds before the addition of BSO is used to determine if they can protect FRDA cells from BSO-mediated cell death.
  • HGOS glutamate induced oxidative stress
  • IL-1 elevation has been associated with many neurodegenerative diseases.
  • AD Alzheimer's Disease
  • Elevated levels of IL-1 ⁇ have been shown to surround amyloid plaques in the disease and recent genetic studies have indicated that a polymorphism in IL-1 ⁇ is linked to an increased risk of AD (3-6 fold increase) (Griffin W S et al., J Leukoc Biol 72(2):233-238, 2002). This polymorphism has also been correlated with rate of cognitive decline in AD patients (Murphy G M et al., Neurology, 56(11)1595-1597, 2001).
  • This assay measures the release of IL-1 ⁇ from a mouse microglial cell line following an inflammatory challenge with LPS and interferon-gamma.
  • the ability of test articles to inhibit microglial cell activation and IL-1 ⁇ release is determined by co-incubation of the test article with the inflammatory challenge. Cytokine release is measured using a mouse IL-1 ⁇ ELISA and cell toxicity is determined using Cell Tracker Green (a fluorescent dye that measures cell viability).
  • Cerebral ischemic insults are modeled in animals by occluding vessels to, or within, the cranium (Molinari, G. F., 1986, in H. J. M. Barnett, et al., (Eds) Stroke: Pathophysiology, Diagnosis and Management , Vol. 1, Churchill Livingstone, N.Y.).
  • the rat middle cerebral artery occlusion (MCAO) model is one of the most widely used techniques to induce transient focal cerebral ischemia approximating cerebral ischemic damage in humans, e.g., those who suffer from a stroke.
  • the middle cerebral artery used as the ischemic trigger in this model is the most affected vessel in human stroke.
  • the model also entails a period of reperfusion, which typically occurs in human stroke victims.
  • MCAO involving a two-hour occlusion has been found to produce the maximum size of cortical infarction obtainable without increased mortality at twenty-four hours.
  • the compounds of this invention are administered at a therapeutically effective dosage, e.g., a dosage sufficient to provide treatment or amelioration for the disease states previously described.
  • Administration of the compounds of the invention or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration for agents that serve similar utilities.
  • a daily dose is from about 0.01 to 10.0 mg/kg of body weight, preferably about 0.1 to 5. mg/kg of body weight, and most preferably about 0.3 to 1.0 mg/kg of body weight.
  • the amount of active compound administered will, of course, be dependent on the subject and disease state being treated, the severity of the affliction, the manner and schedule of administration and the judgment of the prescribing physician.
  • any pharmaceutically acceptable mode of administration can be used.
  • the compounds of this invention can be administered either alone or in combination with other pharmaceutically acceptable excipients, including solid, semi-solid, liquid or aerosol dosage forms, such as, for example, tablets, capsules, powders, liquids, suspensions, suppositories, aerosols or the like.
  • the compounds of this invention can also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills, transdermal (including electrotransport) patches, and the like, for the prolonged administration of the compound at a predetermined rate, preferably in unit dosage forms suitable for single administration of precise dosages.
  • compositions will typically include a conventional pharmaceutical carrier or excipient and a compound of this invention or a pharmaceutically acceptable salt thereof.
  • these compositions may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, and the like, including, but not limited to anticoagulants, blood clot dissolvers, permeability enhancers and slow release formulations.
  • the pharmaceutically acceptable composition will contain about 0.1% to 90%, preferably about 0.5% to 50%, by weight of a compound or salt of Formulae I or II, the remainder being suitable pharmaceutical excipients, carriers, etc.
  • a pharmaceutically acceptable, non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, magnesium carbonate, and the like.
  • excipients such as, for example, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, magnesium carbonate, and the like.
  • Such compositions take the form of solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations and the like.
  • compositions will take the form of a pill or tablet and thus the composition will contain, along with the active ingredient, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose and derivatives thereof, and the like.
  • a diluent such as lactose, sucrose, dicalcium phosphate, or the like
  • a lubricant such as magnesium stearate or the like
  • binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose and derivatives thereof, and the like.
  • Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to thereby form a solution or suspension.
  • a carrier such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like
  • the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, or solubilizing agents, pH buffering agents and the like, for example, sodium acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, etc.
  • composition or formulation to be administered will, in any event, contain a quantity of the active compound in an amount effective to alleviate the symptoms of the subject being treated.
  • Dosage forms or compositions containing active ingredient in the range of 0.005% to 95% with the balance made up from non-toxic carrier may be prepared.
  • a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, talcum, cellulose derivatives, sodium crosscarmellose, glucose, sucrose, magnesium carbonate, sodium saccharin, talcum and the like.
  • excipients such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, talcum, cellulose derivatives, sodium crosscarmellose, glucose, sucrose, magnesium carbonate, sodium saccharin, talcum and the like.
  • Such compositions take the form of solutions, suspensions, tablets, capsules, powders, sustained release formulations and the like.
  • Such compositions may contain 0.01%-95% active ingredient, preferably 0.1-50%.
  • the solution or suspension in for example propylene carbonate, vegetable oils or triglycerides, is preferably encapsulated in a gelatin capsule.
  • a gelatin capsule Such diester solutions, and the preparation and encapsulation thereof, are disclosed in U.S. Pat. Nos. 4,328,245; 4,409,239; and 4,410,545.
  • the solution e.g. in a polyethylene glycol, may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, e.g. water, to be easily measured for administration.
  • liquid or semi-solid oral formulations may be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene glycol esters (e.g. propylene carbonate) and the like, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells.
  • the formulation can be administered in a single unit dosage form for continuous treatment or in a single unit dosage form ad libitum when relief of symptoms is specifically required.
  • the formulation may be administered as a bolus or as a continuous intravenous infusion after onset of symptoms of stroke, myocardial infarction or chronic heart failure.
  • Topical administration refers to application of the present compositions by spreading, spraying, etc. onto the surface of the skin. The typical amount applied may vary from about 0.1 mg of composition per square centimeter of skin to about 25 mg of composition per square centimeter of skin.
  • the compounds of the present invention may be formulated for topical administration to the epidermis as ointments, creams or lotions or as transdermal patch. Formulations suitable for topical administration in the mouth include lozenges, pastilles and mouthwashes.
  • Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously.
  • Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
  • Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like.
  • the pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, solubility enhancers, and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, cyclodextrins, etc.
  • a more recently devised approach for parenteral administration employs the implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained; see, e.g., U.S. Pat. No. 3,710,795.
  • the percentage of active compound contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject. However, percentages of active ingredient of 0.01% to 10% in solution are employable, and will be higher if the composition is a solid which will be subsequently diluted to the above percentages.
  • the composition will comprise 0.2-2% of the active agent in solution.
  • Nasal solutions of the active compound alone or in combination with other pharmaceutically acceptable excipients can also be administered.
  • Formulations of the active compound or a salt may also be administered to the respiratory tract as an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose.
  • the particles of the formulation have diameters of less than 50 microns, preferably less than 10 microns.
  • NMR Nuclear Magnetic Resonance
  • Neurobasal/B27i Neurobasal medium plus 1 ⁇ B27 supplement, 0.5 mM L-glutamine, 25 ⁇ M L-glutamic acid, and 0.5 ⁇ Penicillin/Streptomycin
  • Neurobasal/B27m Neurobasal medium plus 1 ⁇ B27 supplement and 0.5 mM L-glutamine
  • BSS (Ca/Mg free): HBSS (calcium/magnesium free) plus 10 mM Hepes (pH 7.25), 1 ⁇ Penicillin/Streptomycin, and 1 mM Sodium Pyruvate
  • Glucose-free BSS 0 143.6 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 0.8 mM MgSO 4 , 1 mM NaH 2 PO 4 , 26.2 mM NaHCO 3 , 10 mg/l phenol red, 0.25 ⁇ Penicillin/Streptomycin, and 10 mM Hepes (pH 7.4)
  • Papain Quench solution Neurobasal medium plus 1 ⁇ B27 supplement, 1 ⁇ Penicillin/Streptomycin and 0.5 mg/ml DNase1
  • Assay media Neurobasal medium plus 1 ⁇ B27 (minus AO) supplement, 0.5 mM L-glutamine, and 0.25 ⁇ Penicillin/Streptomycin.
  • Hippocampal neurons were isolated from E18 rat embryos as follows. Embryos were decapitated and the heads immersed in cold BSS (Ca/Mg free). Using a dissecting microscope the hippocampi were dissected out and placed in cold BSS (Ca/Mg free). The isolated hippocampi were then centrifuged at 1000 rpm for 2 min, the BSS aspirated off and 2 ml of 2 mg/ml Papain in Neurobasal media added per 10 embryos. After mixing on a rotational shaker for 10 min at 37° C., 5 ml Papain Quench solution was added.
  • a ⁇ (1-42) American Peptide Co, Sunnyvale, Calif.
  • the A ⁇ peptide was dissolved to 1 mM in hexafluoroisopropanol (HFIP) and aliquoted into sterile microcentrifuge tubes. The HFIP was removed under vacuum and the peptide film stored at ⁇ 20° C. The day before the assay, the peptide film was resuspended in dry DMSO to a concentration of 5 mM. Ham's F-12 media was then added to bring the peptide to a final concentration of 100 ⁇ M, and this solution was incubated at 4° C. for 24 hours to allow formation of oligomers.
  • HFIP hexafluoroisopropanol
  • the existing growth medium was aspirated from the hippocampal cultures and the monolayer was washed once with 500 ⁇ l glucose free-BSS 0 .
  • Test articles were diluted to 2-fold the desired testing concentration in assay media and 250 ⁇ L was added to the cells. From the 100 ⁇ M oligomeric beta-amyloid peptide solution described above, a working solution of 6 ⁇ M was made in assay media. 250 ⁇ L of this working solution was also added to the cells. The final volume for each well was 500 ⁇ L and the final concentration of A ⁇ peptide was 3 ⁇ M. As a negative control, cells were incubated with 500 ⁇ L assay media with no additions.
  • RF media DMEM-No glucose, glucose (29.1 mM), L-glutamine (1.4 mM), 10% heat-inactivated FBS, and 1 ⁇ penicillin/streptomycin (P/S)
  • Assay Media DMEM-No glucose, L-glutamine (1.4 mM), 0.5% FBS, and 1 ⁇ P/S
  • a substantia nigra-derived dopaminergic progenitor cell line was seeded in poly-D-lysine-coated 24-well plates at a density of 4500 cells per well in RF media. The cells were left to attach for 16 hours in a 33° C. incubator (5% CO 2 ) after which time they were washed once with 500 ⁇ L wash media and then differentiated into a neuronal phenotype by incubating in low serum media for 24 hours in a 39° C. incubator (5% CO 2 ).
  • mice Male C57/BL6 mice (Harlan, Ind.), weight 25-30 g, were used in all studies. MPTP-HCl (Sigma) was administered i.p. according to one of the following protocols. The maximum volume which was given per injection is 200 ⁇ L. In all studies, animals were euthanized with carbon dioxide and, brains were removed for subsequent determination of dopamine depletion where appropriate.
  • the open field test measures spontaneous activity. Deficits can be observed with hippocampal and basal ganglia lesions, and with hindlimb dysfunction. It is sensitive to moderate dopamine (DA) depletion.
  • DA dopamine
  • the open field test was carried out in a clear, acrylic open box 60 cm ⁇ 60 cm.
  • the base of the box was marked into a 5 ⁇ 5 grid of 12 cm ⁇ 2 cm squares. Animals were individually placed in the box and allowed to roam free. The number of squares an animal crossed in a 90 second time period was recorded. In order to be scored, the animal must either have had all four limbs within a given square or, all four limbs must have left a given square.
  • the tactile adhesion model measures an animal's ability to complete a complex sensorimotor task. It is sensitive to moderate to severe DA depletion.
  • a tactile stimulus (0.5 ⁇ 0.5 cm square of “sticky tape”) was applied to each side of the animal's face and the time taken to remove it is recorded. The following measurements were recorded:
  • the pole test evaluates motor co-ordination.
  • a rough surfaced metal pole (diameter 8 mm, height 50 cm) protruding from a cage filled with animal bedding was used for this test. Animals were placed head upwards at the top of the pole. They were required to turn and descend face downwards and the time taken for this was recorded (latency to reach bedding). Timing was started when the individual animal gripped the top of the pole and was stopped when all four limbs contacted the bedding.
  • test compounds were administered ip. The maximum volume which was given per injection was 200 ⁇ L. Compounds were dosed up to twice daily, two days prior and 7 days post MPTP treatment.
  • a baseline reading was taken for each animal one day prior to MPTP treatment. All subsequent readings were normalized to the individual animal's baseline. Values were expressed as a percent baseline.
  • FRDA-fibroblasts types were derived from donors with a molecular diagnosis of FRDA and control donors with no mitochondrial disease.
  • Lines F2, C2 and C3 were obtained from Coriell Cell Repositories (Camden, N.J., USA; catalog #'s GM04078, GM 08402 and GM08399, respectively). All cell types were diagnosed at the molecular level for intronic GAA triplet repeat length in the trataxin gene using a PCR-based method, according to methods known in the art.
  • FRDA-fibroblasts types had ⁇ 400-450 repeats (F2 line) or more (F1 and F3), whereas control cell lines displayed PCR products of normal length.
  • the cells were seeded in microtiter plates at a density of 4000 cells per 100 ⁇ l in growth medium consisting of 25% (v/v) M199 EBS and 64% (v/v) MEM EBS without phenol red (Bioconcept, Allschwil, Switzerland) supplemented with 10% (v/v) fetal calf serum (PAA Laboratories, Linz, Austria), 100 U/ml penicillin, 100 ⁇ g/ml streptomycin (PAA Laboratories, Linz, Austria), 10 ⁇ g/ml insulin (Sigma, Buchs, Switzerland), 10 ⁇ g/ml EGF (Sigma, Buchs, Switzerland), 10 ⁇ g/ml bFGF (PreproTech, Rocky Hill, N.J., USA) and 2 mM glutamine (Sigma, Buchs, Switzerland).
  • the cells were incubated in the presence of the various test compounds for 24 h before addition of 1 mM BSO (L-buthionine (S,R)-sulfoximine).
  • Cell viability was measured after the first signs of toxicity appeared in the BSO-treated controls (typically after 16-48 h). The cells were stained for 60 min at room temperature in PBS with 1.2 ⁇ m calceinAM and 4 ⁇ m ethidium homodimer (Live/Dead assay, Molecular Probes, Eugene, Oreg., USA). Fluorescence intensity was measured with a Gemini Spectramax XS spectrofluorimeter (Molecular Devices, Sunnyvale, Calif., USA) using excitation and emission wavelengths of 485 and 525 nm, respectively.
  • HGOS High Glutamate-Induced Oxidative Stress Assay
  • HGOS high glutamate-induced oxidative stress
  • the cells were seeded into 96-well plates at a density of 2000 per well and left to grow for 72 hours in a 33° C. incubator with 5% CO 2 in air atmosphere.
  • the passage number of the cells for each assay experiment were no later than p11 in order to minimize experimental variation.
  • VWRBrand DyNA Block 1000 deep well mother plates (VWR Cat. #40002-008) were used for the preparation of the test compounds.
  • DMEM-No Glu containing 1 mM glucose, 30 mM glutamate and 1 ⁇ Pen/Strep.
  • DMEM-No Glu with 1 mM glucose and 1 ⁇ P/S was used as the negative control
  • DMEM-No Glucose with 1 mM glucose, 100 M glutamate was used as a positive control and 100 ⁇ M Glutathione was added to the positive control as a standard. All of the procedures for this involving the making and dilution of compounds were performed using aseptic conditions and with minimal light.
  • the plates were removed from the incubator and examined under the microscope for morphological appearance and density. Using an aseptic technique and an 8-channel aspirator the media was carefully removed from the cells and replaced with 200 ⁇ l of 1 ⁇ HBSS. This was done as quickly as possible to prevent the cells drying out. The plates were then placed in the humidified 37° C. incubators of the Biomek 2000 Side Loader. Four plates were washed at a time so as to minimize the time that the cells were sitting in 1 ⁇ HBSS prior to addition of the compound test solution.
  • the Beckman Biomek workstations were used to load the compounds and controls from the mother plates onto the cell plates that were prewashed with HBSS under sterile conditions.
  • the plates were incubated in the upper HTS incubator at 37° C. in 5% CO 2 for exactly 16 hrs. The following day, using the Beckman Biomek workstations, the plates were removed from the incubator. Using Cell Tracker Addition, the compounds were removed from the plates, washed once with 200 ⁇ M of pre-warmed 1 ⁇ HBSS and then 100 ⁇ L of 5 ⁇ M Cell Tracker Green was added to each well.
  • the plates were incubated at 37° C. for 30 min to allow the dye to enter the cell and be cleaved by the esterases. After washing the cells twice with prewarmed 1 ⁇ HBSS, the plates were read with the 485 excitation; 538 emission filter pair on a Fluoroskan.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)

Abstract

The invention relates the method of treatment or amelioration of mitochondrial disorders such as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy, with chroman derivatives of Formula I or Formula II as described herein.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This U.S. patent application claims priority under 35 U.S.C. 119(e) to U.S. Provisional Applications Ser. No. 60/504,391, filed Sep. 19, 2003, and Ser. No. 60/541,737, filed Feb. 4, 2004 incorporated herein by reference in their entirety.
    • BACKGROUND INVENTION
  • The present invention relates to a method of treatment, amelioration, or prevention of mitochondrial diseases with certain pharmaceutical formulations containing chroman derivatives.
  • Mitochondrial dysfunction leads to impaired calcium buffering, generation of free radicals that may participate in intracellular and extracellular processes, changes in mitochondrial permeability and oxidative damage which is observed in several neurodegenerative diseases. Some disorders involved in mitochondrial dysfunction affecting cellular processes include but are not limited to as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia and other ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS) and other motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy.
  • Friedreich's ataxia (“FRDA”) is an autosomal recessive multi-system degenerative disorder that results in progressive damage to the nervous system and causes symptoms ranging from muscle weakness and speech problems to heart disease. Ataxia results from the degeneration of nerve tissue in the spinal cord and of nerves that control muscle movement in the arms and legs. Symptoms usually begin between the ages of 5 and 15 but can appear as early as 18 months or as late as 30 years of age. The first symptom is usually difficulty in walking. The ataxia gradually worsens and slowly spreads to the arms and then the trunk. Foot deformities such as clubfoot, flexion (involuntary bending) of the toes, hammer toes, or foot inversion (turning in) may be early signs. Rapid, rhythmic, involuntary movements of the eyeball are common. Most people with Friedreich's ataxia develop scoliosis (a curving of the spine to one side), which, if severe, may impair breathing. Other symptoms include chest pain, shortness of breath, and heart palpitations.
  • Mitochondrial myopathy, encephalopathy, lactacidosis, stroke (“MELAS”) is a progressive neurodegenerative disorder. The typical presentation of patients with MELAS syndrome includes features that comprise the name of the disorder such as mitochondrial encephalomyopathy, lactic acidosis, and stroke like episodes. Other features, such as diabetes mellitus and hearing loss, clearly are part of the disorder. MELAS is characterized by stroke-like episodes and a mitochondrial myopathy.
  • Alzheimer's disease (“AD”) is a progressive disease of the human central nervous system. It is manifested by dementia in the elderly, by disorientation, loss of memory, difficulty with language, calculation, or visual-spatial skills, and by psychiatric manifestations. It is associated with degenerating neurons in several regions of the brain. Alzheimer's disease is reviewed by Price, D. L. et al. (Clin. Neuropharm. 14:S9-S14 (1991)); Pollwein, P. et al. (Nucl. Acids Res. 20:63-68 (1992)); Regland, B. et al. (Med. Hypoth. 38:11-19 (1992)) and Johnson, S. A. (In: Review of Biological Research in Aging, Vol. 4., Rothstein, M. (Ed.), Wiley-Liss, NY, 163-170 (1990)).
  • Parkinson's disease (“PD”) is a neurodegenerative disease especially affecting the dopaminergic neurons of the substantia nigra—pars compacta—and its nigrostriatal projections in nearly one million Americans. The symptomatic manifestations are motor disorders such as tremor, muscular rigidity, bradykinesia, poor balance, and walking problems. Secondary symptoms include depression, sleep disturbances, dizziness, stooped posture, constipation, dementia, and problems with speech, breathing, swallowing, and sexual function symptoms.
  • Amyotrophic lateral sclerosis (“ALS”), also known as Lou Gehrig's disease or Charcot syndrome, is a progressive motor neuron disease characterized by both upper and lower motor neuron damage. The disease is characterized by degeneration of motor neurons in the cortex, brainstem and spinal cord (Principles of Internal Medicine, 1991 McGraw-Hill, Inc., New York; Tandan et al. Ann. Neurol., 18:271-280, 419-431, 1985). Generally, the onset is between the third and sixth decade, typically in the sixth decade. Symptoms may include tripping, stumbling and falling, loss of muscle control and strength in hands and arms, difficulty speaking, swallowing and/or breathing, chronic fatigue, and muscle twitching and/or cramping. Symptoms of upper motor neuron damage include stiffness (spasticity), muscle twitching (fasciculations), and muscle shaking (clonus). Symptoms of lower motor neuron damage include muscle weakness and muscle shrinking (atrophy).
  • The use of certain chroman-ylmethylamino derivatives for the treatment of Parkinson's disease and epilepsy has been disclosed in U.S. Pat. Nos. 5,663,294; 5,541,199; 5,670,667; 5,684,039; 5,756,521; 6,235,774; and 6,331,561. The use of chromans for treating mitochondria associated diseases including Alzheimer's disease, diabetes mellitus, Parkinson's disease, neuronal and cardiac ischemia, Huntington's disease, and stroke is disclosed in U.S. Pat. Nos. 6,498,191 and 6,511,966 and U.S. patent application US 2003/0176448. Triphenyl phosphonium tocopherol analogs having cardioprotective or mitochondrially targeted antioxidant properties have been described by Gisar, J M in EP 545,283 and by Murphy, M. in Annals of the New York Academy of Sciences (2002), 959, 263-274 and in U.S. Pat. No. 6,331,532, US 2202/00523242 and US 2003/0069208.
  • The use of antioxidants targeted to mitochondria shown to be effective at slowing disease progression has been reported by Jauslin, M L in FASEB Journal, express article 10.1096/fj.03-0240fje. Therapeutic benefit of administering γ-tocopherol derivatives and metabolites as antioxidants and nitrogen oxide scavengers which treat high blood pressure, thromboembolic diseases, cardiovascular disease, cancer, natriuretic disease, formation of neuropathological lesion and reduced immune system response are disclosed in U.S. Pat. Nos. 6,555,575; 6,242,479; 6,150,402; and 6,410,589. The use of certain chroman derivatives in cosmetic and dermatological preparations is disclosed in US 2002/0127252. Beneficial effects of Vitamin E in the progression of a number of major degenerative diseases of the nervous system is examined in Fryer, Nutritional Neuroscience, (1998) Vol.1, 327-351.
  • The present invention addresses the desire to provide new therapies for conditions characterized by mitochondrial dysfunction. The present invention particularly addresses the method of treating or ameliorating the symptoms of Friedreich's ataxia, a condition affecting young children, for which there is no effective cure or treatment. Most children afflicted by this debilitating condition, Friedreich's ataxia, die in or before early adulthood.
    • SUMMARY OF THE INVENTION
  • It has surprisingly been found that certain compounds limit or prevent damage to organelles, cells, and tissues caused by mitochondrial dysfunction, oxidative stress or neuroinflammation, as demonstrated by providing protection in standard experimental models of mitochondrial dysfunction caused by MPP+/MPTP (1-methyl-4-phenylpyridinium/1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine) or of oxidative stress caused by beta amyloid or high glutamate. These compounds show protection in the experimental model using FRDA fibroplasts and may be used for the treatment of Friedreich's disease and other ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), macular degeneration, Down's syndrome, Creutzfeldt-Jakob syndrome.
  • In a first aspect, the present invention relates to the method of treating or ameliorating a subject suffering from a mitochondrial disorder comprising administering to said subject a therapeutically effective amount of a compound of Formula I or Formula II:
    Figure US20050065099A1-20050324-C00001
    wherein:
      • -A-B— is —CH2—CH2—; —CH═CH— or —CH2—O—;
      • n is 0;
      • R1 is C1-4 alkyl;
      • R2 is C1-20 alkyl or C2-20 alkenyl, halogen, cyano, or R2 and A together with the atoms to which they are attached form a ring;
      • R3 is
        • hydrogen;
        • halogen;
        • aralkyl, optionally substituted with one or more substituents selected from alkyl, haloalkyl, hydroxy, alkoxy, halogen, oxo, cyano, nitro, amino, —SO2NR2 or —C(O)OR;
        • heteroaralkyl optionally substituted with one or more substituents selected from alkyl, haloalkyl, hydroxy, alkoxy, halogen, oxo, cyano, nitro, amino, —SO2NR2 or —C(O)OR;
        • C1-6 alkyl;
        • C2-20 alkenyl;
        • —(CR2)1-3S(O)0-2(CR2)1-3C(O)OR;
        • —(CR2)1-3ORa;
        • —(CR2)1-3NRbRc
        • —C(O)Ra; or
        • nitro;
      • R4 is hydrogen; optionally substituted C1-6 alkyl; C2-12 alkenyl; hydroxyalkyl; acyl; glucoside; phosphoryl; phosphoryloxyalkyl; carboxyalkylcarbonyl; or aminoalkylcarbonyl;
      • R5 and R6 are independently of each other hydrogen, halogen, haloalkyl, nitro, acyl, C1-6 alkyl or C2-12alkenyl; or R5 and R6 taken together with the carbon to which they are attached form a 5-6 membered aliphatic, unsaturated or aromatic ring, optionally substituted with C1-6 alkyl, C1-6 alkoxy, hydroxy, carboxy, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, or hydroxyalkyl;
      • R is hydrogen or C1-6 alkyl;
      • Ra is hydrogen; optionally substituted C1-6 alkyl; optionally substituted C2-12 alkenyl; optionally substituted aryl; optionally substituted cycloalkyl; or optionally substituted saturated, partially unsaturated or unsaturated heterocyclyl;
      • Rband Rc are independently of each other hydrogen; C1-6 alkyl; hydroxyalkyl; aminoalkyl; optionally substituted aryl; optionally substituted benzyl; or optionally substituted heterocyclyl; or Rb and Rc taken together with the atom to which they are attached may form a 5 to 8 membered aromatic, saturated or unsaturated ring, optionally incorporating one additional atom chosen from N, O, or S and optionally substituted with a substituent selected from the group consisting of lower alkyl, halo, cyano, alkylthio, lower alkoxy, oxo, phenyl, benzyl and carboxy;
      • with the proviso that the compound is not alpha-tocopherol;
        or
        Figure US20050065099A1-20050324-C00002
        wherein:
      • G is —O—, —S—, —SO—, —SO2—, a secondary or tertiary amine group, a phosphate group, a phosphoester group, or an unsubstituted or substituted methylene group,
      • R7 and R8 independently are hydrogen, hydroxy, alkyl, aryl, alkenyl, alkynyl, aromatic, ether, ester, unsubstituted or substituted amine, amide, halogen or unsubstituted or substituted sulfonyl, or jointly complete a 5- or 6-member aliphatic or aromatic ring,
      • R9 and R10 independently are hydrogen, hydroxy, alkyl, aryl, alkenyl, alkynyl, aromatic, ether, ester, unsubstituted or substituted amine, amide, halogen or unsubstituted or substituted sulfonyl, or jointly complete a 5- or 6-member aliphatic, aromatic or heterocyclic ring,
      • R11 is hydrogen, hydroxy, alkyl, aryl, alkenyl, alkynyl, aromatic, ester or unsubstituted or substituted amine,
      • R12 is —COOH, —COOR13, —CONH2, —CONHR13 , CONR13R14, —NH2, —NHR13, —NR13R14, or a carboxylate salt,
      • R13 and R14 independently are unsubstituted or substituted alkyl, aryl, alkaryl, aralkyl, alkenyl or alkynyl,
      • p is 0 to 3, and
      • m is 0 to 5;
        or
      • single stereoisomers, mixtures of stereoisomers, or pharmaceutically acceptable salts thereof.
  • In a preferred embodiment the method of treating or ameliorating a subject suffering from a mitochondrial disorder comprises administering to said subject a therapeutically effective amount of a compound of Formula I; in another preferred embodiment the method comprises administering a compound of Formula I wherein R3 is hydrogen, C1-6 alkyl, or C2-20 alkenyl and in another embodiment the the method comprises administering a compound of Formula I wherein R5 and R6are C1-4 alkyl or halogen, preferably wherein R5 and R6 are C1-4 alkyl or halogen and R1 is C1-6 alkyl and R2 is C1-20 alkyl. In another embodiment, the method comprises administering a compound of Formula I wherein R1 is C1-6 alkyl and R2 is C16 alkyl or C16 alkenyl, and in yet another embodiment the method comprises administering a compound of Formula I wherein R5 and R6 taken together with the carbon to which they are attached form a 5-6 membered carbocyclic ring, which may be optionally substituted with C1-6 alkyl, C1-6 alkoxy, hydroxy, carboxy, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, or hydroxyalkyl.
  • In another preferred embodiment the method of treating or ameliorating a subject suffering from a mitochondrial disorder comprises administering to said subject a therapeutically effective amount of a compound of Formula II; and in another preferred embodiment the method comprises administering a compound of Formula II wherein R12 is —COOH or —COOR13 and R13 is C1-6 alkyl.
  • In a preferred embodiment, the invention relates to a method of treating or ameliorating a subject suffering from disorders including but not limited to a disease involving mitochondrial disorders selected from Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy by administering to said subject a therapeutically effective amount of a compound of Formula I or Formula II or a pharmaceutically acceptable salt thereof. In a more preferred embodiment the invention relates to a method of treating or ameliorating a subject suffering from Friedreich's ataxia, MELAS, or MERFF by administering to said subject a therapeutically effective amount of a compound of Formula I or Formula II.
  • In another preferred embodiment the treatment comprises protecting or ameliorating a subject in need of protection of Friedreich's ataxia comprising administering a therapeutically effective amount of a tocopherol selected from beta-tocopherol, delta-tocopherol, gamma-tocopherol, alpha-tocotrienol, beta-tocotrienol, delta-tocotrienol, or gamma-tocotrienol.
  • Particularly preferred are those methods of treatment and uses in the manufacture of pharmaceutical compositions therefor, wherein the compound of Formula I or Formula II is selected from the preferred compounds, and particularly from the compounds selected from:
      • 2,2,7,8-Tetramethyl-2H-chromen-6-ol;
      • 3-(6-Hydroxy-2-methyl-3,4-dihydro-2H-benzo[h]chromen-2-yl)-propionic acid;
      • 3-(5-Bromo-6-hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid methyl ester;
      • 2,7,8-Trimethyl-5-morpholin4-ylmethyl-2-(4,8,12-trimethyl-tridecyl)-chroman-6-ol;
      • 5-(4-Benzyl-piperazin-1-ylmethyl)-2,7,8-trimethyl-2-(4,8,12-trimethyl-tridecyl)-chroman-6-ol;
      • 3-(7,8-Dihydroxy-2-methyl-chroman-2-yl)-propionic acid;
      • 5-[3-(6-Hydroxy-2,7,8-trimethyl-chroman-2-yl)-propyl]-thiazolidine-2,4-dione;
      • 2-Hydroxymethyl-2,5,7,8-tetramethyl-chroman-6-ol;
      • 3-(6-Hydroxy-2,2,7,8-tetramethyl-chroman-5-ylmethylsulfanyl)-2-methyl-propionic acid;
      • 2-Hydroxymethyl-6-(6-hydroxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-tetrahydro-pyran-3,4,5-triol;
      • 3-(6-Hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid;
      • 3-(6-Hydroxy-2-methyl-chroman-2-yl)-propionic acid methyl ester;
      • 3-(6-Hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid methyl ester;
      • 3-[8-(2-Methoxycarbonyl-ethyl)-3,5,6,8-tetramethyl-1,2,3,8,9,10-hexahydro-pyrano[3,2-f]chromen-3-yl]-propionic acid methyl ester;
      • 3-[8-(2-Carboxy-ethyl)-3,5,6,8-tetramethyl-1,2,3,8,9,10-hexahydro-pyrano[3,2-f]chromen-3-yl]-propionic acid;
      • 3-(6-Hydroxy-2-methyl-chroman-2-yl)-propionic acid;
      • 3-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-yl)-propionic acid;
      • 3-(2,5,7,8-Tetramethyl-chroman-2-yl)-propionic acid;
      • 3-(6-Hydroxy-2,7,8-trimethyl-5-nitro-chroman-2-yl)-propionic acid;
      • 3-(5-Bromo-6-hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid;
      • 3-[6-Hydroxy-2,7,8-trimethyl-5-(3-methyl-but-2-enyl)-chroman-2-yl]-propionic acid;
      • 3-(6-Hydroxy-2,8-dimethyl-chroman-2-yl)-propionic acid;
      • 2,2,7,8-Tetramethyl-chroman-6-ol;
      • 2,2,7,8-Tetramethyl-5-(3-methyl-but-2-enyl)-chroman-6-ol;
      • 2,2,7,8-Tetramethyl-5-(3-methyl-butyl)-chroman-6-ol;
      • (6-Hydroxy-2,2,7,8-tetramethyl-chroman-5-ylmethylsulfanyl)-acetic acid methyl ester;
      • 2-(2-Chloro-ethyl)-2,7,8-trimethyl-chroman-6-ol;
      • 2-(3-Chloro-propyl)-2,7,8-trimethyl-chroman-6-ol;
      • 2-(2-Chloro-ethyl)-2,7,8-trimethyl-chroman-6-ol;
      • 2-(2-Chloro-ethyl)-2,7,8-trimethyl-5-(3-methyl-but-2-enyl)-chroman-6-ol;
      • 1-(6-Hydroxy-2,2,7,8-tetramethyl-chroman-5-ylmethyl)-pyrrolidine-2-carboxylic acid methyl ester;
      • 2,2,5,8-Tetramethyl-chroman-6-ol;
      • 7-Bromo-2,2,5,8-tetramethyl-chroman-6-ol;
      • 2,2,7,8-Tetramethyl-5-(3-methyl-pentyl)-chroman-6-ol;
      • 2,2,5,8-Tetramethyl-7-(3-methyl-butyl)-chroman-6-ol;
      • 5-Isopropoxymethyl-2,2,7,8-tetramethyl-chroman-6-ol;
      • 5-Hexyloxymethyl-2,2,7,8-tetramethyl-chroman-6-ol;
      • 5-tert-Butoxymethyl-2,2,7,8-tetramethyl-chroman-6-ol;
      • 3-(5-Bromo-6-hydroxy-2-methyl-3,4-dihydro-2H-benzo[h]chromen-2-yl)-propionic acid
      • 2-(2-Hydroxy-ethyl)-2,7,8-trimethyl-chroman-6-ol;
      • Disodium salt of Phosphoric acid mono-[2,2,7,8-tetramethyl-5-(3-methyl-butyl)-chroman-6-yloxymethyl]ester;
      • 2-(6-Hydroxy-2,2,7,8-tetramethyl-chroman-5-ylmethyl)-propane-1,3-diol;
      • 6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-carbonitrile;
      • 2,2,5,7,8-Pentamethyl-2H-chromen-6-ol;
      • 2-Ethynyl-2,5,7,8-tetramethyl-chroman-6-ol;
      • 10-Methoxy-2,2-dimethyl-3,4-dihydro-2H-benzo[h]chromen-6-ol;
      • 5-(2-Hydroxy-ethyl)-2,2,7,8-tetramethyl-chroman-6-ol;
      • (6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-yl)-morpholin-4-yl-methanone;
      • 5-(1-Hydroxy-ethyl)-2,2,7,8-tetramethyl-chroman-6-ol;
      • 5-Hydroxymethyl-2,2,7,8-tetramethyl-chroman-6-ol;
      • 2,2,5,7-Tetramethyl-8-nitro-chroman-6-ol;
      • 6-Hydroxy-2,2,5,7-tetramethyl-chroman-8-carbaldehyde;
      • 2,2,7,8-Tetramethyl-5-nitro-chroman-6-ol;
      • 2,2,5,7-Tetramethyl-8-(3-methyl-but-2-enyl)-chroman-6-ol;
      • 8-Fluoro-2,2,5,7-tetramethyl-chroman-6-ol;
      • 2,2,5,7-Tetramethyl-8-(3-methyl-butyl-chroman-6-ol;
      • 5-Methoxy-2,2,7,8-tetramethyl-chroman-6-ol;
      • 8-tert-Butyl-2,2,5-trimethyl-chroman-6-ol;
      • 2,2,5,7-Tetramethyl-8-trifluoromethyl-chroman-6-ol;
      • Acetic acid 2,2,5-trimethyl-3,4-dihydro-2H-benzo[h]chromen-6-yl ester;
      • 7-tert-Butyl-2-(3-chloro-propyl)-2-methyl-chroman-6-ol;
      • 2-(3-Chloro-propyl)-8-isopropyl-2,5-dimethyl-chroman-6-ol;
      • 5-Chloro-2-(3-chloro-propyl)-2,8-dimethyl-chroman-6-ol;
      • 8-Chloro-2-(3-chloro-propyl)-2,5-dimethyl-chroman-6-ol;
      • 3-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-yl)-propionic acid methyl ester;
      • 2,5,8-trimethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol;
      • 2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol;
      • 2,8-Dimethyl-2-(4,8,12-trimethyl-tridecyl)-chroman-6-ol;
      • 2,5,7,8-Tetramethyl-2-(4,8,12-trimethyl-trideca-3,7,11-trienyl)-chroman-6-ol;
      • 2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3,7,11-trienyl)-chroman-6-ol;
      • 2,7,8-trimethyl-2-(4,8,12-trimethyl-trideca-3,7,11-trienyl)-chroman-6-ol;
      • 2,8-dimethyl-2-(4,8,12-trimethyl-trideca-3,7,11-trienyl)-chroman-6-ol;
      • or single stereoisomers, mixtures of stereoisomers, or pharmaceutically acceptable salts thereof.
  • Certain embodiments of the invention provide novel and preferred combinations of substituent groups pendant from the formulae of the different inventions
    • DETAILED DESCRIPTION OF THE INVENTION
      • Definitions
  • As used in the present specification, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.
  • The term “optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, “optionally substituted alkyl” means either “alkyl” or “substituted alkyl,” as defined below.
  • It will be understood by those skilled in the art with respect to any group containing one or more substituents that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical and/or physically non-feasible.
  • The term “acyl” refers to the groups —C(O)—H, —C(O)-(optionally substituted alkyl), —C(O)-(optionally substituted cycloalkyl), —C(O)-(optionally substituted alkenyl), —C(O)-(optionally substituted cycloalkenyl), —C(O)-(optionally substituted aryl), and —C(O)-(optionally substituted heterocyclyl).
  • The term “alkenyl” refers to a monoradical branched or unbranched, unsaturated or polyunsaturated hydrocarbon chain, having from about 2 to 20 carbon atoms, more preferably about 2 to 10 carbon atoms. This term is exemplified by groups such as ethenyl, but-2-enyl, 3-methyl-but-2-enyl (also referred to as “prenyl”, octa-2,6-dienyl, 3,7-dimethyl-octa-2,6-dienyl (also referred to as “geranyl”), and the like.
  • The term “alkoxy” refers to the groups —O-alkyl, —O-alkenyl, —O-cycloalkyl, —O-cycloalkenyl, and —O-alkynyl. Preferred alkoxy groups are —O-alkyl and include, by way of example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like.
  • The term “alkyl” refers to a monoradical branched or unbranched saturated hydrocarbon chain preferably having from about 1 to 20 carbon atoms, more preferably about 1 to 10 carbon atoms, and even more preferably about 1 to 6 carbon atoms. The term “alkyl” also means a combination of linear or branched and cyclic saturated hydrocarbon radical consisting solely of carbon and hydrogen atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, n-hexyl, n-decyl, tetradecyl, and the like. The term “lower alkyl refers to a monoradical branched or unbranched saturated hydrocarbon chain of 1 to 6 atoms.
  • The term “substituted alkyl” refers to an alkyl group in which 1 or more (up to about 5, preferably up to about 3) hydrogen atoms is replaced by a substituent independently selected from the group: ═O, ═S, acyl, acyloxy, optionally substituted alkoxy, optionally substituted amino (wherein the amino group may be a cyclic amine), azido, carboxyl, (optionally substituted alkoxy)carbonyl, (optionally substituted amino)carbonyl, cyano, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, halogen, hydroxyl, nitro, sulfamoyl, sulfanyl, sulfinyl, sulfonyl, and sulfonic acid. One of the preferred optional substituents for alkyl is hydroxy, exemplified by hydroxyalkyl groups, such as 2-hydroxyethyl, 3-hydroxypropyl, 3-hydroxybutyl, 4-hydroxybutyl, and the like; dihydroxyalkyl groups (glycols), such as 2,3-dihydroxypropyl, 3,4-dihydroxybutyl, 2,4-dihydroxybutyl, and the like; aminoalkyl groups such as dimethyl aminoalkyl, piperidinylalkyl, morpholinylalkyl, and those compounds known as polyethylene glycols, polypropylene glycols and polybutylene glycols, and the like. Another preferred optional substituent for alkyl is sulfanyl exemplified by allylsulfanyl, carboxypropylsulfanyl, 2-methyl-propionyl-pyrrolidine-2-carboxylic acid, 5-methyl-1-H-benzimidazol-2-yl-sulfanyl, sulfoxyethylsulfanyl, 4,6-dimethyl-pyrimidin-2-ylsulfanyl, 4 carboxy-benzyl-sulfanyl, isobutylsulfanyl, and the like. Other preferred optional substituents for alkyl are —N-hydroxyureidyl, —N-hydroxythioureidyl or —N-hydroxyacetamide.
  • The term “amino” refers to the group —NH2 as well as to the groups —NHR or —NRR where each R is independently selected from the group: optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted cycloalkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, acyl, optionally substituted alkoxy, carboxy and alkoxycarbonyl, and where —NRR may be a cyclic amine.
  • The term “amino acid” or “natural amino acid” refers to any of the twenty (20) common amino acids as generally accepted in the peptide art.
  • The term “aralkyl” refers to the moiety “-alkylene-aryl” each having the meaning as defined herein.
  • The term “aryl” refers to an aromatic cyclic hydrocarbon group of from 6 to 20 carbon atoms having a single ring (e.g., phenyl) or multiple condensed (fused) rings (e.g., naphthyl or anthryl). Preferred aryls include phenyl, naphthyl and the like.
  • The term “substituted aryl” refers to an aryl group as defined above, which unless otherwise constrained by the definition for the aryl substituent, is substituted with from 1 to 5 substituents, and preferably 1 to 3 substituents, independently selected from the group consisting of: hydroxy, thiol, acyl, acyloxy, optionally substituted alkenyl, optionally substituted alkoxy, optionally substituted alkyl (such as tri-halomethyl), optionally substituted alkynyl, optionally substituted amino, optionally substituted aryl, optionally substituted aryloxy, azido, carboxyl, (optionally substituted alkoxy)carbonyl, (optionally substituted amino)carbonyl, cyano, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, halogen, optionally substituted heterocyclyl, optionally substituted heterocyclooxy, hydroxyl, nitro, sulfanyl, sulfinyl, sulfanyl, and sulfonic acid. Preferred aryl substituents include alkyl, alkenyl, alkoxy, halo, cyano, nitro, trihalomethyl, carboxy, amino, amido, sulfonamido, and sulfinyl.
  • The term “carbonyl” refers to the di-radical “—C(═O)—”, which is also illustrated as “—C(O)—”.
  • The term “(optionally substituted amino)carbonyl” refers to the group —C(O)-(optionally substituted amino). This moiety is also referred to as a primary, secondary or tertiary carboxamide.
  • The term “carboxy” or “carboxyl” refers to the moiety “—C(O)OH”, which is also illustrated as “—COOH”.
  • The term “cycloalkyl” refers to non-aromatic cyclic hydrocarbon groups of having about 3 to 40 (preferably about 4 to 15) carbon atoms having a single ring or multiple condensed or bridged rings. Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like, or multiple ring structures such as adamantanyl, and the like. The term “cycloalkyl” additionally encompasses spiro systems wherein the cycloalkyl ring has a carbon ring atom in common with another ring.
  • The term “halo” or “halogen” refers to fluoro, chloro, bromo and iodo.
  • The terms “heterocycle”, “heterocyclic”, “heterocyclo”, and “heterocyclyl” refer to a monovalent, saturated, partially unsaturated or unsaturated (aromatic), carbocyclic radical having one or more rings incorporating one, two, three or four heteroatoms within the ring (chosen from nitrogen, oxygen, and/or sulfur). Preferred heterocycles include morpholine, piperidine, piperazine, thiazole, thiazolidine, isothiazole, oxazole, isoxazole, pyrazole, pyrazolidine, pyrazoline, imidazole, imidazolidine, benzothiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrrole, pyrrolidine, quinoline, quinazoline, purine, carbazole, benzimidazole, pyrimidine, thiophene, benzothiophene, pyran, tetrahydropyran, benzopyran, furan, tetrahydrofuran, indole, indoline, indazole, xanthene, thioxanthene, acridine, quinuclidine, and the like.
  • The terms “substituted heterocycle”, “substituted heterocyclic”, “substituted heterocyclo” and “substituted heterocyclyl” refer to a heterocycle group as defined above, which unless otherwise constrained by the definition for the heterocycle, is substituted with from 1 to 5 substituents, and preferably 1 to 3 substituents, independently selected from the group consisting of: hydroxy, thiol, acyl, acyloxy, optionally substituted alkenyl, optionally substituted alkoxy, optionally substituted alkyl (such as tri-halomethyl), optionally substituted alkynyl, optionally substituted amino, optionally substituted aryl, optionally substituted aryloxy, azido, carboxyl, (optionally substituted alkoxy)carbonyl, (optionally substituted amino)carbonyl, cyano, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, halogen, optionally substituted heterocyclyl, optionally substituted heterocyclooxy, hydroxyl, nitro, sulfanyl, sulfinyl, and sulfonic acid. Preferred substituted heterocycles include thiazolidine-2,4-dione and 3-methyl-5-oxo-4,5-dihydro-1H-pyrazol.
  • The term “heterocycloalkyl” refers to the moiety “-alkylene-heterocycle” each having the meaning as defined herein.
  • The term “substituted heterocycloalkyl” refers to the moiety” -(optionally substituted alkylene)-(optionally substituted heterocycle)”, each having the meaning as defined herein.
  • The term “mitochondrial diseases or disorders” of which hundreds of varieties have been identified—can cause a complex variety of symptoms. These include muscle weakness, muscle cramps, seizures, food reflux, learning disabilities, deafness, short stature, paralysis of eye muscles, diabetes, cardiac problems and stroke—like episodes, to name a few. The symptoms can range in severity from life-threatening to almost unnoticeable, sometimes taking both extremes in members of the same family. Because some people have specific subsets of these symptoms, clinical researchers have grouped those that occur together into “syndromes,” producing a bewildering array of descriptive acronyms such as MELAS (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes) or MERFF (myoclonus epilepsy with ragged red fibers). This term also includes disorders such as Kearns-Sayre syndrome (KSS), Leigh's syndrome, maternally inherited Leigh's syndrome (MILS), Myogastrointestinal encephalomyopathy (MNGIE), Neuropathy, ataxia and retinitis pigmentosa (NARP), Friedreich's ataxia (FRDA), amyotrophic lateral sclerosis (ALS) and other motor neuron diseases, Huntington's disease, macular degeneration, epilepsy, Alzheimer's, Leber's hereditary optic neuropathy (LHON), Progressive external ophthalmoplegia (PEO), and Pearson syndrome.
  • The term “neurodegenerative disorders” refers to disorders characterized by a loss of neurons and may or may not include an inflammatory process. Neurodegenerative disorders include stroke, head trauma, cerebral hypoxia, spinal cord injury, senile dementia, Alzheimer's disease, amyotrophic lateral sclerosis (ALS) and other motor neuron diseases, cerebral amyloid angiopathy, HIV-related dementia, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, Down's syndrome, Creutzfeldt-Jakob disease, Friedreich's ataxia (FRDA), Fergusson and Critchley's ataxia and other ataxias, Leber's hereditary optic neuropathy diabetic neuropathy (LHON), neuropathic pain, encephalitis, meningitis, and Duchenne's muscular dystrophy.
  • The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • The term “pharmaceutically acceptable salt” refers to salts which retain the biological effectiveness and properties of the compounds of this invention and which are not biologically or otherwise undesirable. In many cases, the compounds of this invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto. Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases, include by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, cycloalkyl amines, di(cycloalkyl) amines, tri(cycloalkyl) amines, substituted cycloalkyl amines, disubstituted cycloalkyl amine, trisubstituted cycloalkyl amines, cycloalkenyl amines, di(cycloalkenyl) amines, tri(cycloalkenyl) amines, substituted cycloalkenyl amines, disubstituted cycloalkenyl amine, trisubstituted cycloalkenyl amines, aryl amines, diaryl amines, triaryl amines, heterocyclic amines, diheterocyclic amines, triheterocyclic amines, mixed di- and tri-amines where at least two of the substituents on the amine are different and are selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heterocyclic, and the like. Also included are amines where the two or three substituents, together with the amino nitrogen, form a heterocyclic group.
  • Specific examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.
  • Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.
  • The term “seizure” is used herein as meaning the physical affliction characterized by transient clouding of consciousness, generally associated with a disturbance in the electrical activity of the cortex of the brain. Illustrative of such seizures are those associated with petit mal epilepsy.
  • The term “therapeutically effective amount” refers to that amount of a compound of this invention that is sufficient to effect treatment, as defined below, when administered to a mammal in need of such treatment. The therapeutically effective amount will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the particular compound chosen, the dosing regimen to be followed, timing of administration, the manner of administration and the like, all of which can readily be determined by one of ordinary skill in the art.
  • The term “tocopherol” means any of a family of molecules (including both tocopherols and tocotrienols and derivatives therof) which are characterized by a chroman-6-ol ring structure and a side chain at the 2-position. Tocopherols possess a 4′,8′,12′-trimethyltridecyl phytyl side chain and the trocotrienols differ by the presence of double bonds at 3′,7′,11″ positions of the side chain. The chemical names for the tocopherols are:
      • beta-tocopherol: 2,5,8-trimethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol;
      • gamma-tocopherol: 2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol;
      • delta-tocopherol: 2,8-dimethyl-2-(4,8,12-trimethyl-tridecyl)-chroman-6-ol;
      • alpha-tocotrienol: 2,5,7,8-tetramethyl-2-(4,8,12-trimethyl-trideca-3,7,11-trienyl)-chroman-6-ol
      • beta-tocotrienol: 2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3,7,11-trienyl)-chroman-6-ol;
      • gamma tocotrienol: 2,7,8-trimethyl-2-(4,8,12-trimethyl-trideca-3,7,11-trienyl)-chroman-6-ol;
      • delta tocotrienol: 2,8-dimethyl-2-(4,8,12-trimethyl-trideca-3,7,11-trienyl)-chroman-6-ol.
  • The term “treatment” or “treating” means any treatment of a disease or disorder in a mammal, including:
      • preventing or protecting against the disease or disorder, that is, causing the clinical symptoms not to develop;
      • inhibiting the disease or disorder, that is, arresting or suppressing the development of clinical symptoms; and/or
      • relieving the disease or disorder that is, causing the regression of clinical symptoms.
        It will be understood by those skilled in the art that in human medicine, it is not always possible to distinguish between “preventing” and “suppressing” since the ultimate inductive event or events may be unknown, latent, or the patient is not ascertained until well after the occurrence of the event or events. Therefore, as used herein the term “prophylaxis” is intended as an element of “treatment” to encompass both “preventing” and “suppressing” as defined herein. The term “protection,” as used herein, is meant to include “prophylaxis.”
        Nomenclature
  • In general, the nomenclature used in this Application was generated using or with the help of version 2.2 of the AUTONOM™ naming package within the ChemOffice® version 7.0.3 suite of programs by CambridgeSoft Corp (Cambridge, Mass.).
    • Synthesis of the Compounds of the Invention
  • Synthetic Reaction Parameters
  • The terms “solvent”, “inert organic solvent” or “inert solvent” mean a solvent inert under the conditions of the reaction being described in conjunction therewith. Solvents employed in synthesis of the compounds of the invention include, for example, methanol (“MeOH”), acetone, water, acetonitrile, 1,4-dioxane, dimethylformamide (“DMF”), benzene, toluene, tetrahydrofuran (“THF”), chloroform, methylene chloride (also named dichloromethane( (“DCM”), diethyl ether, ethyl acetate (“EtOAc”), pyridine and the like, as well as mixtures thereof. Unless specified to the contrary, the solvents used in the reactions of the present invention are inert organic solvents.
  • The term “q.s.” means adding a quantity sufficient to achieve a stated function, e.g., to bring a solution to the desired volume (i.e., 100%).
  • Unless specified to the contrary, the reactions described herein take place at atmospheric pressure within a temperature range from 0° C. to 110° C. (preferably from 0° C. to 25° C.; most preferably at “room” or “ambient” temperature (“RT”), e.g., 20° C.). Further, unless otherwise specified, the reaction times and conditions are intended to be approximate, e.g., taking place at about atmospheric pressure within a temperature range of about 0° C. to about 110° C. (preferably from about 0° C. to about 25° C.; most preferably at about “room” or “ambient” temperature, e.g., approximately 20° C.) over a period of about 1 to about 10 hours (preferably about 5 hours).
  • Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had by reference to the examples herein below. However, other equivalent separation or isolation procedures can also be used.
  • Some compounds of the present invention are available commercially or can be synthesized as known in the art. Some exemplary syntheses of compounds of this invention are also described in Examples.
    • Preferred Compounds
  • The compounds of Formula I or Formula II encompass the chroman derivatives of the invention as disclosed, and/or the pharmaceutically acceptable salts of such compounds. In addition, the compounds of this invention include the individual stereochemical isomers and mixtures thereof, arising from the selection of substituent groups. It will be understood by those skilled in the art with respect to any group containing one or more substituents that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical and/or synthetically non-feasible.
  • Preferred for the compounds, pharmaceutical formulations, methods of manufacture and use of the present invention are the following combinations and permutations of substituent groups of Formula I and Formula II.
    • Utility, Testing and Administration
  • General Utility
  • Compound, compositions, formulations, and methods of the present invention are useful for the treatment of disorders characterized by defective mitochondrial activity. In particular, compounds of the present invention can be used in the treatment of diseases such as degenerative diseases of the brain ((Wernicke-Korsakoff disease, Kreuzfeldt-Jakob disease (KJD), Hallervorden-Spatz disease, Schilder's disease, Alzheimer's disease, senile dementia, Down's syndrome in middle age, Abercrombie's disease, Prion diseases, Zellweger syndrome, Alper's Syndrome), spinocerebellar degenerations (spinal ataxia, cerebellar cortical degenerations, Friedreich's ataxia (FRDA) and other ataxias), multiple system degenerations (Menzel, Dejerine-Thomas, Shy-Drager, and Machado Joseph), systemic disorders (Refsum disease, ataxia telangiectasia), epilepsy, mitochondrial disorders (MELAS, MERFF, KSS, Leigh's, MILS, MNGIE, NARP, PEO, Pearson), demyelinating core disorders (multiple sclerosis, acute transverse myelitis), muscular atrophies (amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), infantile spinal muscular atrophy, Huntington's disease, spinobulbar atrophy (SBA), juvenile spinal muscular atrophy, myasthenia gravis and other motor neuron diseases), movement disorder (drug-induced Parkinsonism or Parkinson's disease), retinopathy (Leber's hereditary optic neuropathy, age-related macular degeneration (AMD), cataracts), cerebral ischemia (“stroke” most often caused by thrombosis, vasoconstriction and embolism), myocardial ischemia (including chronic stable angina, angina pectoris, unstable angina and Prinzmetal's angina, silent ischemia, reinfarction, reocclusion, restenosis, myocardial infarction and other forms of heart disease), diabetes, renal disease, pre-menstrual syndrome (PMS), asthma, cardiopulmonary inflammatory disorders, chronic heart failure, rheumatoid arthritis, muscle fatigue, irritable bowel syndrome, inflammatory bowel disease, intermittent claudication and for the preservation of allograft tissue for transplantation. Certain compounds of the present invention are also useful in treating conditions falling with the group of dermatologic conditions, in particular prevention and protecting skin tissue against age-related damage or damage resulting from insults such as harmful ultraviolet (UV) radiation, stress and fatigue, and in the treatment of contact dermatitis, skin irritation, skin pigmentation, psoriasis, or acne.
  • Testing
  • This section describes how compositions incorporating compositions of the present invention are selected, using in vitro and/or in vivo animal models, for example, and used as therapeutic interventions in the exemplary indications, i.e., stroke, epilepsy, Parkinson's disease, Friedreich's ataxia, MELAS, macular degeneration, ALS, and Alzheimer's disease.
  • MPTP/MPP+-induced neurodegeneration of dopaminergic neurons is a well characterized model which is therefore widely used to understand the pathogenesis of Parkinson's disease. The compounds were tested on MPTP/MPP+ induced neuronal death in vitro and in vivo as shown in the following examples.
  • In vitro evaluation of protection against mitochondrial dysfunction is carried out using substantia nigra-derived dopaminergic progenitor cell line as described in Son J H, et al J W. (1999) J Neurosci, 19: 10-20, exposed to 1-methyl-4-phenylpyridinium (MPP+)
  • In vivo evaluation is carried out using mice that have been treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin. MPTP is metabolized by astrocytes into 1-methyl-4-phenylpyridinium (MPP+), a substrate for the dopamine transporter which then selectively inhibits complex 1 of the mitochondrial electron transport chain. This results in depletion of ATP, the production of reactive oxygen species and, consequently cell death. In a number of species, including humans, non-primates and rodents, MPTP produces an irreversible and severe parkinsonian syndrome which includes virtually all the clinical features of the disease. The striking pathologic and clinical similarities between idiopathic Parkinson's disease and MPTP-induced Parkinsonism suggest that the two disorders share common pathogenic mechanism.
  • A cellular assay using FRDA-patient derived fibroblasts (as described by Jauslin, M L et al, Human Molecular Genetics 11; 3055-3063 (2002)); is used to determine the cell protecting effect of the test compounds by analyzing survival of dermal fibroblasts taken from FRDA patients and unaffected normal donors under conditions of partial GSH depletion. Exposure of FRDA fibroblasts to BSO (L-buthionine (S,R)-sulfoximine) under conditions of restricted selenium causes depletion of cellular glutathione (GSH) and severe plasma membrane damage leading to cell death. Preincubation with the test compounds before the addition of BSO is used to determine if they can protect FRDA cells from BSO-mediated cell death.
  • Protection against redox stress can be further evaluated in cell culture using high glutamate induced oxidative stress (HGOS) in mouse dopaminergic cell lines. The cytotoxic effect of glutamate is not due to excitotoxicity, as this cell line is devoid of inotropic glutamate receptors. Rather, the glutamate-induced toxicity of dopaminergic cells is associated with an inhibition of cystine transport which subsequently leads to depletion of intracellular glutathione (GSH) levels (Murphy T. H., et al. Neuron 2, 1547-1558, 1989), activation of neuronal 12-lipoxygenase (Li, Y. et al., Neuron 19,453-463, 1997), increased ROS production (Tan S. et al., J. Cell Biol. 141, 1423-1432, 1998) and elevated intracellular Ca2+ (Li, Y. et al., see supra). Some molecules were measured for their ability to protect such cells against glutamate-induced stress and the assay is detailed in Examples.
  • In addition IL-1 elevation has been associated with many neurodegenerative diseases. There is increasing evidence for a role of IL-1 in Alzheimer's Disease (AD) (Mrak R E et al. Neurobiol Aging 22(6):903-908, 2001). Elevated levels of IL-1β have been shown to surround amyloid plaques in the disease and recent genetic studies have indicated that a polymorphism in IL-1α is linked to an increased risk of AD (3-6 fold increase) (Griffin W S et al., J Leukoc Biol 72(2):233-238, 2002). This polymorphism has also been correlated with rate of cognitive decline in AD patients (Murphy G M et al., Neurology, 56(11)1595-1597, 2001). The risk of AD is increased even further when the polymorphism in IL-1.alpha. is found in combination with another polymorphism in IL-1β (see Griffin W S, supra), providing convincing evidence that these cytokines play an important role in the pathology of the disease.
  • This assay measures the release of IL-1β from a mouse microglial cell line following an inflammatory challenge with LPS and interferon-gamma. The ability of test articles to inhibit microglial cell activation and IL-1β release is determined by co-incubation of the test article with the inflammatory challenge. Cytokine release is measured using a mouse IL-1β ELISA and cell toxicity is determined using Cell Tracker Green (a fluorescent dye that measures cell viability).
  • Cerebral ischemic insults are modeled in animals by occluding vessels to, or within, the cranium (Molinari, G. F., 1986, in H. J. M. Barnett, et al., (Eds) Stroke: Pathophysiology, Diagnosis and Management, Vol. 1, Churchill Livingstone, N.Y.). The rat middle cerebral artery occlusion (MCAO) model is one of the most widely used techniques to induce transient focal cerebral ischemia approximating cerebral ischemic damage in humans, e.g., those who suffer from a stroke. The middle cerebral artery used as the ischemic trigger in this model is the most affected vessel in human stroke. The model also entails a period of reperfusion, which typically occurs in human stroke victims. MCAO involving a two-hour occlusion has been found to produce the maximum size of cortical infarction obtainable without increased mortality at twenty-four hours.
  • Further validation of efficacy in neuroprotection can be assessed in functional tests, such as the grip strength test or the rotorod test. Animals treated with compounds that show neuroprotection maintain their pre-MCAO grip strength values after MCAO, as compared to untreated animals, which showed a significant reduction in grip strength, indicating loss of sensorimotor function. Likewise, animals treated with compounds that show neuroprotection also maintained their pre-MCAO rotorod activity scores after MCAO, as compared to untreated animals, which showed a significant reduction in rotorod scores, indicating loss of sensorimotor function at higher brain levels.
  • Administration
  • The compounds of this invention are administered at a therapeutically effective dosage, e.g., a dosage sufficient to provide treatment or amelioration for the disease states previously described. Administration of the compounds of the invention or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration for agents that serve similar utilities.
  • While human dosage levels have yet to be optimized for the compounds of the invention, generally, a daily dose is from about 0.01 to 10.0 mg/kg of body weight, preferably about 0.1 to 5. mg/kg of body weight, and most preferably about 0.3 to 1.0 mg/kg of body weight. The amount of active compound administered will, of course, be dependent on the subject and disease state being treated, the severity of the affliction, the manner and schedule of administration and the judgment of the prescribing physician.
  • In employing the compounds of this invention for treatment or amelioration of the above conditions, any pharmaceutically acceptable mode of administration can be used. The compounds of this invention can be administered either alone or in combination with other pharmaceutically acceptable excipients, including solid, semi-solid, liquid or aerosol dosage forms, such as, for example, tablets, capsules, powders, liquids, suspensions, suppositories, aerosols or the like. The compounds of this invention can also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills, transdermal (including electrotransport) patches, and the like, for the prolonged administration of the compound at a predetermined rate, preferably in unit dosage forms suitable for single administration of precise dosages. The compositions will typically include a conventional pharmaceutical carrier or excipient and a compound of this invention or a pharmaceutically acceptable salt thereof. In addition, these compositions may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, and the like, including, but not limited to anticoagulants, blood clot dissolvers, permeability enhancers and slow release formulations.
  • Generally, depending on the intended mode of administration, the pharmaceutically acceptable composition will contain about 0.1% to 90%, preferably about 0.5% to 50%, by weight of a compound or salt of Formulae I or II, the remainder being suitable pharmaceutical excipients, carriers, etc.
  • One preferred manner of administration for the conditions detailed above is oral, using a convenient daily dosage regimen which can be adjusted according to the degree of affliction. For such oral administration, a pharmaceutically acceptable, non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, magnesium carbonate, and the like. Such compositions take the form of solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations and the like.
  • Preferably the compositions will take the form of a pill or tablet and thus the composition will contain, along with the active ingredient, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose and derivatives thereof, and the like.
  • Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, or solubilizing agents, pH buffering agents and the like, for example, sodium acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 15th Edition, 1975. The composition or formulation to be administered will, in any event, contain a quantity of the active compound in an amount effective to alleviate the symptoms of the subject being treated.
  • Dosage forms or compositions containing active ingredient in the range of 0.005% to 95% with the balance made up from non-toxic carrier may be prepared.
  • For oral administration, a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, talcum, cellulose derivatives, sodium crosscarmellose, glucose, sucrose, magnesium carbonate, sodium saccharin, talcum and the like. Such compositions take the form of solutions, suspensions, tablets, capsules, powders, sustained release formulations and the like. Such compositions may contain 0.01%-95% active ingredient, preferably 0.1-50%.
  • For a solid dosage form, the solution or suspension, in for example propylene carbonate, vegetable oils or triglycerides, is preferably encapsulated in a gelatin capsule. Such diester solutions, and the preparation and encapsulation thereof, are disclosed in U.S. Pat. Nos. 4,328,245; 4,409,239; and 4,410,545. For a liquid dosage form, the solution, e.g. in a polyethylene glycol, may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, e.g. water, to be easily measured for administration.
  • Alternatively, liquid or semi-solid oral formulations may be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene glycol esters (e.g. propylene carbonate) and the like, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells.
  • Other useful formulations include those set forth in U.S. Pat. No. Re. 28,819 and U.S. Pat. No. 4,358,603.
  • The formulation can be administered in a single unit dosage form for continuous treatment or in a single unit dosage form ad libitum when relief of symptoms is specifically required. For example, the formulation may be administered as a bolus or as a continuous intravenous infusion after onset of symptoms of stroke, myocardial infarction or chronic heart failure.
  • Another preferred manner of administration is the topical administration. “Topical administration” refers to application of the present compositions by spreading, spraying, etc. onto the surface of the skin. The typical amount applied may vary from about 0.1 mg of composition per square centimeter of skin to about 25 mg of composition per square centimeter of skin. The compounds of the present invention may be formulated for topical administration to the epidermis as ointments, creams or lotions or as transdermal patch. Formulations suitable for topical administration in the mouth include lozenges, pastilles and mouthwashes.
  • Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like. In addition, if desired, the pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, solubility enhancers, and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, cyclodextrins, etc.
  • A more recently devised approach for parenteral administration employs the implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained; see, e.g., U.S. Pat. No. 3,710,795. The percentage of active compound contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject. However, percentages of active ingredient of 0.01% to 10% in solution are employable, and will be higher if the composition is a solid which will be subsequently diluted to the above percentages. Preferably the composition will comprise 0.2-2% of the active agent in solution.
  • Nasal solutions of the active compound alone or in combination with other pharmaceutically acceptable excipients can also be administered.
  • Formulations of the active compound or a salt may also be administered to the respiratory tract as an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case, the particles of the formulation have diameters of less than 50 microns, preferably less than 10 microns.
    • EXAMPLES
  • The following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.
  • General Characterization Methods
  • As reported in the following examples, Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker DTX 300 spectrometer using, in most cases, tetramethyl silane (TMS) as the internal reference. Mass spectra were obtained on an Agilent 1100 LC/MSD instrument using either electrospray ionization (positive or negative mode) (ESI) or atmospheric pressure chemical ionization (positive or negative mode) (APCI).
    • Example 1 Beta-Amyloid Cell Death Assay
  • Media Composition
  • Neurobasal/B27i: Neurobasal medium plus 1×B27 supplement, 0.5 mM L-glutamine, 25 μM L-glutamic acid, and 0.5× Penicillin/Streptomycin
  • Neurobasal/B27m: Neurobasal medium plus 1×B27 supplement and 0.5 mM L-glutamine
  • BSS (Ca/Mg free): HBSS (calcium/magnesium free) plus 10 mM Hepes (pH 7.25), 1× Penicillin/Streptomycin, and 1 mM Sodium Pyruvate
  • Glucose-free BSS0: 143.6 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgSO4, 1 mM NaH2PO4, 26.2 mM NaHCO3, 10 mg/l phenol red, 0.25× Penicillin/Streptomycin, and 10 mM Hepes (pH 7.4)
  • Papain Quench solution: Neurobasal medium plus 1×B27 supplement, 1× Penicillin/Streptomycin and 0.5 mg/ml DNase1
  • Assay media: Neurobasal medium plus 1×B27 (minus AO) supplement, 0.5 mM L-glutamine, and 0.25× Penicillin/Streptomycin.
  • Experimental Procedure
  • Hippocampal Cell Culture
  • Hippocampal neurons were isolated from E18 rat embryos as follows. Embryos were decapitated and the heads immersed in cold BSS (Ca/Mg free). Using a dissecting microscope the hippocampi were dissected out and placed in cold BSS (Ca/Mg free). The isolated hippocampi were then centrifuged at 1000 rpm for 2 min, the BSS aspirated off and 2 ml of 2 mg/ml Papain in Neurobasal media added per 10 embryos. After mixing on a rotational shaker for 10 min at 37° C., 5 ml Papain Quench solution was added. Cells were then centrifuged at 1000 rpm for 2 min, the supernatant was aspirated and 2 ml of Neurobasal/B27i was added. The cells were triturated 6 times with siliconized pipettes (decreasing bore size) after which an additional 5 ml Neurobasal/B27i was added. The cell suspension was then centrifuged at 1000 rpm for 2 min, the supernatant was aspirated and 2 ml of Neurobasal/B27i was added. Cells were triturated again as described above and the volume of Neurobasal/B27i was adjusted to 1 ml/embryo. Cells were then counted and seeded at a density of 75,000 cells per well in a poly-D-lysine coated 24-well plate. After four days media was removed from the cells and replaced with Neurobasal/B27m media+5 μM Ara-C (cytosine arabinoside). Seven days after isolation the media was removed again and replaced with fresh Neurobasal/B27m media. Ten days after isolation the hippocampal cultures were used in the assay described below.
  • Preparation of Oligomeric Beta-Amyloid (Aβ) Peptide
  • Aggregation of Aβ(1-42) (American Peptide Co, Sunnyvale, Calif.) into oligomers was carried out according to the method of Dahlgren et al, (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277: 32046-32053. The Aβ peptide was dissolved to 1 mM in hexafluoroisopropanol (HFIP) and aliquoted into sterile microcentrifuge tubes. The HFIP was removed under vacuum and the peptide film stored at −20° C. The day before the assay, the peptide film was resuspended in dry DMSO to a concentration of 5 mM. Ham's F-12 media was then added to bring the peptide to a final concentration of 100 μM, and this solution was incubated at 4° C. for 24 hours to allow formation of oligomers.
  • Treatment of HippocamDal Neurons with Oligomeric Aβ
  • The existing growth medium was aspirated from the hippocampal cultures and the monolayer was washed once with 500 μl glucose free-BSS0. Test articles were diluted to 2-fold the desired testing concentration in assay media and 250 μL was added to the cells. From the 100 μM oligomeric beta-amyloid peptide solution described above, a working solution of 6 μM was made in assay media. 250 μL of this working solution was also added to the cells. The final volume for each well was 500 μL and the final concentration of Aβ peptide was 3 μM. As a negative control, cells were incubated with 500 μL assay media with no additions.
  • Cells were incubated in a 39° C. incubator (5% CO2) for 24 hours. After this time, the number of live neurons remaining in each well was determined using a fluorescent vital cell stain, Cell Tracker Green (Molecular Probes, Eugene, Oreg.). Assay media was aspirated from the cells and 400 μL of 2.5 μM Cell Tracker Green was added to each well. Cells were placed in a 37° C. incubator for 5 minutes after which time the cell stain was aspirated off and 500 μl of HBSS (Invitrogen, Life Technologies, Carlsbad, Calif.) was added to each well. The number of live cells in each well was then quantitated using an automated fluorescent microscope/imaging system (Universal Imaging, Downingtown Pa.).
  • Certain compounds of the present invention such as
      • 2,2,7,8-Tetramethyl-chroman-6-ol; and
      • 3-(5-Bromo-6-hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid methyl ester;
        when tested as described above exhibited assay between 10% and 40% protection in the β amyloid cell assay
    Example 2 MPP+Cell Death Assay
  • Media Composition
  • RF media: DMEM-No glucose, glucose (29.1 mM), L-glutamine (1.4 mM), 10% heat-inactivated FBS, and 1× penicillin/streptomycin (P/S)
  • Wash media: DMEM-No glucose and 1×P/S
  • Low serum media: DMEM-No glucose, glucose (29.1 mM), L-glutamine (1.4 mM), 0.5% FBS, and 1×P/S
  • Assay Media: DMEM-No glucose, L-glutamine (1.4 mM), 0.5% FBS, and 1×P/S
  • Experimental Procedure
  • A substantia nigra-derived dopaminergic progenitor cell line was seeded in poly-D-lysine-coated 24-well plates at a density of 4500 cells per well in RF media. The cells were left to attach for 16 hours in a 33° C. incubator (5% CO2) after which time they were washed once with 500 μL wash media and then differentiated into a neuronal phenotype by incubating in low serum media for 24 hours in a 39° C. incubator (5% CO2).
  • After 24 hours the low serum medium was aspirated from the cells and the monolayer was washed once with 500 μL wash media. Test articles were diluted to 2-fold the desired testing concentration in assay media and 250 μL was added to the cells. From a 10 mM stock, a working solution of 140 μM 1-methyl-4-phenylpyridinium (MPP+) (Sigma, St. Louis, Mo.) was made in assay media and 250 μL of this working solution was also added to the cells. The final volume in each well was 500 μL and the final concentration of MPP+was 70 μM. As a negative control, cells were incubated with 500 μL assay media with no additions.
  • Cells were incubated in a 39° C. incubator (5% CO2) for 24 hours. After this time, the number of live neurons remaining in each well was determined using a fluorescent vital cell stain, Cell Tracker Green (Molecular Probes, Eugene, Oreg.). Assay media was aspirated from the cells and 400 μL of 2.5 μM Cell Tracker Green was added to each well. Cells were placed in a 37° C. incubator for 5 minutes after which time the cell stain was aspirated off and 500 μL of HBSS (Invitrogen Life Technologies, Carlsbad, Calif.) was added to each well. The number of live cells in each well was then quantitated using an automated fluorescent microscope/imaging system (University Imaging, Downingtown Pa.)
  • Results:
  • Certain compounds of the present invention such as
      • 2,2,7,8-Tetramethyl-chroman-6-ol;
      • 4-[1-(Carboxymethyl-carbamoyl)-2-mercapto-ethylcarbamoyl]-2-[3-(6-hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionylamino]-butyric acid;
      • 3-(5-Bromo-6-hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid methyl ester;
      • 2,2,-Dimethyl-3,4,7,8,9,10-hexahydro-7,10-methano-2H-benzo[h]chromen-6-ol;
      • Tetramethyl-5-(3-methyl-butyl)-chroman-6-ol;
      • 5,6,9-Trimethyl-8-oxa-tricyclo[7.3.1.02,7]trideca-2,4,6-trien4-ol;
      • (6-Hydroxy-2,2,7,8-tetramethyl-chroman-5-ylmethylsulfanyl)-acetic acid methyl ester;
      • 2-Methyl-2-thiophen-2-yl-3,4,7,8,9,10-hexahydro-7,10-methano-2H-benzo[h]chromen-6-ol;
      • 2-(2-Chloro-ethyl)-2,7,8-trimethyl-5-(3-methyl-but-2-enyl)-chroman-6-ol; and
      • 2,2-Dimethyl-5-(3-methyl-but-2-enyl)-3,4,7,10-tetrahydro-7,10-ethano-2H-benzo[h]chromen-6ol
        when tested as described above provided protection in at least 30%, preferably in at least 50% of the cells tested at concentrations ranging from 1 to 25 μM.
    Example 3 MPTP Animal Model
  • Male C57/BL6 mice (Harlan, Ind.), weight 25-30 g, were used in all studies. MPTP-HCl (Sigma) was administered i.p. according to one of the following protocols. The maximum volume which was given per injection is 200 μL. In all studies, animals were euthanized with carbon dioxide and, brains were removed for subsequent determination of dopamine depletion where appropriate.
  • Subacute Model
  • Animals received 25 mg/kg of MPTP once a day for 5 consecutive days. The end point was 2 days after the final dose.
  • Acute Model
  • Animals received 4×20 mg/kg of MPTP at 2 hour intervals. The end point was at either 7 or 14 days.
  • Subchronic Model
  • Animals received 2×40 mg/kg of MPTP with this repeated 16 hours later. The end point was at either 14 or 28 days.
  • Chronic Model
  • Animals received 25 mg/kg of MPTP, given twice weekly for 5 weeks. The end point was either 1, 3 or 24 weeks after the final dose.
  • Neurobehavioral Outcome Measures
  • Compound efficacy was examined with the use of neurobehavioral models. These models allowed the determination of a given compound's ability to reverse the motor deficits seen with MPTP treatment.
  • All animals received pre-training for the individual model and a baseline reading was obtained one day prior to the commencement of MPTP treatment.
  • Open Field Test
  • The open field test measures spontaneous activity. Deficits can be observed with hippocampal and basal ganglia lesions, and with hindlimb dysfunction. It is sensitive to moderate dopamine (DA) depletion.
  • The open field test was carried out in a clear, acrylic open box 60 cm×60 cm. The base of the box was marked into a 5×5 grid of 12 cm×2 cm squares. Animals were individually placed in the box and allowed to roam free. The number of squares an animal crossed in a 90 second time period was recorded. In order to be scored, the animal must either have had all four limbs within a given square or, all four limbs must have left a given square.
  • Tactile Adhesion Model
  • The tactile adhesion model measures an animal's ability to complete a complex sensorimotor task. It is sensitive to moderate to severe DA depletion.
  • A tactile stimulus (0.5×0.5 cm square of “sticky tape”) was applied to each side of the animal's face and the time taken to remove it is recorded. The following measurements were recorded:
      • a. Latency to contact left side tape
      • b. Latency to contact right side tape
      • c. Order of side contacted (left vs. right)
      • d. Latency to remove left side tape
      • e. Latency to remove right side tape
        Pole Test
  • The pole test evaluates motor co-ordination.
  • A rough surfaced metal pole (diameter 8 mm, height 50 cm) protruding from a cage filled with animal bedding was used for this test. Animals were placed head upwards at the top of the pole. They were required to turn and descend face downwards and the time taken for this was recorded (latency to reach bedding). Timing was started when the individual animal gripped the top of the pole and was stopped when all four limbs contacted the bedding.
  • Compound Administration
  • All test compounds were administered ip. The maximum volume which was given per injection was 200 μL. Compounds were dosed up to twice daily, two days prior and 7 days post MPTP treatment.
  • Data Analysis
  • A baseline reading was taken for each animal one day prior to MPTP treatment. All subsequent readings were normalized to the individual animal's baseline. Values were expressed as a percent baseline.
  • Data was percent baseline and expressed as mean±std dev:
  • Summary
  • Compound and vehicle given for 9 days in total, 2 days prior to MPTP and 7 days after MPTP treatment. L-DOPA given 1 hour prior to the pole test, each day.
  • Results
  • Certain compounds of the present invention such as
      • 2,2,7,8-Tetramethyl-2H-chromen-6-ol;
      • 3-(5-Bromo-6-hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid methyl ester;
      • 3-[6-Hydroxy-2,7,8-trimethyl-5-(3-methyl-but-2-enyl)-chroman-2-yl]-propionic acid;
      • 3-(6-Hydroxy-2,8-dimethyl-chroman-2-yl)-propionic acid;
      • 2,2,7,8-Tetramethyl-5-(3-methyl-but-2-enyl)-chroman-6-ol;
      • (6-Hydroxy-2,2,7,8-tetramethyl-chroman-5-ylmethylsulfanyl)-acetic acid methyl ester.
        at a dose of 30 mg/kg/day significantly reduced the functional deficit produced by MPTP on each of days 1-3. Functional outcome was significantly better on days 1 and 2 than in vehicle treated animals and in both cases were comparable to that of the negative control group.
  • Doses of 10 mg/kg/day and 3 mg/kg/day reduced the MPTP induced deficit on days 2 and 3 but this may not be significantly different from vehicle treated animals.
    • Example 4 FRDA Fibroblast Assay for Protection from Oxidative Stress
  • A. Cell Culture and Reagents
  • Primary fibroblasts were derived from donors with a molecular diagnosis of FRDA and control donors with no mitochondrial disease. Lines F2, C2 and C3 were obtained from Coriell Cell Repositories (Camden, N.J., USA; catalog #'s GM04078, GM 08402 and GM08399, respectively). All cell types were diagnosed at the molecular level for intronic GAA triplet repeat length in the trataxin gene using a PCR-based method, according to methods known in the art. FRDA-fibroblasts types had ˜400-450 repeats (F2 line) or more (F1 and F3), whereas control cell lines displayed PCR products of normal length. The cells were seeded in microtiter plates at a density of 4000 cells per 100 μl in growth medium consisting of 25% (v/v) M199 EBS and 64% (v/v) MEM EBS without phenol red (Bioconcept, Allschwil, Switzerland) supplemented with 10% (v/v) fetal calf serum (PAA Laboratories, Linz, Austria), 100 U/ml penicillin, 100 μg/ml streptomycin (PAA Laboratories, Linz, Austria), 10 μg/ml insulin (Sigma, Buchs, Switzerland), 10 μg/ml EGF (Sigma, Buchs, Switzerland), 10 μg/ml bFGF (PreproTech, Rocky Hill, N.J., USA) and 2 mM glutamine (Sigma, Buchs, Switzerland). The cells were incubated in the presence of the various test compounds for 24 h before addition of 1 mM BSO (L-buthionine (S,R)-sulfoximine).
  • B. Cell Viability Measurements
  • Cell viability was measured after the first signs of toxicity appeared in the BSO-treated controls (typically after 16-48 h). The cells were stained for 60 min at room temperature in PBS with 1.2 μm calceinAM and 4 μm ethidium homodimer (Live/Dead assay, Molecular Probes, Eugene, Oreg., USA). Fluorescence intensity was measured with a Gemini Spectramax XS spectrofluorimeter (Molecular Devices, Sunnyvale, Calif., USA) using excitation and emission wavelengths of 485 and 525 nm, respectively.
  • C. Data and Statistics
  • In experiments carried out in support of the present invention, certain compounds such as
      • 2,2,7,8-Tetramethyl-2H-chromen-6-ol;
      • 4-[1-(Carboxymethyl-carbamoyl)-2-mercapto-ethylcarbamoyl]-2-[3-(6-hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionylamino]-butyric acid);
      • 3-(5-Bromo-6-hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid methyl ester;
      • 2-Amino-4-{1-(carboxymethyl-carbamoyl)-2-[6-hydroxy-2,7,8-trimethyl-2-(4,8,12-trimethyl-tridecyl)-chroman-5-ylmethylsulfanyl]-ethylcarbamoyl}-butyric acid;
      • 5-[3-(6-Hydroxy-2,7,8-trimethyl-chroman-2-y)-propyl]-thiazolidine-2,4-dione;
      • Delta tocopherol;
      • Delta tocotrienol;
      • Gamma-tocopherol;
      • Gamma-tocotrienol;
      • 3-(6-Hydroxy-2,8-dimethyl-chroman-2-yl)-propionic acid;
      • 2,2,7,8-Tetramethyl-5-(3-methyl-butyl)-chroman-6-ol;
      • 2-(2-Chloro-ethyl)-2,7,8-trimethyl-chroman-6-ol;
      • 2-(2-Chloro-ethyl)-2,7,8-trimethyl-5-(3-methyl-but-2-enyl)-chroman-6-ol; and
        significantly reduced cell death in FRDA fibroblasts compared to untreated FRDA fibroblasts with an EC50 of between 0.01 μM and 6 μM.
    Example 5 High Glutamate-Induced Oxidative Stress Assay (HGOS)
  • This procedure was used to induce high glutamate-induced oxidative stress (HGOS) in a dopaminergic neuronal cell line. Using this assay the potency and efficacy of test articles against HGOS neuronal cell injury and cell death was established in a high throughput manner.
  • Materials
  • Dopaminergic neuronal cell lines
  • DMEM-No Glucose (Life Technologies Cat #11966-025)
  • L-glutamine (Life Technologies Cat #25030-081)
  • L-glutamic acid, monosodium salt (Sigma Cat #G5889)
  • D-glucose (Sigma Cat #G-6151)
  • 10×HBSS buffer(pH 7.4) (950 ml Pyrogen-free water, 2.44 g/L MgCl2.6H20, 3.73 g/L KCl, 59.58 g/L Hepes, 58.44 g/L NaCl, 1.36 g/L KH2PO4, 1.91 g/L CaCl2.2H2O and pH to 4.5 with HCl)
  • Cell Tracker Green fluorescent dye (Molecular Probes, Cat #2925). Prepare a 5 μM solution in pre-warmed HBSS just prior to use.
  • Sterile 96-well plates precoated with poly-D-lysine (Corning Catalog #3665)
  • 96-well deep well mother plate, DyNA Block 1000 (VWR Catalog #40002-008)
  • Neuronal Cells
  • The cells were seeded into 96-well plates at a density of 2000 per well and left to grow for 72 hours in a 33° C. incubator with 5% CO2 in air atmosphere. The passage number of the cells for each assay experiment were no later than p11 in order to minimize experimental variation.
  • Compound PreDaration in Deep-Well Mother Plates
  • VWRBrand DyNA Block 1000, deep well mother plates (VWR Cat. #40002-008) were used for the preparation of the test compounds.
  • All compounds were dissolved in DMEM-No Glu containing 1 mM glucose, 30 mM glutamate and 1× Pen/Strep. DMEM-No Glu with 1 mM glucose and 1×P/S was used as the negative control, DMEM-No Glucose with 1 mM glucose, 100 M glutamate was used as a positive control and 100 μM Glutathione was added to the positive control as a standard. All of the procedures for this involving the making and dilution of compounds were performed using aseptic conditions and with minimal light.
  • Cell Preparation
  • The plates were removed from the incubator and examined under the microscope for morphological appearance and density. Using an aseptic technique and an 8-channel aspirator the media was carefully removed from the cells and replaced with 200 μl of 1×HBSS. This was done as quickly as possible to prevent the cells drying out. The plates were then placed in the humidified 37° C. incubators of the Biomek 2000 Side Loader. Four plates were washed at a time so as to minimize the time that the cells were sitting in 1×HBSS prior to addition of the compound test solution.
  • Experimental Setup
  • The Beckman Biomek workstations were used to load the compounds and controls from the mother plates onto the cell plates that were prewashed with HBSS under sterile conditions. The plates were incubated in the upper HTS incubator at 37° C. in 5% CO2 for exactly 16 hrs. The following day, using the Beckman Biomek workstations, the plates were removed from the incubator. Using Cell Tracker Addition, the compounds were removed from the plates, washed once with 200 μM of pre-warmed 1×HBSS and then 100 μL of 5 μM Cell Tracker Green was added to each well. The plates were incubated at 37° C. for 30 min to allow the dye to enter the cell and be cleaved by the esterases. After washing the cells twice with prewarmed 1×HBSS, the plates were read with the 485 excitation; 538 emission filter pair on a Fluoroskan.
  • Certain compounds of the present invention such as:
      • 6-Hydroxy-2,2,5,7-tetramethyl-chroman-8-carbaldehyde;
      • 2,2,5,7-Tetramethyl-8-nitro-chroman-6-ol;
      • 5-(1-Hydroxy-ethyl)-2,2,7,8-tetramethyl-chroman-6-ol;
      • 5-Hydroxymethyl-2,2,7,8-tetramethyl-chroman-6-ol;
      • 5-(2-Hydroxy-ethyl)-2,2,7,8-tetramethyl-chroman-6-ol;
      • 10-Methoxy-2,2-dimethyl-3,4-dihydro-2H-benzo[h]chromen-6-ol;
      • 2-Ethynyl-2,5,7,8-tetramethyl-chroman-6-ol;
      • 2-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-N-(3-trifluoromethyl-phenyl)-acetamide;
      • (6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-yl)-piperazin-1-yl-methanone;
      • 6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxamidine;
      • N-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-ylmethyl)-N-methyl-acetamide;
      • 2,2,5,7,8-Pentamethyl-2H-chromen-6-ol;
      • 2-(6-Hydroxy-2,2,7,8-tetramethyl-chroman-5-ylmethyl)-propane-1,3-diol;
      • 2-(2-Chloro-ethyl)-2,7,8-trimethyl-5-(3-methyl-but-2-enyl)-chroman-6-ol;
      • 2,2,5,8-Tetramethyl-chroman-6-ol;
      • 2-(3-Chloro-propyl)-2,7,8-trimethyl-chroman-6-ol;
      • 2-(2-Chloro-ethyl)-2,7,8-trimethyl-chroman-6-ol;
      • 2-(2-Chloro-ethyl)-2,7,8-trimethyl-chroman-6-ol;
      • (6-Hydroxy-2,2,7,8-tetramethyl-chroman-5-ylmethylsulfanyl)-acetic acid methyl ester;
      • 5,6,9-Trimethyl-8-oxa-tricyclo[7.3.1.02,7]trideca-2,4,6-trien-4-ol;
      • 2,2,7,8-Tetramethyl-5-(3-methyl-butyl)-chroman-6-ol;
      • 3-(5-Bromo-6-hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid;
      • 2-Hydroxymethyl-2,5,7,8-tetramethyl-chroman-6-ol;
      • 5-[3-(6-Hydroxy-2,7,8-trimethyl-chroman-2-yl)-propyl]-thiazolidine-2,4-dione;
      • 5-(4-Benzyl-piperazin-1-ylmethyl)-2,7,8-trimethyl-2-(4,8,12-trimethyl-tridecyl)-chroman-6-ol;
      • 3-(5-Bromo-6-hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid methyl ester;
      • 3-(6-Hydroxy-2-methyl-3,4-dihydro-2H-benzo[h]chroman-2-yl)-propionic acid; and
      • 2,2,7,8-Tetramethyl-chroman-6-ol;
        were considered to be active when they exhibited protection against HGOS cell injury and cell death with an EC50 in a range of 5 μM or less.
    Example 6 2-(2-chloro-ethyl)-2,7,8-trimethyl-chroman-6-ol
  • Figure US20050065099A1-20050324-C00003
    Step 1:
  • To a solution of 4-chloro-butanone-2 (2.65 g, 25 mmol) in 25 ml of THF at −20° C. was added dropwise a solution of 1M vinyl magnesium bromide (40 ml, 40 mmol). After the completion of addition the mixture was stirred for one more hours at room temperature. To the mixture was added 10 ml of water at 0° C. with stirring. The mixture was dried over MgSO4. After the removal of the solvent, the residue was purified via flash column purification with 1:3 ethyl acetate and hexane as elute to afford 800 mg of 5-chloro-3-methyl-pent-1-en-3-ol. 1H-NMR (300 MHz, CDCl3) δ (ppm): 5.86-5.90 (dd, 1H); 5.29 (d, 1H), 5.13 (d, 1H), 3.50-3.59 (t, 3H); 1.87-1.83 2.18 (m, 2H); 1.63-1.69 (m, 2H), 1.31 (s, 3H)
  • Step 2:
  • A mixture of, 2,3-dimethyl-dihydroquinone (794 mmol), 1.0 ml (3.97 mmol) of BF3.Et2O and 25 ml of dioxane was heated up to 110° C. under a nitrogen atmosphere. A solution of 5-chloro-3-methyl-pent-1-en-3-ol (1.12 g, 8.6 mmol) in 24 ml of dioxane was added slowly to the mixture. The addition was completed after two hours and the mixture was continued to reflux for an additional 3 hours. After cooling down to room temperature, the mixture was poured to water, extracted with ethyl acetate, washed with water and dried over MgSO4. After the removal of solvents, the residue was mixed with methanol/HCl and let stirred overnight at room temperature. After the removal of the solvents the residue was purified via flash column chromatography (1:3 EtOAc/Hex) twice to give 2-(2-chloro-ethyl)-2,7,8-trimethyl-chroman-6-ol 1H-NMR (300 MHz, CDCl3) δ (ppm): 6.39 (s. 1H), 4.26 (S, 1H), 3.80-3.65 (m, 2H), 2.85-2.70 (m, 2H), 2.16 (s, 3H), 2.12 ( s, 3H), 2.20-2.05 (m, 2H), 1.85-1.75 (m, 2H) 1.31 (s, 3H). MS: 255 (M+H+, 100%)
    • Example 7 2,2,7,8-Tetramethyl-4H-benzo[1,3]dioxin-6-ol
  • Figure US20050065099A1-20050324-C00004
    Step 1
  • To a mixture of 2,3-dimethylhydroquinone (1.38 g, 10 mmol), K2CO3 (2.76 g, 20 mmol), potassium iodide (0.83 g, 5 mmol) in 50 mL dry acetone was added benzyl bromide (1.88 g, 11 mmol). The resulting suspension was vigorously stirred for 48 at RT. The solid was filtered off and the liquid was concentrated. The residue was chromatographed to afford the benzyl derivative, 4-benzyloxy-3-methyl-phenol, as a light brown solid (1.15 g). 1H-NMR (300 MHz, CDCl3) δ (ppm): 7.49-7.35 (m, 5 H), 6.70 (d, J=8.7, 1 H), 6.61 (d, J=8.7, 1 H), 5.03 (s, 2 H), 4.43 (s, 1 H), 2.26 (s, 3 H), 2.22 (s, 3 H); MS (ESI) m/z 229 (M+H+, 100%).
  • Step 2:
  • To 684 mg (3 mmol) of 4-benzyloxy-3-methyl-phenol in 10 mL toluene and 1.5 mL DME (dimethoxyethane) in a sealable tube was added paraformaldehyde (1.8 g, 60 mmol). The tube was flushed with argon and sealed. It was heated to 130° C. for 48 h under stirring. After cooling to room temperature, the solid was filtered off and washed with 1:1 hexane/EtOAc and the liquid was concentrated. The residue was chromatographed to afford 4-benzyloxy-6-hydroxymethyl-2,3-dimethyl-phenol, as a light brown solid (640 mg). 1H-NMR (300 MHz, CDCl3/CD3OD)) δ (ppm): 7.43-7.29 (m, 5 H), 6.55 (s, 1 H), 4.95 (s, 2 H), 4.70 (s, 2 H), 2.18 (s, 3 H), 2.16 (s, 3 H); MS (ESI) m/z 241 (M−OH−, 100%).
  • Step 3:
  • A solution of 4-benzyloxy-6-hydroxymethyl-2,3-dimethyl-phenol (86 mg, 0.33 mmol) in dimethoxypropane (10 mL) in the presence of toluene sulfonic acid (7 mg) was stirred at RT for 15 h. It was added 30 mg of anion-exchange resin and stirring was continued for 20 more min. The resin was then filtered off and the solution was concentrated. The crude product was purified by chromatography on a silicagel column to afford 6-benzyloxy-2,2,7,8-tetramethyl-4H-benzo[1,3]dioxine as a white sticky solid (86 mg). 1H-NMR (CDCl3, 300 MHz) δ (ppm): 7.51-7.35 (m, 5 H), 6.45 (s, 1 H), 5.02 (s, 2 H), 4.85 (s, 2 H), 2.26 (s, 3 H), 2.19 (s, 3 H), 1.59 (s, 6 H); 13C-NMR δ (ppm): 150.6, 143.3, 137.8, 128.5, 127.8, 126.3, 125.8, 115.9, 105.4, 99.1, 70.9, 61.1, 24.9, 12.2, 11.5.
  • Step 4
  • To a solution of 6-benzyloxy-2,2,7,8-tetramethyl-4H-benzo[1,3]dioxine (86 mg, 0.29 mmol) in 10 mL EtOH was added Pd/C (15 mg, 10%). It was stirred in a hydrogen atmosphere for 1.5 h and filtered. The solution was concentrated and the crude product was purified by chromatography on silicagel to afford 2,2,7,8-tetramethyl-4H-benzo[1,3]dioxin-6-ol as a white solid (54 mg). 1H-NMR (CDCl3, 300 MHz) δ (ppm): 6.28 (s, 1 H), 4.77 (s, 1 H), 4.76 (s, 2 H), 2.17 (s, 3 H), 2.13 (s, 1 H) 1.55 (s, 3 H), 1.54 (s, 3 H); 13C-NMR δ (ppm): 147.1, 142.9, 126.1, 122.7, 116.6, 107.5, 99.1, 60.9, 24.8, 11.9, 11.5.
    • Example 8 2,2,7,8-Tetramethyl-chroman-6-ol
  • Figure US20050065099A1-20050324-C00005
    Step 1
  • To a solution of 2,3-dimethylhydroquinone (2 g, 14.5 mmol) and BF3.Et2O (3.3 g, 23.2 mmol) in 30 mL of dioxane was slowly added a dilute solution of 2-methyl-but-3-en-2-ol (1.0 g, 11.6 mmol) in 10 mL of dioxane over a period of 30 min. Upon the completion of the alcohol addition, it was allowed to stir for 4 h. The reaction was quenched by pouring over ice (70 g) and the mixture was extracted with EtOAc (3×50 mL). The combined organic layers were dried over Na2SO4 and concentrated. The crude product was purified by chromatography (hexane/EtOAc=9:1) to afford 2,3-dimethyl-5-(3-methyl-but-2-enyl)-benzene-1,4-diol as a light brown oil (2 g). MS (ESI) m/z: 207 (M+H+, 100%).
  • Step 2
  • A solution of 2,3-dimethyl-5-(3-methyl-but-2-enyl)-benzene-1,4-diol (2.54 g, 12.3 mmol) and BF3.Et2O (2.8 mL, 22.4 mmol) in 50 mL dioxane was heated to reflux for 5 h. It was cooled to RT and quenched onto ice (100 g). The mixture was extracted with EtOAc (3×60 mL) and dried over Na2SO4. The residue was purified by chromatography (Hexane/EtOAc=5:1) to afford 2,2,7,8-Tetramethyl-chroman-6-ol as a brown oil (1.5 g). 1H-NMR (300 MHz, CDCl3) δ (ppm): 6.28 (s, 1 H), 5.30 (s, 1 H), 2.6 (t, J=6.8 2 H), 2.10 (s, 3 H), 2.09 (s, 3 H), 1.70 (t, J=6.8, 2 H), 1.26 (s, 6 H); 13C-NMR δ (ppm): 145.4, 145.9, 125.8, 122.2, 118.1, 112.6, 73.6, 33.0, 27.0, 22.7, 12.1; (ESI) m/z: 207 (M+H+, 100%).
    • Example 9 2,2,7,8-Tetramethyl-5-(3-methyl-but-2-enyl)-chroman-6-ol
  • Figure US20050065099A1-20050324-C00006
  • To a solution of 2,2,7,8-tetramethyl-chroman-6-ol (305 mg, 1.39 mmol), prepared as described above, in 5 mL dry dioxane was added boron trifluoride (296 mg, 2.1 mmol). It was stirred for 3 min followed by dropwise addition of 2-methyl-but-3-en-2-ol solution (143 mg, 1.66 mmol, in 3 mL of dioxane). The reaction was allowed to stir for 5 h at RT before quenching on to ice (80 g). The mixture was extracted with DCM (3×50 mL) and the combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The crude product was purified by chromatography (hexane) to afford 2,2,7,8-tetramethyl-5-(3-methyl-but-2-enyl)-chroman-6-ol as a light brown oil (229 mg). 1H-NMR (300 MHz, CDCl3) δ (ppm): 5.16 (m, 1 H), 4.70 (s, 1 H), 3.34 (d, J=6.8, 2.18 (s, 3 H), 2.14 (s, 3 H), 1.86 (s, 3 H), 1.81 (t, J=13.8, 2 H), 1.77 (s, 3 H), 1.32 (s, 6 H); 13C-NMR δ (ppm): 145.7, 145.4, 134.1, 123.5, 122.2, 122.0, 121.8, 116.3, 72.5, 33.1, 26.7, 25.8, 20.8, 17.9, 12.1, 11.9; (ESI) m/z: 275 (M+H+, 100%).
    • Example 10 3-[6-Hydroxy-2,7,8-trimethyl-5-(3-methyl-but-2-enyl)-chroman-2-yl]-propionic acid
  • Figure US20050065099A1-20050324-C00007
  • A solution of 3-(6-hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid (150 mg, 0.557 mmol) in 1M aq. NaOH (1.11 mL, 1.11 mmol) was cooled to 0° C., and treated with prenyl bromide (0.064 mL, 0.557 mmol). Following stirring for 2 h at ambient temperature the reaction mixture was made slightly acidic with 0.5M HCl and shaken with EtOAc. The organic phase was evaporated yielding a brown residue which was subjected to column chromatography (SiO2: hexane:EtOAc, 8:2 v/v) yielded 3-[6-hydroxy-2,7,8-trimethyl-5-(3-methyl-but-2-enyl)-chroman-2-yl]-propionic acid as a pale brown solid (50 mg). 1H-NMR (300 MHz, CDCl3) δ (ppm): 5.15 (t, J=7, 1H), 3.33 (d, J=7, 2H), 2.73 (t, J=7, 2H), 2.59 (t, J=7, 2H), 2.17 (s, 3H), 2.12 (s, 3H), 1.86-2.10 (m, 2H), 1.85 (s, 3H), 1.80-1.85 (m, 2H), 1.76 (s, 3H), 1.26 (s, 3H). 13C-NMR (75 MHz, CDCl3,) δ (ppm): 180.2, 145.7, 145.2, 134.3, 123.7, 122.5, 122.0, 121.9, 116.2, 73.4, 34.4, 31.8, 28.7, 25.9, 25.6, 23.3, 20.4, 18.0, 12.2, 11.9. MS ESI-Pos m/z 333.2 (M+H+).
    • Example 11 2-Hydroxymethyl-2,5,7,8-tetramethyl-chroman-6-ol
  • Figure US20050065099A1-20050324-C00008
  • To a solution of 6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid (1.0 g, 4 mmol) in 50 mL dry THF at RT under argon atmosphere was added small portions of LiAlH4 over a period of 30 min. The reaction was stirred for 2 h and quenched on to ice water (100 mL). It was extracted with EtOAc (3×50 mL) and the combined organic layers were washed with water (100 mL). The organic solution was dried over Na2SO4 and concentrated. The residue was chromatographed with hexane/EtOAc (3:1) and the desired compound 2-hydroxymethyl-2,5,7,8-tetramethyl-chroman-6-ol was isolated as a cream-colored solid (655 mg). 1H-NMR (300 MHz, CDCl3,) δ (ppm): 4.90 (s, 1 H), 3.68 (m, 2 H), 2.70 (m, 2 H), 2.46 (m, 1 H), 2.20 (s, 3 H), 2.16 (s, 3 H), 2.15 (s, 3 H), 2.03 (m, 1 H), 1.76 (m, 1 H), 1.26 (s, 3 H); 13C-NMR δ (ppm): 145.2, 144.98, 122.6, 121.9, 119.3, 117.4, 75.2, 69.4, 27.9, 20.5, 20.4, 12.4, 12.0, 11.5; MS (ESI) m/z: 259 (M+Na+, 100%), 237 (M+H+, 45%).
    • Example 12 5-(4-Benzyl-piperazin-1-ylmethyl)-2,7,8-trimethyl-2-(4,8,12-trimethyl-tridecyl)-chroman-6-ol
  • Figure US20050065099A1-20050324-C00009
  • To a solution of bromo-tocopherol prepared as described above (1.00 g) in 25 ml of methylene chloride was added 1-benzylpiperazine (0.8 g) at room temperature. The solution was stirred at room temperature for 2 hours. More methylene chloride was added, washed with water, and dried over magnesium sulfate. Evaporation and chromatography (silica gel, methylene chloride) gave 250 mg of 5-(4-benzyl-piperazin-1-ylmethyl)-2,7,8-trimethyl-2-(4,8,12-trimethyl-tridecyl)-chroman-6-ol. 1H-NMR (300 MHz, CDCl3) δ (ppm) 7.35-7.20 (m, 5H), 3.63 (s, 2H), 3.51 (s, 2H), 2.14 (s, 3H), 2.10 (s, 3H). MS (PAl-ES) m/z 605 (M+H+, 100%).
  • Similarly replacing benzylpiperazine with other amines the following compounds were produced:
      • 2,7,8-trimethyl-5-piperazin-1-ylmethyl-2-(4,8,12-trimethyl-tridecyl)-chroman-6-ol. 1H-NMR (300 MHz, CDCl3) δ (ppm) 3.62 (s, 2H), 2.14 (s, 3H), 2.10 (s, 3H). MS (PAI-ES) m/z 515 (M+H+, 100%).
      • 2,7,8-trimethyl-5-morpholin-4-ylmethyl-2-(4,8,12-trimethyl-tridecyl)-chroman-6-ol 1H-NMR (300 MHz, CDCl3) δ (ppm) 3.74 (br. s, 4H), 3.64 (s, 2H), 2.65-2.50 (m, 6H), 2.14 (s, 3H), 2.10 (s, 3H).
      • 2,7,8-trimethyl-5-pyrrolidin-1-ylmethyl-2-(4,8,12-trimethyl-tridecyl)-chroman-6-ol; MS (ESI) m/z: 500 (M+H+, 100%), and
      • 2,7,8-trimethyl-5-piperidin-1-ylmethyl-2-(4,8,12-trimethyl-tridecyl)-chroman-6-ol; MS (ESI) m/z: 514 (M+H+, 100%)
    Example 13 2,2,7,8-Tetramethyl-2H-chromen-6-ol
  • Figure US20050065099A1-20050324-C00010
    Step 1:
  • A mixture of 2,3-dimethyl-1,4-dihydroquinone (5.0 g, mmol), acetone (80 mL), anhydrous potassium carbonate (18 g, ) and dimethyl sulfate (14 mL) was gently refluxed under nitrogen for 10 hours. The suspension was cooled to room temperature and poured into 300 mL of water. The precipitate was collected and washed with water, then dried in air to give 5.5 g of 1,4-dimethoxy-2,3-dimethyl-benzene as a purple solid.
  • Step 2:
  • A solution of 1,4-dimethoxy-2,3-dimethyl-benzene (1 g) in dichloromethane was stirred and cooled in an ice-water bath, and TiCl4 (1.1 mL) was slowly added, followed by the addition of CHCl2OCH3 (0.58 g). The solution was stirred for another 15 min with ice-water bath, 30 min at RT, then 15 min at 35° C. Then the red solution was poured into ice and extract with dichloromethane. Workup and purification by chromatography (silicagel column, eluting with EtOAc/:hexane 1:4) gave 973 mg of 2,5-dimethoxy-3,4-dimethyl-benzaldehyde.
  • Step 3:
  • A solution of 2,5-dimethoxy-3,4-dimethyl-benzaldehyde (155 mg) in dichloromethane was stirred and cooled in an ice-water bath. BBr3 (1M in CH2Cl2, 1.80 mL) was slowly added and the solution was stirred for another hour, then the red solution was poured into ice and extracted with dichloromethane. Workup and purification by chromatography (silicagel column, eluting with EtOAc/:hexane 1:4) gave 110 mg of 2,5-dihydroxy-3,4-dimethyl-benzaldehyde.
  • Step 4:
  • To a solution of 2,5-dihydroxy-3,4-dimethyl-benzaldehyde (2.0 g) in dichloromethane (50 mL) was added 3,4-dihydro-2H-pyran (DHP)(1.5 g), followed by p-toluenesulfonic acid monohydrate (200 mg). The solution was stirred at RT for 1 hour and quenched by adding 1 mL of a sodium bicarbonate solution. Then dichloromethane was dried over MgSO4 and concentrated. The residue was purified by silica gel column chromatography eluting with hexane and ethyl acetate (8:2) to give 1.5 g of 2-hydroxy-3,4-dimethyl-5-(tetrahydro-pyran-2-yloxy)-benzaldehyde.
  • Step 5:
  • A mixture of 2-hydroxy-3,4-dimethyl-5-(tetrahydro-pyran-2-yloxy)-benzaldehyde (300 mg), methyl 3,3-dimethylacrylate (300 mg), and K2CO3 (300 mg) in 10 mL of DMF was stirred at 160° C. for 5 h. After letting it cool down to room temperature, it was worked up and purified by silica gel column chromatography eluting with 5% ethyl acetate in hexane, to give the THP-protected 2,2,7,8-tetramethyl-2H-chromen-6-ol intermediate. Removal of the protection group was accomplished as described above with toluenesulfonic acid in MeOH for 5 h. Purification by chromatography (silica gel column, eluting with 15% EtOAc in hexane) gave 83 mg of colorless solid of 2,2,7,8-tetramethyl-2H-chromen-6-ol. 1H NMR (300 MHz, CDCl3) δ (ppm) d: 6.30 (s, 1H), 6.20 (d, J=9.6 Hz,1H), 5.58 (d, J=9.6 Hz, 1H), 4.50 (s, 1H, OH), 2.13, 2.12 (2s, 6H), 1.39 (s, 6H) ppm. 13C NMR (CDCl3, 75 MHz) d: 147.02, 144.56, 130.88, 125.55, 123.59, 122.47, 119.03, 109.80, 75.49, 27.57, 12.18, 11.74. MS (m/z): 205 (M+H+).
  • While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto. All patents and publications cited above are hereby incorporated by reference

Claims (14)

1. A method of treating or ameliorating a subject suffering from a mitochondrial disorder comprising administering to said subject a therapeutically effective amount of a compound of Formula I or Formula II:
Figure US20050065099A1-20050324-C00011
wherein:
-A-B— is —CH2—CH2—; —CH═CH— or —CH2—O—;
n is 0;
R1 is C1-4 alkyl;
R2 is C1-20 alkyl or C2-20 alkenyl, halogen, cyano, or R2 and A together with the atoms to which they are attached form a ring;
R3 is
hydrogen;
halogen;
aralkyl, optionally substituted with one or more substituents selected from alkyl, haloalkyl, hydroxy, alkoxy, halogen, oxo, cyano, nitro, amino, —SO2NR2 or —C(O)OR;
heteroaralkyl optionally substituted with one or more substituents selected from alkyl, haloalkyl, hydroxy, alkoxy, halogen, oxo, cyano, nitro, amino, —SO2NR2 or —C(O)OR;
C1-6 alkyl;
C2-20 alkenyl;
—(CR2)1-3S(O)0-2(CR2)1-3C(O)OR;
—(CR2)1-3ORa;
—(CR2)1-3NRbRc
—C(O)Ra; or
nitro;
R4 is hydrogen; optionally substituted C1-6 alkyl; C2-12 alkenyl; hydroxyalkyl; acyl; glucoside; phosphoryl; phosphoryloxyalkyl; carboxyalkylcarbonyl; or aminoalkylcarbonyl;
R5 and R6 are independently of each other hydrogen, halogen, haloalkyl, nitro, acyl, C1-6 alkyl or C2-12alkenyl; or R5 and R6 taken together with the carbon to which they are attached form a 5-6 membered aliphatic, unsaturated or aromatic ring, optionally substituted with C1-6 alkyl, C1-6 alkoxy, hydroxy, carboxy, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, or hydroxyalkyl;
R is hydrogen or C1-6 alkyl;
Ra is hydrogen; optionally substituted C1-6 alkyl; optionally substituted C2-12 alkenyl; optionally substituted aryl; optionally substituted cycloalkyl; or optionally substituted saturated, partially unsaturated or unsaturated heterocyclyl;
Rb and Rc are independently of each other hydrogen; C1-6 alkyl; hydroxyalkyl; aminoalkyl; optionally substituted aryl; optionally substituted benzyl; or optionally substituted heterocyclyl; or Rb and Rc taken together with the atom to which they are attached form a 5 to 8 membered aromatic, saturated or unsaturated ring, optionally incorporating one additional atom chosen from N, O, or S and optionally substituted with a substituent selected from the group consisting of lower alkyl, halo, cyano, alkylthio, lower alkoxy, oxo, phenyl, benzyl and carboxy;
with the proviso that the compound is not alpha-tocopherol;
or
Figure US20050065099A1-20050324-C00012
wherein:
G is —O—, —S—, —SO—, —SO2—, a secondary or tertiary amine group, a phosphate group, a phosphoester group, or an unsubstituted or substituted methylene group,
R7 and R8 independently are hydrogen, hydroxy, alkyl, aryl, alkenyl, alkynyl, aromatic, ether, ester, unsubstituted or substituted amine, amide, halogen or unsubstituted or substituted sulfonyl, or jointly complete a 5- or 6-member aliphatic or aromatic ring,
R9 and R10 independently are hydrogen, hydroxy, alkyl, aryl, alkenyl, alkynyl, aromatic, ether, ester, unsubstituted or substituted amine, amide, halogen or unsubstituted or substituted sulfonyl, or jointly complete a 5- or 6-member aliphatic, aromatic or heterocyclic ring,
R11 is hydrogen, hydroxy, alkyl, aryl, alkenyl, alkynyl, aromatic, ester or unsubstituted or substituted amine,
R12 is —COOH, —COOR13, —CONH2, —CONHR13, —CONR13R14, —NH2, —NHR13, —NR13R14, or a carboxylate salt,
R13 and R14 independently are unsubstituted or substituted alkyl, aryl, alkaryl, aralkyl, alkenyl or alkynyl,
p is 0 to 3, and
m is 0 to 5;
or
single stereoisomers, mixtures of stereoisomers, or pharmaceutically acceptable salts thereof.
2. The method of claim 1, comprising administering to said subject a therapeutically effective amount of a compound of Formula I.
3. The method of claim 2, comprising administering the compound of Formula I wherein R3 is hydrogen, C1-6 alkyl, or C2-20 alkenyl.
4. The method of claim 2, comprising administering the compound of Formula I wherein R5 and R6 are independently of each other C1-4 alkyl or halogen.
5. The method of claim 4, comprising administering the compound of Formula I wherein R1 is C1-6 alkyl and R2 is C1-6 alkyl.
6. The method of claim 2, comprising administering the compound of Formula I wherein R1 is C1-6 alkyl, and R2 is C16 alkyl or C16 alkenyl.
7. The method of claim 2, comprising administering the compound of Formula I wherein R5 and R6 taken together with the carbon to which they are attached form a 5-6 membered carbocyclic ring, optionally substituted with C1-6 alkyl, C1-6 alkoxy, hydroxy, carboxy, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, or hydroxyalkyl.
8. The method of claim 1, comprising administering to said subject a therapeutically effective amount of a compound of Formula II.
9. The method of claim 8, comprising administering the compound of Formula II, wherein R12 is —COOH, or —COOR13 and R13 is C1-6 alkyl.
10. The method of claim 1, comprising administering a compound selected from:
8-Chloro-2-(3-chloro-propyl)-2,5-dimethyl-chroman-6-ol;
5-Chloro-2-(3-chloro-propyl)-2,8-dimethyl-chroman-6-ol;
7-tert-Butyl-2-(3-chloro-propyl)-2-methyl-chroman-6-ol;
Acetic acid 2,2,5-trimethyl-3,4-dihydro-2H-benzo[h]chromen-6-yl ester;
2,2,5,7-Tetramethyl-8-trifluoromethyl-chroman-6-ol;
5-Methoxy-2,2,7,8-tetramethyl-chroman-6-ol;
8-Fluoro-2,2,5,7-tetramethyl-chroman-6-ol;
2,2,5,7-Tetramethyl-8-(3-methyl-butyl-chroman-6-ol;
6-Hydroxy-2,2,5,7-tetramethyl-chroman-8-carbaldehyde;
2,2,5,7-Tetramethyl-8-nitro-chroman-6-ol;
5-(1-Hydroxy-ethyl)-2,2,7,8-tetramethyl-chroman-6-ol;
5-Hydroxymethyl-2,2,7,8-tetramethyl-chroman-6-ol;
5-(2-Hydroxy-ethyl)-2,2,7,8-tetramethyl-chroman-6-ol;
10-Methoxy-2,2-dimethyl-3,4-dihydro-2H-benzo[h]chromen-6-ol;
2-Ethynyl-2,5,7,8-tetramethyl-chroman-6-ol;
2-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-N-(3-trifluoromethyl-phenyl)-acetamide;
(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-yl)-piperazin-1-yl-methanone;
6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxamidine;
N-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-ylmethyl)-N-methyl-acetamide;
2,2,5,7,8-Pentamethyl-2H-chromen-6-ol;
2-(6-Hydroxy-2,2,7,8-tetramethyl-chroman-5-ylmethyl )-propane-1,3-diol;
2-(2-Chloro-ethyl)-2,7,8-trimethyl-5-(3-methyl-but-2-enyl)-chroman-6-ol;
2,2,5,8-Tetramethyl-chroman-6-ol;
2-(2-Chloro-ethyl)-2,7,8-trimethyl-5-(3-methyl-but-2-enyl)-chroman-6-ol;
2-(3-Chloro-propyl)-2,7,8-trimethyl-chroman-6-ol;
2-(2-Chloro-ethyl)-2,7,8-trimethyl-chroman-6-ol;
2-(2-Chloro-ethyl)-2,7,8-trimethyl-chroman-6-ol;
(6-Hydroxy-2,2,7,8-tetramethyl-chroman-5-ylmethylsulfanyl)-acetic acid methyl ester;
5,6,9-Trimethyl-8-oxa-tricyclo[7.3.1.02,7]trideca-2,4,6-trien4-ol;
2,2,7,8-Tetramethyl-5-(3-methyl-butyl)-chroman-6-ol;
2,2,7,8-Tetramethyl-5-(3-methyl-but-2-enyl)-chroman-6-ol;
3-(6-Hydroxy-2,8-dimethyl-chroman-2-yl)-propionic acid;
2,2,7,8-Tetramethyl-chroman-6-ol;
3-[6-Hydroxy-2,7,8-trimethyl-5-(3-methyl-but-2-enyl)-chroman-2-yl]-propionic acid;
3-(5-Bromo-6-hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid;
3-(6-Hydroxy-2,7,8-trimethyl-5-nitro-chroman-2-yl)-propionic acid;
3-(2,5,7,8-Tetramethyl-chroman-2-yl)-propionic acid;
3-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-yl)-propionic acid;
3-(6-Hydroxy-2-methyl-chroman-2-yl)-propionic acid;
3-(6-Hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid methyl ester;
3-(6-Hydroxy-2-methyl-chroman-2-yl)-propionic acid methyl ester;
3-(6-Hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid;
2-Hydroxymethyl-2,5,7,8-tetramethyl-chroman-6-ol;
5-[3-(6-Hydroxy-2,7,8-trimethyl-chroman-2-yl)-propyl]-thiazolidine-2,4-dione;
2-Amino-4-{1-(carboxymethyl-carbamoyl)-2-[6-hydroxy-2,7,8-trimethyl-2-(4,8,12-trimethyl-tridecyl)-chroman-5-ylmethylsulfanyl]-ethylcarbamoyl}-butyric acid;
5-(4-Benzyl-piperazin-1-ylmethyl)-2,7,8-trimethyl-2-(4,8,12-trimethyl-tridecyl)-chroman-6-ol;
3-(5-Bromo-6-hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid methyl ester;
3-(6-Hydroxy-2-methyl-3,4-dihydro-2H-benzo[h]chroman-2-yl)-propionic acid;
4-[1-(Carboxymethyl-carbamoyl)-2-mercapto-ethylcarbamoyl]-2-[3-(6-hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionylamino]-butyric acid);
2,2,7,8-Tetramethyl-chroman-6-ol;
Delta tocopherol;
Delta tocotrienol;
Gamma-tocopherol;
Gamma-tocotrienol; and
Alpha tocotrienol;
or
single stereoisomers, mixtures of stereoisomers, or pharmaceutically acceptable salts thereof.
11. The method of claim 1, comprising administering a therapeutically effective amount of a compound of Formula I or of Formula II to a subject suffering from a disease involving mitochondrial dysfunctions selected from Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy.
12. The method of claim 1, comprising administering a therapeutically effective amount of a compound of Formula I or of Formula II to a subject suffering from Friedreich's ataxia (FRDA), MELAS, or MERFF.
13. The method of claim 12, comprising administering a therapeutically effective amount of a compound selected from:
8-Chloro-2-(3-chloro-propyl)-2,5-dimethyl-chroman-6-ol;
5-Chloro-2-(3-chloro-propyl)-2,8-dimethyl-chroman-6-ol;
7-tert-Butyl-2-(3-chloro-propyl)-2-methyl-chroman-6-ol;
Acetic acid 2,2,5-trimethyl-3,4-dihydro-2H-benzo[h]chromen-6-yl ester;
2,2,5,7-Tetramethyl-8-trifluoromethyl-chroman-6-ol;
5-Methoxy-2,2,7,8-tetramethyl-chroman-6-ol;
8-Fluoro-2,2,5,7-tetramethyl-chroman-6-ol;
2,2,5,7-Tetramethyl-8-(3-methyl-butyl-chroman-6-ol;
6-Hydroxy-2,2,5,7-tetramethyl-chroman-8-carbaldehyde;
2,2,5,7-Tetramethyl-8-nitro-chroman-6-ol;
5-(1-Hydroxy-ethyl)-2,2,7,8-tetramethyl-chroman-6-ol;
5-Hydroxymethyl-2,2,7,8-tetramethyl-chroman-6-ol;
5-(2-Hydroxy-ethyl)-2,2,7,8-tetramethyl-chroman-6-ol;
10-Methoxy-2,2-dimethyl-3,4-dihydro-2H-benzo[h]chromen-6-ol;
2-Ethynyl-2,5,7,8-tetramethyl-chroman-6-ol;
2-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-N-(3-trifluoromethyl-phenyl)-acetamide;
(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-yl)-piperazin-1-yl-methanone;
6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxamidine;
N-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-ylmethyl)-N-methyl-acetamide;
2,2,5,7,8-Pentamethyl-2H-chromen-6-ol;
2-(6-Hydroxy-2,2,7,8-tetramethyl-chroman-5-ylmethyl)-propane-1,3-diol;
2-(2-Chloro-ethyl)-2,7,8-trimethyl-5-(3-methyl-but-2-enyl)-chroman-6-ol;
2,2,5,8-Tetramethyl-chroman-6-ol;
2-(2-Chloro-ethyl)-2,7,8-trimethyl-5-(3-methyl-but-2-enyl)-chroman-6-ol;
2-(3-Chloro-propyl)-2,7,8-trimethyl-chroman-6-ol;
2-(2-Chloro-ethyl)-2,7,8-trimethyl-chroman-6-ol;
2-(2-Chloro-ethyl)-2,7,8-trimethyl-chroman-6-ol;
(6-Hydroxy-2,2,7,8-tetramethyl-chroman-5-ylmethylsulfanyl)-acetic acid methyl ester;
5,6,9-Trimethyl-8-oxa-tricyclo[7.3.1.02,7]trideca-2,4,6-trien4-ol;
2,2,7,8-Tetramethyl-5-(3-methyl-butyl)-chroman-6-ol;
2,2,7,8-Tetramethyl-5-(3-methyl-but-2-enyl)-chroman-6-ol;
3-(6-Hydroxy-2,8-dimethyl-chroman-2-yl)-propionic acid;
2,2,7,8-Tetramethyl-chroman-6-ol;
3-[6-Hydroxy-2,7,8-trimethyl-5-(3-methyl-but-2-enyl)-chroman-2-yl]-propionic acid;
3-(5-Bromo-6-hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid;
3-(6-Hydroxy-2,7,8-trimethyl-5-nitro-chroman-2-yl)-propionic acid;
3-(2,5,7,8-Tetramethyl-chroman-2-yl)-propionic acid;
3-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-yl)-propionic acid;
3-(6-Hydroxy-2-methyl-chroman-2-yl)-propionic acid;
3-(6-Hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid methyl ester;
3-(6-Hydroxy-2-methyl-chroman-2-yl)-propionic acid methyl ester;
3-(6-Hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid;
2-Hydroxymethyl-2,5,7,8-tetramethyl-chroman-6-ol;
5-[3-(6-Hydroxy-2,7,8-trimethyl-chroman-2-yl)-propyl]-thiazolidine-2,4-dione;
2-Amino-4-{1-(carboxymethyl-carbamoyl)-2-[6-hydroxy-2,7,8-trimethyl-2-(4,8,12-trimethyl-tridecyl)-chroman-5-ylmethylsulfanyl]-ethylcarbamoyl}-butyric acid;
5-(4-Benzyl-piperazin-1-ylmethyl)-2,7,8-trimethyl-2-(4,8,12-trimethyl-tridecyl)-chroman-6-ol;
3-(5-Bromo-6-hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid methyl ester;
3-(6-Hydroxy-2-methyl-3,4-dihydro-2H-benzo[h]chroman-2-yl)-propionic acid;
4-[1-(Carboxymethyl-carbamoyl)-2-mercapto-ethylcarbamoyl]-2-[3-(6-hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionylamino]-butyric acid);
2,2,7,8-Tetramethyl-chroman-6-ol;
Delta tocopherol;
Delta tocotrienol;
Gamma-tocopherol;
Gamma-tocotrienol; and
Alpha tocotrienol;
or
single stereoisomers, mixtures of stereoisomers, or pharmaceutically acceptable salts thereof.
14. The method of claim 12, comprising treating or ameliorating a subject in need of protection of Friedreich's ataxia comprising administering a therapeutically effective amount of a tocopherol selected from beta-tocopherol, delta-tocopherol, gamma-tocopherol, alpha-tocotrienol, beta-tocotrienol, delta-tocotrienol, and gamma-tocotrienol.
US10/941,126 2003-09-19 2004-09-15 Treatment of mitochondrial diseases Abandoned US20050065099A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/941,126 US20050065099A1 (en) 2003-09-19 2004-09-15 Treatment of mitochondrial diseases
US13/869,872 US20130267538A1 (en) 2003-09-19 2013-04-24 Treatment of mitochondrial diseases
US15/189,948 US20160324823A1 (en) 2003-09-19 2016-06-22 Treatment of mitochondrial diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50439103P 2003-09-19 2003-09-19
US54173704P 2004-02-04 2004-02-04
US10/941,126 US20050065099A1 (en) 2003-09-19 2004-09-15 Treatment of mitochondrial diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/869,872 Continuation US20130267538A1 (en) 2003-09-19 2013-04-24 Treatment of mitochondrial diseases

Publications (1)

Publication Number Publication Date
US20050065099A1 true US20050065099A1 (en) 2005-03-24

Family

ID=34425947

Family Applications (8)

Application Number Title Priority Date Filing Date
US10/941,121 Expired - Fee Related US7470798B2 (en) 2003-09-19 2004-09-15 7,8-bicycloalkyl-chroman derivatives
US10/941,126 Abandoned US20050065099A1 (en) 2003-09-19 2004-09-15 Treatment of mitochondrial diseases
US10/941,125 Expired - Fee Related US7514461B2 (en) 2003-09-19 2004-09-15 Chroman derivatives
US12/277,083 Expired - Fee Related US7875607B2 (en) 2003-09-19 2008-11-24 7,8-bicycloakyl-chroman derivatives
US12/393,836 Expired - Fee Related US8044097B2 (en) 2003-09-19 2009-02-26 Chroman derivatives
US13/245,741 Expired - Fee Related US8791155B2 (en) 2003-09-19 2011-09-26 Chroman derivatives
US13/869,872 Abandoned US20130267538A1 (en) 2003-09-19 2013-04-24 Treatment of mitochondrial diseases
US15/189,948 Abandoned US20160324823A1 (en) 2003-09-19 2016-06-22 Treatment of mitochondrial diseases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/941,121 Expired - Fee Related US7470798B2 (en) 2003-09-19 2004-09-15 7,8-bicycloalkyl-chroman derivatives

Family Applications After (6)

Application Number Title Priority Date Filing Date
US10/941,125 Expired - Fee Related US7514461B2 (en) 2003-09-19 2004-09-15 Chroman derivatives
US12/277,083 Expired - Fee Related US7875607B2 (en) 2003-09-19 2008-11-24 7,8-bicycloakyl-chroman derivatives
US12/393,836 Expired - Fee Related US8044097B2 (en) 2003-09-19 2009-02-26 Chroman derivatives
US13/245,741 Expired - Fee Related US8791155B2 (en) 2003-09-19 2011-09-26 Chroman derivatives
US13/869,872 Abandoned US20130267538A1 (en) 2003-09-19 2013-04-24 Treatment of mitochondrial diseases
US15/189,948 Abandoned US20160324823A1 (en) 2003-09-19 2016-06-22 Treatment of mitochondrial diseases

Country Status (3)

Country Link
US (8) US7470798B2 (en)
CA (3) CA2580584C (en)
WO (3) WO2005033092A1 (en)

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060128790A1 (en) * 2004-12-13 2006-06-15 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
US20060281809A1 (en) * 2005-06-01 2006-12-14 Miller Guy M Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20070072943A1 (en) * 2005-09-15 2007-03-29 Miller Guy M Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US7365095B2 (en) 2005-04-22 2008-04-29 Wyeth Chromane and chromene derivatives and uses thereof
WO2007100652A3 (en) * 2006-02-22 2008-07-03 Edison Pharmaceuticals Inc Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20090258095A1 (en) * 2006-07-27 2009-10-15 Arnold Munnich Use of a Ginkgo Biloba Extract for the Treatment of Mitochondrial Disease of Genetic Origin
US20100120916A1 (en) * 2007-04-05 2010-05-13 Sbi Alapromo Co., Ltd. Therapeutic agent and diagnostic agent for mitochondrial dysfunction brain diseases
US20100234326A1 (en) * 2007-04-11 2010-09-16 Skulachev Maxim V Composition for decelerating the aging in the organism and for extending the life time thereof and the use of said composition
WO2010126911A1 (en) * 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
WO2010126910A1 (en) * 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
WO2010126909A1 (en) * 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Formulation of tocotrienol quinones for the treatment of ophthalmic diseases
US20100292625A1 (en) * 2007-01-29 2010-11-18 Skulachev Vladimir P Pharmaceutical and cosmetic compositions for accelerated healing of wounds and other surface damages
US20100323992A1 (en) * 2006-10-20 2010-12-23 Skulachev Vladimir P Pharmaceutical compositions for preventing and treating eye pathologies
US20110046219A1 (en) * 2008-01-08 2011-02-24 Edison Pharmaceuticals, Inc (het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
US20110053895A1 (en) * 2007-06-29 2011-03-03 Maxim Vladimirovich Skulachev Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases
US20110077159A1 (en) * 2006-10-20 2011-03-31 Skulachev Vladimir P Composition for regenerating and stimulating growth of plants and for adapting plants to different stress factors
EP2332534A1 (en) 2006-02-22 2011-06-15 Edison Pharmaceuticals, Inc. Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers
US20110207828A1 (en) * 2009-08-26 2011-08-25 Miller Guy M Methods for the prevention and treatment of cerebral ischemia
US20110218208A1 (en) * 2008-06-25 2011-09-08 Edison Phamaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US8044097B2 (en) 2003-09-19 2011-10-25 Ampere Life Sciences, Inc. Chroman derivatives
WO2012167236A1 (en) * 2011-06-03 2012-12-06 Mitotech Sa Oral formulations of mitochondrially-targeted antioxidants and their preparation and use
US20130116336A1 (en) * 2010-04-06 2013-05-09 William D. Shrader Treatment of ataxia telangiectasia
WO2013082570A1 (en) * 2011-12-02 2013-06-06 First Tech International Limited Tocotrienol derivatives and associated methods
US8653144B2 (en) 2008-09-10 2014-02-18 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US8716527B2 (en) 2008-03-05 2014-05-06 Edison Pharmaceuticals, Inc. 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
US9169196B2 (en) 2007-11-06 2015-10-27 Edison Pharmaceuticals, Inc. 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
WO2015193365A1 (en) * 2014-06-17 2015-12-23 Sulfateq B.V. 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
US9233903B2 (en) 2009-11-13 2016-01-12 Mitotech Sa Pharmaceutical substances on the basis of mitochondria-addressed antioxidants
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9308214B2 (en) 2008-11-12 2016-04-12 Mitotech S.A. Method for moderately increasing the proton conductivity of biological membranes with the aid of mitochondria-targeted delocalized cations
EP2872497B1 (en) 2012-07-12 2017-03-08 Khondrion Ip B.V. Chromanyl derivatives for treating mitochondrial disease
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9724313B2 (en) 2009-06-10 2017-08-08 Mitotech Sa Pharmaceutical composition for use in medical and veterinary ophthalmology
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
JP2018520106A (en) * 2015-05-22 2018-07-26 スルファテック・ベスローテン・フェンノートシャップＳｕｌｆａｔｅｑ Ｂ．Ｖ． Compounds for the prevention or treatment of organ damage
US10039722B2 (en) 2008-10-14 2018-08-07 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
US10251847B2 (en) 2014-12-16 2019-04-09 Bioelectron Technology Corporation Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
US10738014B2 (en) 2016-11-15 2020-08-11 Ptc Therapeutics, Inc. 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds or pharmaceutically acceptable salts thereof
US11174212B2 (en) 2018-10-17 2021-11-16 Ptc Therapeutics, Inc. 2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US11786486B2 (en) 2021-07-08 2023-10-17 Ptc Therapeutics, Inc. Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045534A2 (en) * 2002-11-15 2004-06-03 Galileo Pharmaceuticals, Inc. Chroman derivatives for the reduction of inflammation symptoms
WO2006044556A2 (en) * 2004-10-14 2006-04-27 Galileo Pharmaceuticals, Inc. Dual inhibitors of lipoxygenase for treating diabetes
WO2007098139A2 (en) * 2006-02-21 2007-08-30 The Ohio State University Research Foundation Anticancer agents
US8318812B2 (en) * 2006-06-02 2012-11-27 The Ohio State University Research Foundation Therapeutic agents for the treatment of lymphoid malignancies
DE102007002410A1 (en) * 2007-01-17 2008-07-24 Merck Patent Gmbh Synthesis of chroman derivatives
EP2042172A1 (en) * 2007-09-26 2009-04-01 Inserm Use of tocopherol derivatives as inhibitors of the notch signalling pathway
CA2719658C (en) 2008-04-01 2019-10-01 Antipodean Pharmaceuticals, Inc. Compositions and methods for skin care
MY185183A (en) 2008-10-28 2021-04-30 Bioelectron Tech Corp Process for the production of alpha-tocotrienol and derivatives
WO2010120711A1 (en) * 2009-04-13 2010-10-21 The Ohio State University Research Foundation Protein phosphatase 2a-activating agents
CA2759011A1 (en) * 2009-04-17 2010-10-21 The Ohio State University Research Foundation Antiadhesion agents
WO2012074960A2 (en) 2010-11-29 2012-06-07 The Ohio State University Research Foundation Fty720-derived anticancer agents
EP3730135A1 (en) 2011-04-26 2020-10-28 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
EP2701695B1 (en) 2011-04-26 2019-04-03 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating pufas
WO2012148929A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Disorders implicating pufa oxidation
KR102110200B1 (en) 2011-04-26 2020-05-13 레트로토프 인코포레이티드 Oxidative retinal diseases
EP2720689A4 (en) 2011-06-14 2014-11-26 Edison Pharmaceuticals Inc CATÉCHOL DERIVATIVES FOR THE TREATMENT OF OXIDATIVE STRESS DISEASES
WO2013013078A1 (en) 2011-07-19 2013-01-24 Edison Pharmeceuticals, Inc. Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
CN102600430B (en) * 2012-03-31 2013-05-01 沈庆坡 Medicine for curing femoral head necrosis
WO2013184780A1 (en) * 2012-06-06 2013-12-12 Unither Virology, Llc Novel iminosugars and their applications
WO2014039862A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
EP2970158B1 (en) 2013-03-15 2019-02-20 BioElectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
WO2015138773A2 (en) 2014-03-13 2015-09-17 Retrotope, Inc. Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances
US9507649B2 (en) 2014-05-29 2016-11-29 Apple Inc. Web browser for spoofing supported features
WO2017106786A1 (en) 2015-12-16 2017-06-22 Bioelectron Technology Corporation Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
US11166930B2 (en) 2016-11-17 2021-11-09 Retrotope, Inc. Isotopically modified components and therapeutic uses thereof
CA3156499A1 (en) 2019-10-04 2021-04-08 Stealth Biotherapeutics Inc. Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases
WO2021202986A1 (en) 2020-04-03 2021-10-07 Stealth Biotherapeutics Corp Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
US20250205193A1 (en) * 2022-03-22 2025-06-26 Regents Of The University Of Minnesota Therapeutic compound and salts

Citations (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3574627A (en) * 1969-02-06 1971-04-13 Eastman Kodak Co Color photographic elements
US3801603A (en) * 1971-01-14 1974-04-02 Bayer Ag Process for the preparation of 6-hydroxy chromans
US4360532A (en) * 1981-01-29 1982-11-23 E. R. Squibb & Sons, Inc. Substituted chromans
US4452801A (en) * 1981-09-24 1984-06-05 E. R. Squibb & Sons, Inc. Chromans including heterocyclic substituent
US4511685A (en) * 1980-03-19 1985-04-16 Basf Aktiengesellschaft Chroman derivatives and stabilized polypropylene composition
US4515975A (en) * 1980-11-24 1985-05-07 Basf Aktiengesellschaft Chroman derivatives and their preparation
US4645845A (en) * 1983-03-15 1987-02-24 Basf Aktiengesellschaft Novel optically active chroman derivatives, their preparation and novel intermediates
US4716238A (en) * 1983-02-15 1987-12-29 Alkaloida Vegyeszeti Gyar Chromene derivatives useful as insecticides
US4728650A (en) * 1985-05-13 1988-03-01 Kuraray Co., Ltd. 3,4-dihydrobenzopyran derivatives and medicinal uses thereof
US4877810A (en) * 1988-02-05 1989-10-31 Eastman Kodak Company Protection of heart tissue from reperfusion injury
US5099012A (en) * 1990-12-11 1992-03-24 Eastman Kodak Company Chroman-2-carboxamide conjugates and their use for treatment of reperfusion injury
US5290797A (en) * 1991-03-08 1994-03-01 Adir Et Compagnie Benzopyran compounds
US5326771A (en) * 1991-12-09 1994-07-05 Bayer Aktiengesellschaft Piperidylmethyl-substituted chroman derivatives
US5350751A (en) * 1990-04-04 1994-09-27 Hoechst Aktiengesellschaft Substituted imidazoles, pharmaceutical compositions containing these, and the use thereof as antagonists of angiotensin II receptors for the treatment of high blood pressure
US5385931A (en) * 1989-04-05 1995-01-31 Pierre Fabre Medicament Sulfonamides derived from benzocyclic or benzoheterocyclic acids, their preparation and application in therapeutics
US5424321A (en) * 1993-12-08 1995-06-13 Alcon Laboratories, Inc. Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
US5484810A (en) * 1992-01-02 1996-01-16 Merrell Dow Pharmaceuticals Inc. Tissue protective tocopherol analogs
US5500444A (en) * 1989-11-14 1996-03-19 Hoechst Marion Roussel, Inc. Cardioprotective tocopherol analogs
US5534536A (en) * 1993-08-24 1996-07-09 Ono Pharmaceuticals Co. Ltd. Fused phenol derivatives
US5541199A (en) * 1995-06-02 1996-07-30 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5607966A (en) * 1994-12-23 1997-03-04 Alcon Laboratories, Inc. Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory prodrugs
US5646149A (en) * 1993-12-08 1997-07-08 Alcon Laboratories, Inc. Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
US5663294A (en) * 1991-06-21 1997-09-02 Temple University Of The Commonwealth System Of Higher Education Calpain-inhibiting peptide analogs of the kininogen heavy chain
US5670667A (en) * 1995-07-25 1997-09-23 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5672710A (en) * 1995-11-03 1997-09-30 Allergan Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity
US5684039A (en) * 1995-07-25 1997-11-04 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5719180A (en) * 1993-12-07 1998-02-17 Koichi Shudo Chroman derivatives having vitamin E-like activities
US5747528A (en) * 1996-02-21 1998-05-05 Warner-Lambert Company Chroman derivatives as anti-oxidants
US5756521A (en) * 1996-04-03 1998-05-26 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5811438A (en) * 1994-12-23 1998-09-22 Alcon Laboratories, Inc. Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory products
US5821130A (en) * 1994-05-06 1998-10-13 Pharmacopeia, Inc. Combinatorial dihydrobenzopyran library
US5849755A (en) * 1996-11-14 1998-12-15 Hoechst Aktiengesellschaft 3-amidochromanylsulfonyl(thio)ureas, processes for their preparation, their use, and pharmaceutical preparations comprising them
US5874461A (en) * 1994-12-28 1999-02-23 Janssen Pharmaceutica N.V. Use of Nebivolol as an anti-atherogenic
US5981530A (en) * 1995-03-29 1999-11-09 Senju Pharmaceutical Co., Ltd. Piperazine derivative
US5981572A (en) * 1996-05-14 1999-11-09 Glaxo Wellcome Inc. Benzofurans and benzopyrans as chronobiological agents
US6133277A (en) * 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
US6133322A (en) * 1998-10-29 2000-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6150402A (en) * 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
US6222051B1 (en) * 1997-04-28 2001-04-24 Sk Corporation Alpha-tocopherol 4-aminobenzoic acid ester compounds and method for preparing the same
US6235774B1 (en) * 1997-11-24 2001-05-22 Bayer Aktiengesellschaft Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
US6242479B1 (en) * 1998-12-17 2001-06-05 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
US6331532B1 (en) * 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
US20020010195A1 (en) * 1998-01-26 2002-01-24 Ghosh Soumitra S. Mitochondria protecting agents for treating mitochondria associated diseases
US6342602B1 (en) * 1995-11-22 2002-01-29 Allergan Sales, Inc. Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thichroman and 1,2,3,4-tetrahydroquinolinecarboxlic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US6387899B1 (en) * 1997-09-18 2002-05-14 Astrazeneca Ab Substituted chroman derivatives
US20020082292A1 (en) * 2000-09-27 2002-06-27 Sahoo Soumya P. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
US6417223B1 (en) * 1998-09-23 2002-07-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses therof
US20020127252A1 (en) * 2000-12-22 2002-09-12 Klaus Kramer Use of chroman derivatives in cosmetic or dermatological preparations
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US20020165273A1 (en) * 2001-02-27 2002-11-07 Plata-Salaman Carlos R. Carbamate compounds for use in preventing or treating neurodegenerative disorders
US6479497B1 (en) * 1997-09-18 2002-11-12 Astrazeneca Ab Substituted chroman derivatives
US6518250B2 (en) * 1998-02-06 2003-02-11 Cci Corporation Agent for preventing and curing hindrance of ischemic reperfusion
US20030069208A1 (en) * 1997-11-25 2003-04-10 University Of Otago Mitochondrially targeted antioxidants
US20030103895A1 (en) * 2000-10-24 2003-06-05 Cyr John E. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans
US20030103899A1 (en) * 2000-10-24 2003-06-05 Cyr John E. Stabilization of radiopharmaceutical compositions using hydrophilic 6-hydroxy-chromans
US6596745B2 (en) * 2001-05-30 2003-07-22 Alteon, Inc. Method for treating fibrotic diseases with azolium chroman compounds
US20030158237A1 (en) * 2001-09-04 2003-08-21 Colba R & D Inc. Combination of antioxidant substances for the treatment of alzheimer's disease
US20030233002A1 (en) * 2000-06-02 2003-12-18 James Kanter Synthesis of 2-Acyl substituted chromanes and intermediates thereof
US20040044220A1 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
US20090170814A1 (en) * 2003-09-19 2009-07-02 Edison Pharmaceuticals, Inc. 7,8-bicycloakyl-chroman derivatives

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3154565A (en) 1962-03-22 1964-10-27 Merck & Co Inc Chromenyl compounds and method of preparing
US3160638A (en) 1963-03-19 1964-12-08 Merck & Co Inc 5-phosphomethyl derivatives of 6-chromanols and processes for preparing same
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
JPS4892372A (en) 1972-03-14 1973-11-30
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4523024A (en) 1982-11-26 1985-06-11 Kuraray Co., Ltd. 3,4-Dihydro-2H-benzopyran derivatives, a method of producing them, a method of using them as stabilizers for organic materials, and organic compositions containing such stabilizers
JPS601177A (en) 1983-06-16 1985-01-07 Kuraray Co Ltd α-Amino acids and their derivatives and their production methods
CA1261835A (en) 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
DE3484473D1 (en) 1984-12-06 1991-05-23 Kuraray Co CHROMAN CONNECTIONS AND THEIR PRODUCTION.
JPS61148173A (en) 1984-12-20 1986-07-05 Kuraray Co Ltd Novel amines and their salts
WO1987005020A1 (en) 1986-02-21 1987-08-27 Kuraray Co., Ltd. 3,4-dihydro-2h-benzopyran derivatives and their medicinal use
JPS62292777A (en) 1986-06-12 1987-12-19 Daikin Ind Ltd Fluorine-containing coumarones
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
US5059609A (en) * 1987-10-19 1991-10-22 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
US4950684A (en) 1988-05-20 1990-08-21 G. D. Searle & Co. 2,2-di-substituted benzopyran leukotriene-D4 antagonists
US5093353A (en) * 1988-05-20 1992-03-03 G. D. Searle & Co. 2,2-di-substituted benzopyran leukotriene-D4 antagonists
US5260294A (en) 1988-08-09 1993-11-09 Hoffman-La Roche Inc. Chromanes and their pharmaceutical compositions and methods
US5132310A (en) * 1988-08-09 1992-07-21 Hoffmann-La Roche Inc. Pharmacologically active chromanes
US5015661A (en) * 1988-08-09 1991-05-14 Hoffmann-La Roche Inc. Chromanes and their pharmaceutical compositions and methods
DE3842029A1 (en) 1988-12-14 1990-06-21 Basf Ag 2-(3'-Halo-n-propyl)-2,5,7,8-tetramethyl-6-chromanols, process for their preparation, and intermediates of this process
CA2011899A1 (en) 1989-03-13 1990-09-13 Masaaki Toda Benzopyran derivatives
US5082849A (en) 1989-07-13 1992-01-21 Huang Fu Chich Quinolinyl-benzopyran derivatives as antagonists of leukotriene D4
US5155130A (en) * 1989-08-11 1992-10-13 Ciba-Geigy Corporation Certain benzopyran and benzothiopyran derivatives
US5591772A (en) * 1991-11-22 1997-01-07 Lipogenics, Inc. Tocotrienols and tocotrienol-like compounds and methods for their use
US5250547A (en) * 1991-08-29 1993-10-05 Syntex (U.S.A.) Inc. Benzopyran derivatives
EP0535283A1 (en) 1991-10-02 1993-04-07 Merrell Dow Pharmaceuticals Inc. Cardioprotective tocopherol analogs
US5331561A (en) * 1992-04-23 1994-07-19 Alliant Techsystems Inc. Active cross path position correlation device
FR2695387B1 (en) * 1992-09-09 1994-10-21 Adir New benzopyran compounds, process for their preparation and pharmaceutical compositions containing them.
JPH0841008A (en) 1994-07-29 1996-02-13 Ono Pharmaceut Co Ltd Nitrogen monoxide synthetase inhibitor
FR2727414A1 (en) 1994-11-25 1996-05-31 Pf Medicament 3,4-DIHYDRO-2,5,7,8-TETRAMETHYL-BENZOPYRAN-6-OL DERIVATIVES USEFUL AS MEDICINAL PRODUCTS
US5925673A (en) * 1994-12-23 1999-07-20 Alcon Laboratories, Inc. Benzofurans and benzopyrans as cytoprotective agents
US6232060B1 (en) 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
ES2127106B1 (en) * 1996-03-21 1999-11-16 Menarini Lab BENZOPYRANIC DERIVATIVES WITH ANTAGONISTIC ACTION OF THE LEUCOTRENEES, PROCEDURE FOR THEIR PREPARATION AND USE OF THE SAME.
ATE201204T1 (en) * 1996-03-25 2001-06-15 Alcon Lab Inc DERIVATIVES OF THIAZOLIDINE-4-CARBONIC ACID AS CYTOPROTECTIVE AGENTS
GB9702310D0 (en) * 1997-02-05 1997-03-26 Univ Hertfordshire Invention
JPH10251247A (en) 1997-03-14 1998-09-22 Takasago Internatl Corp Chroman derivative having alkylthiomethyl group, its production and antioxidant containing the same
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
FI991634L (en) 1999-07-21 2001-01-22 Valtion Teknillinen Comonomer and the polymer stabilized by it during the polymerization stage
US6426362B1 (en) 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US20020016359A1 (en) 2000-06-29 2002-02-07 Hellberg Mark R. Compositions and methods of treating neurodegenerative diseases
US7034054B2 (en) 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US20020132845A1 (en) 2000-12-15 2002-09-19 Miller Guy Michael Compositions and methods for the prevention and treatment of tissue ischemia
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
WO2003015494A2 (en) * 2001-08-21 2003-02-27 Galileo Pharmaceuticals, Inc. Tocopherol enriched compositions and amelioration of inflammatory symptoms
AU2002352726A1 (en) 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US6653346B1 (en) 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
US7078541B2 (en) 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
US7491312B2 (en) 2002-10-30 2009-02-17 Edison Pharmaceuticals, Inc. Identifying therapeutic compounds based on their physical-chemical properties
AU2003286907A1 (en) * 2002-11-05 2004-06-07 Ranpak Corp. System and method for making a coiled strip of dunnage
WO2004045534A2 (en) * 2002-11-15 2004-06-03 Galileo Pharmaceuticals, Inc. Chroman derivatives for the reduction of inflammation symptoms
US20050228041A1 (en) * 2003-08-08 2005-10-13 The Ohio State University Research Foundation Protective and therapeutic uses for tocotrienols
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
MX359292B (en) 2005-06-01 2018-09-24 Bioelectron Tech Corp Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers.
EA021818B1 (en) 2005-09-15 2015-09-30 Эдисон Фармасьютикалз, Инк. VERSIONS OF THE TAIL PART OF REDOX-ACTIVE MEDICINES FOR THE TREATMENT OF MITOCHONDRIAL DISEASES AND MODULATION OF THE BIOMARKER ENERGY EXCHANGE Q10
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
CN101610782A (en) 2007-01-10 2009-12-23 爱迪生药物公司 Use has the compounds for treating respiratory chain disorders of erythropoietin or TPO activity
SI3456707T1 (en) 2007-11-06 2020-10-30 Ptc Therapeutics, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
CA2710253A1 (en) 2008-01-07 2009-07-16 Centocor Ortho Biotech Inc. Method of treating erythropoietin hyporesponsive anemias
US8952071B2 (en) 2008-01-08 2015-02-10 Edison Pharmaceuticals, Inc. (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
US20110046156A1 (en) 2008-03-05 2011-02-24 Miller Guy M Treatment of hearing and balance impairments with redox-active therapeutics
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
EP2310038A4 (en) 2008-05-15 2012-03-14 Edison Pharmaceuticals Inc TREATMENT OF HEARING AND BALANCE DISORDERS WITH COMPOUNDS HAVING ERYTHROPOIETIN ACTIVITY
EA201001814A1 (en) 2008-05-22 2011-04-29 Эдисон Фармасьютикалз, Инк. TREATMENT OF MITOCHONDRIAL DISEASES BY ERYTHROPOIETIN MEMETICS
WO2009158348A1 (en) 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US20100010100A1 (en) 2008-07-09 2010-01-14 Hinman Andrew W Dermatological compositions with anti-aging and skin even-toning properties
US20100029784A1 (en) 2008-07-30 2010-02-04 Hinman Andrew W Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties
LT3827815T (en) 2008-09-10 2023-10-10 Ptc Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US10039722B2 (en) 2008-10-14 2018-08-07 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
MY185183A (en) 2008-10-28 2021-04-30 Bioelectron Tech Corp Process for the production of alpha-tocotrienol and derivatives
JP2012525399A (en) 2009-04-28 2012-10-22 エジソン ファーマシューティカルズ， インコーポレイテッド Treatment of Leber hereditary optic neuropathy and dominant hereditary optic atrophy using tocotrienol quinone
BRPI1015006A2 (en) 2009-04-28 2019-09-24 Ampere Life Sciences Inc topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
CA2759984A1 (en) 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Formulation of tocotrienol quinones for the treatment of ophthalmic diseases
EP2445519A4 (en) 2009-06-25 2012-12-26 Ampere Life Sciences Inc Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
MX337990B (en) 2009-08-26 2016-03-30 Edison Pharmaceuticals Inc Methods for the prevention and treatment of cerebral ischemia.
WO2011041452A2 (en) 2009-10-01 2011-04-07 Ampere Life Sciences, Inc. Mouse model for identifying compounds for the treatment of oxidative stress
EP2519232A1 (en) 2009-12-31 2012-11-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
WO2011113018A1 (en) 2010-03-12 2011-09-15 Ampere Life Sciences, Inc. Measurement and control of biological time
CA2795726A1 (en) 2010-04-06 2011-10-13 Edison Pharmaceuticals, Inc. Treatment of ataxia telangiectasia
BR112012027543A8 (en) 2010-04-27 2019-12-03 Bioelectron Tech Corp quinone formulations for treating ophthalmic diseases
US20120101169A1 (en) 2010-07-14 2012-04-26 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
JP2013538799A (en) 2010-08-06 2013-10-17 アンペア ライフ サイエンシーズ，インコーポレイテッド Treatment of mitochondrial diseases with vitamin K
US20130345312A1 (en) 2010-08-06 2013-12-26 Orion D. Jankowski Treatment of mitochondrial diseases with naphthoquinones
WO2012068552A1 (en) 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control
WO2012154613A1 (en) 2011-05-06 2012-11-15 Edison Pharmaceuticals, Inc. Improved process for the preparation of d-alpha-tocotrienol from natural extracts
WO2012170773A1 (en) 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
EP2720689A4 (en) 2011-06-14 2014-11-26 Edison Pharmaceuticals Inc CATÉCHOL DERIVATIVES FOR THE TREATMENT OF OXIDATIVE STRESS DISEASES
JP6728520B2 (en) 2011-07-06 2020-07-22 ピーティーシー セラピューティクス， インコーポレイテッド Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic aciduria with tocotrienol quinone
WO2013006736A1 (en) 2011-07-06 2013-01-10 Edison Pharmaceuticals, Inc Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones
WO2013013078A1 (en) 2011-07-19 2013-01-24 Edison Pharmeceuticals, Inc. Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols

Patent Citations (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3574627A (en) * 1969-02-06 1971-04-13 Eastman Kodak Co Color photographic elements
US3801603A (en) * 1971-01-14 1974-04-02 Bayer Ag Process for the preparation of 6-hydroxy chromans
US4511685A (en) * 1980-03-19 1985-04-16 Basf Aktiengesellschaft Chroman derivatives and stabilized polypropylene composition
US4515975A (en) * 1980-11-24 1985-05-07 Basf Aktiengesellschaft Chroman derivatives and their preparation
US4360532A (en) * 1981-01-29 1982-11-23 E. R. Squibb & Sons, Inc. Substituted chromans
US4452801A (en) * 1981-09-24 1984-06-05 E. R. Squibb & Sons, Inc. Chromans including heterocyclic substituent
US4716238A (en) * 1983-02-15 1987-12-29 Alkaloida Vegyeszeti Gyar Chromene derivatives useful as insecticides
US4645845A (en) * 1983-03-15 1987-02-24 Basf Aktiengesellschaft Novel optically active chroman derivatives, their preparation and novel intermediates
US4728650A (en) * 1985-05-13 1988-03-01 Kuraray Co., Ltd. 3,4-dihydrobenzopyran derivatives and medicinal uses thereof
US4877810A (en) * 1988-02-05 1989-10-31 Eastman Kodak Company Protection of heart tissue from reperfusion injury
US5385931A (en) * 1989-04-05 1995-01-31 Pierre Fabre Medicament Sulfonamides derived from benzocyclic or benzoheterocyclic acids, their preparation and application in therapeutics
US5500444A (en) * 1989-11-14 1996-03-19 Hoechst Marion Roussel, Inc. Cardioprotective tocopherol analogs
US5350751A (en) * 1990-04-04 1994-09-27 Hoechst Aktiengesellschaft Substituted imidazoles, pharmaceutical compositions containing these, and the use thereof as antagonists of angiotensin II receptors for the treatment of high blood pressure
US5099012A (en) * 1990-12-11 1992-03-24 Eastman Kodak Company Chroman-2-carboxamide conjugates and their use for treatment of reperfusion injury
US5290797A (en) * 1991-03-08 1994-03-01 Adir Et Compagnie Benzopyran compounds
US5663294A (en) * 1991-06-21 1997-09-02 Temple University Of The Commonwealth System Of Higher Education Calpain-inhibiting peptide analogs of the kininogen heavy chain
US5326771A (en) * 1991-12-09 1994-07-05 Bayer Aktiengesellschaft Piperidylmethyl-substituted chroman derivatives
US5484810A (en) * 1992-01-02 1996-01-16 Merrell Dow Pharmaceuticals Inc. Tissue protective tocopherol analogs
US5750544A (en) * 1993-08-24 1998-05-12 Ono Pharmaceuticals Co., Ltd. Fused phenol derivatives
US5534536A (en) * 1993-08-24 1996-07-09 Ono Pharmaceuticals Co. Ltd. Fused phenol derivatives
US5719180A (en) * 1993-12-07 1998-02-17 Koichi Shudo Chroman derivatives having vitamin E-like activities
US5424321A (en) * 1993-12-08 1995-06-13 Alcon Laboratories, Inc. Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
US5646149A (en) * 1993-12-08 1997-07-08 Alcon Laboratories, Inc. Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
US5821130A (en) * 1994-05-06 1998-10-13 Pharmacopeia, Inc. Combinatorial dihydrobenzopyran library
US6150402A (en) * 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
US5607966A (en) * 1994-12-23 1997-03-04 Alcon Laboratories, Inc. Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory prodrugs
US5811438A (en) * 1994-12-23 1998-09-22 Alcon Laboratories, Inc. Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory products
US5874461A (en) * 1994-12-28 1999-02-23 Janssen Pharmaceutica N.V. Use of Nebivolol as an anti-atherogenic
US5981530A (en) * 1995-03-29 1999-11-09 Senju Pharmaceutical Co., Ltd. Piperazine derivative
US5541199A (en) * 1995-06-02 1996-07-30 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5684039A (en) * 1995-07-25 1997-11-04 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5670667A (en) * 1995-07-25 1997-09-23 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5672710A (en) * 1995-11-03 1997-09-30 Allergan Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity
US6342602B1 (en) * 1995-11-22 2002-01-29 Allergan Sales, Inc. Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thichroman and 1,2,3,4-tetrahydroquinolinecarboxlic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5747528A (en) * 1996-02-21 1998-05-05 Warner-Lambert Company Chroman derivatives as anti-oxidants
US5756521A (en) * 1996-04-03 1998-05-26 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5981572A (en) * 1996-05-14 1999-11-09 Glaxo Wellcome Inc. Benzofurans and benzopyrans as chronobiological agents
US5849755A (en) * 1996-11-14 1998-12-15 Hoechst Aktiengesellschaft 3-amidochromanylsulfonyl(thio)ureas, processes for their preparation, their use, and pharmaceutical preparations comprising them
US6222051B1 (en) * 1997-04-28 2001-04-24 Sk Corporation Alpha-tocopherol 4-aminobenzoic acid ester compounds and method for preparing the same
US6479497B1 (en) * 1997-09-18 2002-11-12 Astrazeneca Ab Substituted chroman derivatives
US6387899B1 (en) * 1997-09-18 2002-05-14 Astrazeneca Ab Substituted chroman derivatives
US6235774B1 (en) * 1997-11-24 2001-05-22 Bayer Aktiengesellschaft Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
US20010018530A1 (en) * 1997-11-24 2001-08-30 Thomas Fahrig Use of substituted amino-methyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration
US6331561B2 (en) * 1997-11-24 2001-12-18 Bayer Aktiengesellschaft Use of substituted amino-methyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration
US20030069208A1 (en) * 1997-11-25 2003-04-10 University Of Otago Mitochondrially targeted antioxidants
US20020052342A1 (en) * 1997-11-25 2002-05-02 University Of Otago Mitochondrially targeted antioxidants
US6133277A (en) * 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
US20030176448A1 (en) * 1998-01-26 2003-09-18 Mitokor Mitochondria protecting agents for treating mitochondria associated diseases
US6511966B2 (en) * 1998-01-26 2003-01-28 Mitokor Mitochondria protecting agents for treating mitochondria associated diseases
US20020010195A1 (en) * 1998-01-26 2002-01-24 Ghosh Soumitra S. Mitochondria protecting agents for treating mitochondria associated diseases
US6498191B2 (en) * 1998-01-26 2002-12-24 Mitokor Mitochondria protecting agents for treating mitochondria associated diseases
US6518250B2 (en) * 1998-02-06 2003-02-11 Cci Corporation Agent for preventing and curing hindrance of ischemic reperfusion
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6417223B1 (en) * 1998-09-23 2002-07-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses therof
US6645998B2 (en) * 1998-09-23 2003-11-11 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6133322A (en) * 1998-10-29 2000-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6331532B1 (en) * 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
US6410589B2 (en) * 1998-12-17 2002-06-25 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
US6242479B1 (en) * 1998-12-17 2001-06-05 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
US6555575B2 (en) * 1998-12-17 2003-04-29 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
US20030233002A1 (en) * 2000-06-02 2003-12-18 James Kanter Synthesis of 2-Acyl substituted chromanes and intermediates thereof
US20020082292A1 (en) * 2000-09-27 2002-06-27 Sahoo Soumya P. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
US20030103895A1 (en) * 2000-10-24 2003-06-05 Cyr John E. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans
US20030103899A1 (en) * 2000-10-24 2003-06-05 Cyr John E. Stabilization of radiopharmaceutical compositions using hydrophilic 6-hydroxy-chromans
US20020127252A1 (en) * 2000-12-22 2002-09-12 Klaus Kramer Use of chroman derivatives in cosmetic or dermatological preparations
US20020165273A1 (en) * 2001-02-27 2002-11-07 Plata-Salaman Carlos R. Carbamate compounds for use in preventing or treating neurodegenerative disorders
US6596745B2 (en) * 2001-05-30 2003-07-22 Alteon, Inc. Method for treating fibrotic diseases with azolium chroman compounds
US20030158237A1 (en) * 2001-09-04 2003-08-21 Colba R & D Inc. Combination of antioxidant substances for the treatment of alzheimer's disease
US20040044220A1 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
US20090170814A1 (en) * 2003-09-19 2009-07-02 Edison Pharmaceuticals, Inc. 7,8-bicycloakyl-chroman derivatives

Cited By (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044097B2 (en) 2003-09-19 2011-10-25 Ampere Life Sciences, Inc. Chroman derivatives
US8791155B2 (en) 2003-09-19 2014-07-29 Edison Pharmaceuticals, Inc. Chroman derivatives
US20060128790A1 (en) * 2004-12-13 2006-06-15 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
US7576094B2 (en) 2004-12-13 2009-08-18 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors
US7365095B2 (en) 2005-04-22 2008-04-29 Wyeth Chromane and chromene derivatives and uses thereof
US20080182891A1 (en) * 2005-04-22 2008-07-31 Wyeth Chromane and chromene derivatives and uses thereof
US9447006B2 (en) 2005-06-01 2016-09-20 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
JP2008542389A (en) * 2005-06-01 2008-11-27 エジソン ファーマシューティカルズ， インコーポレイテッド Redox-active therapeutics for the treatment of mitochondrial diseases and other conditions, and for modulation of energy biomarkers
WO2006130775A3 (en) * 2005-06-01 2007-05-10 Edison Pharmaceuticals Inc Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
JP2013091672A (en) * 2005-06-01 2013-05-16 Edison Pharmaceuticals Inc Redox-active therapeutics for treatment of mitochondrial disease and other condition and modulation of energy biomarker
US20060281809A1 (en) * 2005-06-01 2006-12-14 Miller Guy M Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EA035619B1 (en) * 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Compositions for use in a method of treatment of mitochondrial disorders
EA016226B1 (en) * 2005-06-01 2012-03-30 Эдисон Фармасьютикалз, Инк. Redox-active therapeutics for treatment of mitochondrial diseases
US11021424B2 (en) 2005-06-01 2021-06-01 Ptc Therapeutics, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US7432305B2 (en) 2005-09-15 2008-10-07 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20070072943A1 (en) * 2005-09-15 2007-03-29 Miller Guy M Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9932286B2 (en) 2006-02-22 2018-04-03 Bioelectron Technology Corporation Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
JP2009527567A (en) * 2006-02-22 2009-07-30 エジソン ファーマシューティカルズ， インコーポレイテッド Modulation of redox-activated therapeutic side chain variants and energy biomarkers for the treatment of mitochondrial diseases and other conditions
EP2617417A1 (en) 2006-02-22 2013-07-24 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EP2617418A1 (en) 2006-02-22 2013-07-24 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9278085B2 (en) 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EA019675B1 (en) * 2006-02-22 2014-05-30 Эдисон Фармасьютикалз, Инк. REDOX-ACTIVE THERAPEUTIC MEANS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES AND MODULATION OF BIOMARKER COENZYM Q
EP2332534A1 (en) 2006-02-22 2011-06-15 Edison Pharmaceuticals, Inc. Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers
WO2007100652A3 (en) * 2006-02-22 2008-07-03 Edison Pharmaceuticals Inc Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US8097287B2 (en) * 2006-07-27 2012-01-17 Ipsen Pharma S.A.S. Use of a Ginkgo biloba extract for the treatment of mitochondrial disease of genetic origin
US20090258095A1 (en) * 2006-07-27 2009-10-15 Arnold Munnich Use of a Ginkgo Biloba Extract for the Treatment of Mitochondrial Disease of Genetic Origin
US9572821B2 (en) 2006-10-20 2017-02-21 Mitotech Sa Pharmaceutical compositions for preventing and treating eye pathologies
US20110077159A1 (en) * 2006-10-20 2011-03-31 Skulachev Vladimir P Composition for regenerating and stimulating growth of plants and for adapting plants to different stress factors
US8658624B2 (en) 2006-10-20 2014-02-25 Mitotech Sa Pharmaceutical compositions for preventing and treating eye pathologies
US8557733B2 (en) 2006-10-20 2013-10-15 Mitotech S.A. Composition for regenerating and stimulating growth of plants and for adapting plants to different stress factors
US20100323992A1 (en) * 2006-10-20 2010-12-23 Skulachev Vladimir P Pharmaceutical compositions for preventing and treating eye pathologies
US20100292625A1 (en) * 2007-01-29 2010-11-18 Skulachev Vladimir P Pharmaceutical and cosmetic compositions for accelerated healing of wounds and other surface damages
US9427444B2 (en) 2007-01-29 2016-08-30 Mitotech Sa Pharmaceutical and cosmetic compositions for accelerated healing of wounds and other surface damages
US8927532B2 (en) 2007-04-05 2015-01-06 Sbi Pharmaceuticals Co., Ltd. Therapeutic agent and diagnostic agent for mitochondrial dysfunction brain diseases
US20100120916A1 (en) * 2007-04-05 2010-05-13 Sbi Alapromo Co., Ltd. Therapeutic agent and diagnostic agent for mitochondrial dysfunction brain diseases
RU2435595C2 (en) * 2007-04-05 2011-12-10 ЭсБиАй АЛАпромо КО., ЛТД. Therapeutic agent and diagnostic agent for cerebral diseases of caused by mitochondrial dysfunction
US20100234326A1 (en) * 2007-04-11 2010-09-16 Skulachev Maxim V Composition for decelerating the aging in the organism and for extending the life time thereof and the use of said composition
US9439916B2 (en) 2007-04-11 2016-09-13 Mitotech Sa Composition for decelerating the aging in the organism and for extending the life time thereof and the use of said composition
US20110053895A1 (en) * 2007-06-29 2011-03-03 Maxim Vladimirovich Skulachev Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases
US8518915B2 (en) 2007-06-29 2013-08-27 Mitotech Sa Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases
US10968166B2 (en) 2007-11-06 2021-04-06 Ptc Therapeutics, Inc. 4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US9169196B2 (en) 2007-11-06 2015-10-27 Edison Pharmaceuticals, Inc. 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US11840497B2 (en) 2007-11-06 2023-12-12 Ptc Therapeutics, Inc. 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US10167251B2 (en) 2007-11-06 2019-01-01 Bioelectron Technology Corporation 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US9546132B2 (en) 2007-11-06 2017-01-17 Edison Pharmaceuticals, Inc. 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US20110046219A1 (en) * 2008-01-08 2011-02-24 Edison Pharmaceuticals, Inc (het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
US8952071B2 (en) 2008-01-08 2015-02-10 Edison Pharmaceuticals, Inc. (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
US9486435B2 (en) 2008-01-08 2016-11-08 Edison Pharmaceuticals, Inc. (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
US8716527B2 (en) 2008-03-05 2014-05-06 Edison Pharmaceuticals, Inc. 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
US9090576B2 (en) 2008-03-05 2015-07-28 Edison Pharmaceuticals, Inc. 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
US8716486B2 (en) 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US20110218208A1 (en) * 2008-06-25 2011-09-08 Edison Phamaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US9073873B2 (en) 2008-06-25 2015-07-07 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US9399612B2 (en) 2008-09-10 2016-07-26 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US8969420B2 (en) 2008-09-10 2015-03-03 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US10736857B2 (en) 2008-09-10 2020-08-11 Ptc Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US10105325B2 (en) 2008-09-10 2018-10-23 Bioelectron Technology Corporation Treatment of pervasive developmental disorders with redox-active therapeutics
US8653144B2 (en) 2008-09-10 2014-02-18 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US10039722B2 (en) 2008-10-14 2018-08-07 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
US9308214B2 (en) 2008-11-12 2016-04-12 Mitotech S.A. Method for moderately increasing the proton conductivity of biological membranes with the aid of mitochondria-targeted delocalized cations
EA031126B1 (en) * 2009-04-28 2018-11-30 Биоэлектрон Текнолоджи Корпорейшн METHOD OF TREATMENT OF DOMINANT ATROPHY OF THE SURGICAL NERVE TO TOKOTRIENOL-QUINON
EP3332766A1 (en) * 2009-04-28 2018-06-13 BioElectron Technology Corporation Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
US9370496B2 (en) 2009-04-28 2016-06-21 Edison Pharmaceuticals, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
WO2010126911A1 (en) * 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
WO2010126910A1 (en) * 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
WO2010126909A1 (en) * 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Formulation of tocotrienol quinones for the treatment of ophthalmic diseases
US20120136048A1 (en) * 2009-04-28 2012-05-31 Miller Guy M Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
US10195161B2 (en) 2009-04-28 2019-02-05 Bioelectron Technology Corporation Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
JP2012525398A (en) * 2009-04-28 2012-10-22 アンペア ライフ サイエンシーズ，インコーポレイテッド Topical, periocular or intraocular use of tocotrienol to treat ophthalmic disorders
US10213392B2 (en) * 2009-06-10 2019-02-26 Mitotech Sa Pharmaceutical composition for use in medical and veterinary ophthalmology
US9724313B2 (en) 2009-06-10 2017-08-08 Mitotech Sa Pharmaceutical composition for use in medical and veterinary ophthalmology
US20110207828A1 (en) * 2009-08-26 2011-08-25 Miller Guy M Methods for the prevention and treatment of cerebral ischemia
US9233903B2 (en) 2009-11-13 2016-01-12 Mitotech Sa Pharmaceutical substances on the basis of mitochondria-addressed antioxidants
US20130116336A1 (en) * 2010-04-06 2013-05-09 William D. Shrader Treatment of ataxia telangiectasia
US9192676B2 (en) 2011-06-03 2015-11-24 Mitotech Sa Oral formulations of mitochondrially-targeted antioxidants and their preparation and use
US9572890B2 (en) 2011-06-03 2017-02-21 Mitotech Sa Oral formulations of mitochondrially-targeted antioxidants and their preparation and use
EA031399B1 (en) * 2011-06-03 2018-12-28 Общество С Ограниченной Ответственностью "Митотех" Preparation and use of oral pharmaceutical formulations of mitochondrially-targeted antioxidants
WO2012167236A1 (en) * 2011-06-03 2012-12-06 Mitotech Sa Oral formulations of mitochondrially-targeted antioxidants and their preparation and use
US8816071B2 (en) 2011-12-02 2014-08-26 First Tech International Limited Tocotrienol derivatives and associated methods
US9115145B2 (en) 2011-12-02 2015-08-25 First Tech International Limited Tocotrienol derivatives and associated methods
CN103987717B (en) * 2011-12-02 2017-03-29 一德国际有限公司 Tocotrienol derivatives and related methods
WO2013082570A1 (en) * 2011-12-02 2013-06-06 First Tech International Limited Tocotrienol derivatives and associated methods
CN103987717A (en) * 2011-12-02 2014-08-13 一德国际有限公司 Tocotrienol derivatives and related methods
EP2872497B2 (en) † 2012-07-12 2019-10-09 Khondrion Ip B.V. Chromanyl derivatives for treating mitochondrial disease
EP2872497B1 (en) 2012-07-12 2017-03-08 Khondrion Ip B.V. Chromanyl derivatives for treating mitochondrial disease
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US10426771B2 (en) 2014-06-17 2019-10-01 Sulfateq B.V. 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
US10322124B2 (en) 2014-06-17 2019-06-18 Sulfateq B.V. 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
JP2017524674A (en) * 2014-06-17 2017-08-31 スルファテック・ベスローテン・フェンノートシャップＳｕｌｆａｔｅｑ Ｂ．Ｖ． 6-hydroxy-2,5,7,8-tetramethylchroman-compound for the treatment of chronic obstructive airway disease
AU2015276186B2 (en) * 2014-06-17 2020-09-10 Sulfateq B.V. 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
WO2015193365A1 (en) * 2014-06-17 2015-12-23 Sulfateq B.V. 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
NL2013012B1 (en) * 2014-06-17 2016-07-05 Sulfateq Bv Compounds for the treatment of chronic obstructive airway diseases.
US11304914B2 (en) 2014-12-16 2022-04-19 Ptc Therapeutics, Inc. Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
US10251847B2 (en) 2014-12-16 2019-04-09 Bioelectron Technology Corporation Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
US11938101B2 (en) 2014-12-16 2024-03-26 Ptc Therapeutics, Inc. Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
US10751302B2 (en) 2014-12-16 2020-08-25 Ptc Therapeutics, Inc. Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
JP2018520106A (en) * 2015-05-22 2018-07-26 スルファテック・ベスローテン・フェンノートシャップＳｕｌｆａｔｅｑ Ｂ．Ｖ． Compounds for the prevention or treatment of organ damage
JP2021120381A (en) * 2015-05-22 2021-08-19 スルファテック・ベスローテン・フェンノートシャップSulfateq B.V. Compounds for the prevention or treatment of organ damage
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
US11680034B2 (en) 2015-12-17 2023-06-20 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
US10981855B2 (en) 2015-12-17 2021-04-20 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
US11390588B2 (en) 2016-11-15 2022-07-19 Ptc Therapeutics, Inc. 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof
US10738014B2 (en) 2016-11-15 2020-08-11 Ptc Therapeutics, Inc. 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds or pharmaceutically acceptable salts thereof
US12281083B2 (en) 2016-11-15 2025-04-22 Ptc Therapeutics, Inc. 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof
US11174212B2 (en) 2018-10-17 2021-11-16 Ptc Therapeutics, Inc. 2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US11667596B2 (en) 2018-10-17 2023-06-06 Ptc Therapeutics, Inc. 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US11746077B2 (en) 2018-10-17 2023-09-05 Ptc Therapeutics, Inc. 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US11786486B2 (en) 2021-07-08 2023-10-17 Ptc Therapeutics, Inc. Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione

Also Published As

Publication number Publication date
CA2580584C (en) 2015-07-28
US7875607B2 (en) 2011-01-25
CA2583084C (en) 2010-12-07
CA2583087A1 (en) 2005-04-14
US20160324823A1 (en) 2016-11-10
US8791155B2 (en) 2014-07-29
CA2583087C (en) 2012-07-10
WO2005033092A1 (en) 2005-04-14
US7470798B2 (en) 2008-12-30
CA2580584A1 (en) 2006-04-14
US20050065150A1 (en) 2005-03-24
US20090170814A1 (en) 2009-07-02
US8044097B2 (en) 2011-10-25
US20130267538A1 (en) 2013-10-10
WO2005033093A1 (en) 2005-04-14
US20120088783A1 (en) 2012-04-12
WO2005032544A1 (en) 2005-04-14
US20090192179A1 (en) 2009-07-30
US20050065149A1 (en) 2005-03-24
CA2583084A1 (en) 2005-04-14
US7514461B2 (en) 2009-04-07

Similar Documents

Publication Publication Date Title
US20050065099A1 (en) Treatment of mitochondrial diseases
WO2005027900A1 (en) Benzofuran derivatives
US7078541B2 (en) Benzofuran derivatives
US7576094B2 (en) Spiro derivatives as lipoxygenase inhibitors
CA2599352A1 (en) Novel lipoxygenase inhibitors
IL314473A (en) Amide compound as potassium channel regulator, and preparation therefor and use thereof
CA2982769A1 (en) Methods for treating lysosomal storage disorders
US20060009503A1 (en) Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
JP5861182B2 (en) Flavanol derivative-acetone derivative adduct, production method thereof, amyloid β protein aggregation inhibitor and Alzheimer preventive or therapeutic agent using the same
US20080207588A1 (en) Spiro-Heterocyclic Chromans, Thiochromans and Dihydroquinolines
KR101896398B1 (en) Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration
EP4570798A1 (en) Aromatic heterocyclic cyclohexyl aminoalkyl piperidine derivative, preparation method and use thereof
KR101040760B1 (en) Novel flavone derivatives, preparation methods thereof, and compositions for preventing and treating cerebral nervous system diseases, including the same
EP1353670A2 (en) Use of chromanes
JP5561648B2 (en) Rhodocyanin derivative and pharmaceutical composition for treating leishmania infection
CA2580563A1 (en) Benzofuran derivatives

Legal Events

Date Code Title Description
AS Assignment

Owner name: GALILEO PHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WALKINSHAW, GAIL;BODDUPALLI, SEKHAR;WANG, BING;AND OTHERS;REEL/FRAME:016063/0731

Effective date: 20041206

AS Assignment

Owner name: ALLOY VENTURES, INC., CALIFORNIA

Free format text: SECURITY AGREEMENT;ASSIGNOR:GALILEO PHARMACEUTICALS, INC.;REEL/FRAME:016936/0079

Effective date: 20051222

AS Assignment

Owner name: GALILEO PHARMACEUTICALS, INC., CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:ALLOY VENTURES, INC. AS SECURED PARTY AND AS COLLATERAL AGENT FOR ADDITIONAL SECURED PARTIES UNDER THE SECURED NOTE PURCHASE AGREEMENT DATED AS OF DECEMBER 22, 2005;REEL/FRAME:019009/0088

Effective date: 20070301

AS Assignment

Owner name: EDISON PHARMACEUTICALS INC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GALILEO PHARMACEUTICALS, INC.;REEL/FRAME:019295/0809

Effective date: 20070301

AS Assignment

Owner name: AMPERE LIFE SCIENCES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EDISON PHARMACEUTICALS, INC.;REEL/FRAME:027792/0432

Effective date: 20101020

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: EDISON PHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AMPERE LIFE SCIENCES, INC.;REEL/FRAME:030619/0207

Effective date: 20130612